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Abstract 
Inositol phosphates (IPs) are important signalling molecules with various biological roles 
in a cell. One such role it is often associated with is DNA repair. The DNA repair process 
following DNA insult is considered crucial for the genomic integrity and stability. Failure 
to perform this task will result in mutations and possibly disease. Thus, it is important that 
we expand our knowledge on how these repair processes occur and identify the key factors 
involved in its regulation. 
The aim of this project was to investigate whether DNA repair was mediated by inositol 
diphosphates (IDPs). Using a family of yeast knockout mutants with modulated levels of 
IPs, it was found that IDPs are crucial in repair of DNA following insult with bleomycin 
and 5-fluorouracil. The observed sensitivity of the mutants was thought to be due to lack of 
functional repair protein, UDG-like or APE-like, in the absence of essential cofactor such 
as IDPs. Experiments conducted revealed that the hypersensitive kcs1Δ contain both the 
repair proteins required to process the DNA lesions. However, extreme extraction methods 
were required to access these proteins, suggesting that the proteins are mislocalised and 
unavailable to access the damage site and perform DNA repair. GFP-tagging the proteins 
Ung1, Apn1 and Rad52 in kcs1Δ proved to be of little use as it failed to show exact 
localisation, movement and functionality status of these proteins following bleomycin 
insult.   
The enzymes accountable for the dephosphorylation of the IDPs in vivo are the 
diphosphoinositol polyphosphate phosphohydrolases (DIPPs). Little is known regarding 
the Michaelis-Menten kinetics parameters for Ddp1p/DIPPs. In this study, using improved 
methods for the enzymatic synthesis and electrophoretic purification of 1-InsP7, 5-InsP7 
and InsP8, the DIPP family has been kinetically characterised. Each DIPP was found to 
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display similar Km values for every substrate tested (range: 35-148 nM). The rank order of 
Kcat values (1-InsP7 > 5-InsP7 = InsP8) was identical for each enzyme, although DIPP-1 
activity was observed to be 10- to 60-fold more than DIPP-2α/β and DIPP-3α/β, 
irrespective of the substrate. This study reveals that Ddp1, the yeast DIPP, is capable of 
hydrolysing not only 5-InsP7 but also 1-InsP7 and InsP8 to a single product, InsP6. The 
HPLC data found InsP7 accumulation to be relatively little during InsP8 breakdown by 
DIPPs. Such low build-up was found to be due to rapid conversion of InsP7 to InsP6. 
Through this study it is also clear that InsP8 prefers to dephosphorylate through 1-InsP7. In 
contrary, metabolically and functionally significant steady-state route of InsP8 synthesis 
was observed to be via 5-InsP7.  
Oesophageal cancer is considered as one of the deadliest cancers worldwide because of its 
aggressive nature and low survival rate. Epidemiologic studies have shown that low-dose 
daily intake of aspirin can decrease the incidence of oesophageal cancer. The data 
presented in this study show the effects of a number of in-house synthesized novel aspirin 
analogues on oesophageal cancer cell lines, squamous cell carcinoma (SSC) and 
adenocarcinoma (ADC). The aspirin analogues, fumaryldiaspirin (PN517) and 
benzoylsalicylates (PN524, PN528 and PN529), were observed to be more potent against 
the oesophageal cell lines than aspirin itself.  Both, quantitative and qualitative apoptosis 
experiments conducted revealed that these compounds largely induced apoptosis, although 
some necrosis was evident with PN528 and PN529. Failure to recover following the 
treatment with these analogues emphasized that these drugs are largely cytotoxic in nature. 
The SSC cells (oe21) displayed increased sensitivity to the aspirin analogues compared to 
the ADC cell lines (flo-1 and oe33). The anticancer properties of these novel aspirin 
compounds appear to not involve the COX-enzymes at the tested concentrations. These 
initial findings support further studies into the potential of these aspirin analogues as 
chemotherapeutic agents against oesophageal cancer.  
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1.1 Role of inositol diphosphates in DNA repair 
1.1.1 History of inositol signalling 
Diphosphoinositide, the first inositide, was isolated from brain by Jordi Folch in 1949 
(Folch, 1949). Later in 1950s, in response to agonist such as acetylcholine, the 
phosphoinositides were observed to exhibit rapid turnover by cells (Hokin and Hokin, 
1953). Following these findings, many phosphoinositides and inositol phosphates (IPs) 
were identified. Subsequent studies involved exploration of the functions and contributions 
of these identified molecules to cell signalling pathways. A study by Lapetina and Michell 
(1973) demonstrated an association of phosphoinositides turnover rate to membrane related 
receptors that induce intracellular calcium transport. Cleavage of Phosphatidylinositol 4,5-
bisphosphate [PtdIns(4,5)P2 or PIP2] to yield inositol 1,4,5-trisphosphate [Ins(1,4,5)P3 or 
InsP3] and diacylglycerol, which are involved in the release of calcium and activation of 
protein kinase C, respectively, remains to be the most well characterised inositide 
signalling pathway (Berridge, 1983; Streb et al., 1983; Toker, 2012). Since the discovery 
of phospholipase C (Plc) mediated breakdown of PIP2, inositol lipids are considered as the 
precursor for the inositol polyphosphate that are involved in cellular signalling. Once 
detached from the diacylglycerol tail, the soluble InsP3 can be further phosphorylated to 
form higher IPs and inositol diphosphates (IDPs), or hydrolysed to yield myo-inositol 
(Wilson et al., 2013). However, in Dictyostelium discoideum, synthesis of higher IP forms 
can bypass Plc, as they have developed an independent phosphorylation route from myo-
inositol to inositol hexakisphosphate (InsP6) (Stephens and Irvine, 1990). This finding of 
distinct phosphorylation and dephosphorylation properties of inositol lipids and IPs led to 
the concept of IP signalling pathway 
. 
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1.1.2 Structure and nomenclature of inositol 
The simple myo-inositol, a hexahydroxycyclohexane in nature, forms the basis of the 
diverse family of IPs. This six-carbon sugar molecule is likely to exist in the more 
thermodynamically stable chair configuration in vivo. In this confirmation, one group is 
axial at D-2 with the rest being equatorial. Visualizing this confirmation three 
dimensionally has been made easier by relating it to a turtle with the axial D-2 hydroxyl 
indicating the turtle’s head and the other five hydroxyl groups, turtle’s limbs and tail, 
numbered in a counterclockwise fashion with the tail indicating the D-5. Replacing the 
hydroxyl groups of the inositol molecule with phosphates, thus results in a variety of 
inositol polyphosphates. Phosphatidylinositol on the other hand  is formed by connecting a 
diacylglycerol to the D-1 of the inositol ring through a phosphodiester bond [Irvine and 
Schell (2001)]. The three commonly used structural representations of inositol are shown 
in Fig. 1.1.1  
 
Figure 1.1.1  Structure of myo-inositol: (a) Haworth projection, (b) stable chair 
conformation and (c) Agranoff’s turtle, a mnemonic. Adapted from Irvine and Schell 
(2001). 
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1.1.3 Higher inositol polyphosphates 
The focus of this thesis is the higher IDPs that are derived from inositol pentakisphosphate 
(InsP5) and InsP6. InsP5, which serves as a metabolic centre in higher IP metabolism are 
found primarily in the mammalian cells in the form Ins(1,3,4,5,6)P5, although studies 
report that they exist  in Ins(1,2,4,5,6) P5 and Ins(2,3,4,5,6) P5 forms in Jurkat T cells and 
T5-1B cells (Irvine and Schell, 2001). Further phosphorylation of the phosphate groups in 
InsP5 generates the IDPs such as diphosphoinositol tetrakisphosphate (PP-InsP4) and bis-
diphosphoinositol trisphosphate [(PP)2-InsP3] (Wilson et al., 2013) (Fig. 1.1.2). On the 
other hand, phosphorylation of InsP6 results in IDPs such as diphosphoinositol 
pentakisphosphate (PP-InsP5 or InsP7) and bis-diphosphoinositol tetrakisphosphate [(PP)2-
InsP4 or InsP8] (Stephens et al., 1993). InsP7 in yeast has been found to have 
pyrophosphate at position-5 or 1 or 3 (Ye et al., 2013) whereas in mammalian cells it is 
found at position-5 (Irvine and Schell, 2001). Isomeric forms of InsP8 present in 
mammalian cells and yeast have pyrophosphates at position-1 or 5 (Lin et al., 2009; 
Wilson et al., 2013). Despite similar enzymology, InsP8 in D. discoideum has been found 
to contain pyrophosphates at positions-5 or 6 and in Polysphondylium, it has  been found to 
be at 1,5 and/or 3,5 isomer (Laussmann et al., 1998). The structure of higher inositol 
polyphosphates are shown in the Fig. 1.1.2.  
1.1.3a Properties and regulation of higher inositol polyphosphates 
Unlike inositol lipids, which are hydrophobic in nature and confined to cellular 
membranes, IPs are water soluble and free to move in a cell. InsP5 and InsP6 are the most 
abundantly found IPs in almost all eukaryotic cells (Safrany, Caffrey, et al., 1999). InsP5 
concentration in the cells has been found to vary between 1-5 µM, whilst InsP6 levels are 
between 15-100 µM (Jones and Divecha, 2004; Shears, 2004).  However, their free 
concentration could be much lower as they may be firmly bound to proteins or be isolated 
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in the subcellular compartments. At physiologically relevant ionic concentrations, InsP6 
has been proposed to form ‘InsP6-cation-phospholipid sandwich’ at the intracellular 
membrane surface (Poyner et al., 1993; Shears, 2001). InsP5 and InsP6 levels have been 
reported to vary during the key stages of cell cycle and cellular differentiation (Shears, 
1998, 2001). In Schizosaccharomyces pombe, hyperosmotic stress induces overexpression 
of InsP6 (Ongusaha et al., 1998). Studies have also reported increase in InsP8 levels in 
DDT1-MF2 and human embryonic kidney mammalian cell lines in response to 
hyperosmotic stress (Pesesse et al., 2004; Safrany, 2004). The highly phosphorylated IDPs 
are found at much lower concentrations, InsP7 having the highest concentration of 1-5M 
(Shears, 2004).  
Although the cellular concentration of IDPs remains mostly constant in most cells, in 
mammalian cells, the inter-conversion of InsP7 and InsP8 marks the most rapid turnovers 
(Glennon and Shears, 1993). Inhibition of dephosphorylation by fluoride exposure has 
been found to result in increased concentration of the IDPs in mammalian cells. This 
experiment revealed that in an hour about 50% of the InsP6 pool, as well as 20% of the 
InsP5 pool, were converted into IDPs (Menniti et al., 1993). Although these observations 
have led to the idea that IDPs have a dynamic role with a potential molecular switch 
regulating activity (Safrany, Caffrey, et al., 1999), the physiological significance of these 
molecules remains largely unknown, mainly because fluoride exhibits multiple effects on 
cell signalling. Moreover, fluoride was found to be specific to mammalian cells and was 
observed to not affect IDP concentration in yeast or D. discoideum (Wilson et al., 2013).    
IDPs, being highly negative charged molecules generated by high degree phosphorylation 
of InsP6, could influence the electrostatics of the molecules leading to weak and non-
specific protein-protein interactions. Several methodological criteria has been put forth to 
overcome issues of various interactions and influence of other IPs when exploring the 
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exact role of InsP6. Few of those conditions include: a) controls using other IPs and inositol 
hexakissulphate (InsS6) , a non-physiological InsP6 analogue, that exhibits specificity for 
InsP6, and b) presence of divalent cations (Ca
2+
 and Mg
2+
) to simulate the intracellular 
ionic environment (Shears, 2001). 
1.1.3b Metabolism of the higher inositol phosphates  
Pathway for the synthesis of IPs (Fig. 1.1.2) has been well characterized in yeast at a 
molecular level. Although some information is available on the mammalian pathways, it 
still remains less well defined. Mammalian pathway of synthesis slightly differs from the 
yeast pathway. This difference might only be seen in humans due to evolutionary 
advancement or due to tissue specificity of certain enzymes.  
In general, breakdown of PIP2 to InsP3 in the presence of Plc is believed to be the first step 
towards the synthesis of higher IPs. However, in plants and Dictyostelium, Plc-independent 
pathway involving production of InsP3 from InsP5 was observed (Van Dijken et al., 1995). 
Investigations of biochemical fate of InsP3 inside the cell have revealed the presence of a 
family of IP kinases, known as inositol polyphosphate multikinases (IPMK) in mammals, 
that phosphorylates the hydroxyl groups on the inositol ring to generate inositol 
tetrakisphosphate (InsP4), InsP5 and InsP6. IPMK was cloned primarily as ARGRIII/Arg82, 
a transcriptional regulatory protein of arginine metabolism, and is now known as inositol 
polyphosphate kinase 2 (Ipk2) (Lee et al., 2012; Saiardi et al., 2000).  Kcs1 was thought to 
be the only kinase involved in the phosphorylation of monophosphate to pyrophosphate 
groups in InsP7 and PP-InsP4 in yeast up until recently. Presence of second kinase, inositol 
diphosphoryl synthase (Ids1), in yeast that mimics the activity of InsP6 kinase (IP6K, in 
mammals) has been observed in kcs1ddp1 double knockouts. Ids1 has been reported to 
be more actively involved in the synthesis of InsP7 than PP-InsP4, although a small amount 
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of the latter was observed with ipk1kcs1ddp1 mutant cells (York et al., 2005). 
However, there is a possibility that Ids1 protein does not exist at all and the effect seen are 
as a result of Arg82 activity. Arg82 have been reported to act as InsP6 kinase under 
extreme conditions to generate InsP7 (Zhang et al., 2001). The kinase responsible for the 
conversion of InsP7 to InsP8 has been identified to be PPIP5K (PP-IP5 kinases), IP7K and 
Vip1 respectively in mammals and yeast (Mulugu et al., 2007). Vip1 has also been 
reported to aid in the addition of pyrophosphates to the 1/3-hydroxyl group of InsP6, to 
yield 1/3-InsP7 (Wilson et al., 2013) (Fig. 1.2.1). 
The catabolism of the IDPs in vitro can be achieved by dephosphorylation or by reversing 
reaction of the kinases through the action of multiple inositol polyphosphate phosphatase 
(MIPP). InsP5 and InsP6 are the preferred substrates in vivo for MIPP (Craxton et al., 
1997). A direct non-enzymatical phosphorylation action on proteins in the presence of 
Mg
2+
 has been proposed for high energetic pyrophosphates such as InsP7. Nsr1p, a protein 
that has a role in ribosomal assembly and export, and Srp40p, that acts as a ribosomal 
chaperone are the two proteins identified to be phosphorylated in an acidic serine rich 
region (Saiardi et al., 2004). The enzymes accountable for the dephosphorylation of the 
IDPs in vivo are the diphosphoinositol polyphosphate phosphohydrolases (DIPPs). These 
enzymes which exhibit a high affinity for InsP7 and InsP8, possess a nudix motif and are 
capable of metabolising nucleoside polyphosphates (Leslie et al., 2002; Safrany, Caffrey, 
et al., 1999). The DIPPs will be described in more detail later in this chapter (Section 1.2).  
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Figure 1.1.2  Pathways for production of inositol polyphosphates and IDPs in yeast. The route of IDPs synthesis is through sequential 
phosphorylation of PtdIns(4,5)P2. Enzymes catalysing each step are indicated in red. P represents a single phosphate group (PO3
2-
); R and R′ 
indicates fatty acid chains. Adapted from Wilson et al., (2013). 
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1.1.4 Biological significance of IDPs 
IPs are implicated in a range of cellular processes but their specific roles in such processes 
are not clearly defined. The uncertainty of specific roles of IPs could be due to their highly 
polar nature and their structural similarity. The rapid turnover of the IDPs and the presence 
of highly energetic pyrophosphate bonds in their structure suggest that they must have 
defined dynamic cellular function with potential molecular switch activity (Wilson et al., 
2013). With a portion of research being carried out in this area, it is now evident that all the 
IDPs have a specific role to play in the biological system. Use of yeast mutants lacking 
specific enzymes necessary for the formation of relevant IDPs and following reverse 
metabolism reactions of such IPs has contributed to understanding the fate of these 
molecules in the system.  
1.1.4a IDPs in endocytosis 
The complications in identifying the clear role of IPs are evident with its proposed role in 
endocytic membrane trafficking. InsP6 was primarily shown to bind to clathrin-associated 
proteins such as AP3 and AP180 to regulate endocytic trafficking (Norris et al., 1995). 
Later, InsP7 (0.58 nM) and PP-InsP4 (1.1 nM) were shown to compete with high affinity 
and specificity to bind to these assembly proteins than InsP6 (1.7 nM) (Saiardi et al., 2002). 
Further investigation reported a role for PIP2 in membrane trafficking (Itoh et al., 2001). 
Epsin N-terminal homology domain containing proteins involved in endocytic machinery 
was proposed to efficiently bind to PIP2 than InsP7 and InsP8. However, phenotypic studies 
revealed accumulation of membranous structures in yeast mutants arg82, ipk1, kcs1 
and ipk1/kcs1 double knockouts. Dye-labelling and electron microscopic studies 
identified these structures to be endocytic vesicles and reported that endocytosis was 
inhibited in the mutants. Abnormal vesicular morphology observed particularly in double 
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knockout mutants lacking IDPs (InsP7 and InsP8) in their study is noteworthy. Although 
both InsP7 and InsP8 mutants had the same phenotype, the levels of PIP2 was found 
considerably increased in the arg82 and decreased in kcs1, thereby confirming the 
proposed role of InsP7 and/or InsP8 and not PIP2 in endocytosis (Saiardi et al., 2002).  
1.1.4b IDPs role in Akt signalling, insulin regulation and weight gain 
Akt signalling regulates glucose homeostasis and protein translation through the GSK3β 
and mTOR signalling pathways, respectively (Chakraborty et al., 2010). These signalling 
pathways are not only implicated in several cancers but also in diet-induced obesity (Wang 
et al., 2009). InsP7, by binding to Pleckstrin Homology domains of Akt, prevents its 
phosphorylation and expression of 3-phosphoinositide-dependent kinase-1 (PDK-1) both in 
vitro and in vivo, and thus results in inhibition of Akt signalling. The knockout mice 
lacking the enzyme that synthesizes InsP7 was reported to show insulin sensitivity and 
resistance to obesity caused by high fat diet or aging (Chakraborty et al., 2010).  Mouse 
knock-out models (male) lacking IP6K1 form showed infertility, defects in spermiogenesis 
and reduced serum insulin levels, whereas IP6K2 (human homologue of yeast Kcs1) form 
showed no fertility issues and displayed normal insulin levels (Bhandari et al., 2008; 
Morrison et al., 2001).   
1.1.4c IDPs role in cell growth, environmental stress response and implications in 
cancer 
1-InsP7, a pyrophosphorylated product of InsP6 by Vip1, synthesized in yeast during 
phosphate starvation conditions, is found bound to Pho80-Pho85 (Cyclin-dependent 
kinases, CDKs) leading to activation of phosphate-scavenging genes (Lee et al., 2007). 
Both 1 and 5 forms of InsP7 are reported to act together to regulate class I Histone 
deacetylases (HDAC) and therefore several stress-related gene expressions (Worley et al., 
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2013). In yeast, this means activation of phosphate starvation pathway and the 
environmental stress response (ESR) by 1-InsP7, and downregulation of glycolysis while 
activating the ESR by 5-InsP7. This study also concluded that the IDPs act in parallel with 
the known coregulator of transcription in eukaryotes, transducer of regulated CREB 
activity 1(TORC1), to control Rpd3L HDAC complex (Worley et al., 2013). 
Findings of Worley et al. (2013) study have important implication for cancer research. 
Studies on human cells report that IP6K2 (Kcs1 in yeast), is crucial for the initiation of 
apoptosis during stress conditions and is found missing in few squamous cell cancers 
(Morrison et al., 2001; Morrison et al., 2009; Nagata et al., 2005). According to another 
study, cells that lacked IDPs failed to activate apoptosis or pro-apoptotic genes and rather 
faultily induced a number of cell cycle arrest genes during stress (Koldobskiy et al., 2010). 
The finding that IDPs are required for activation of HDAC explains why cells suffer cell-
cycle-arrest before they undergo apoptosis. HDAC1 (homologue of Rpd3L) needs to work 
with p53 to downregulate the cell-cycle-arrest genes during stress (Lagger et al., 2003). 
Thus it is possible that activation of HDAC1 by IDPs may push cancer cells to undergo 
apoptosis and not cell cycle arrest during an external stress such as chemotherapy. 
However, HDAC inhibition is stated to be necessary for the upregulation of p21, which 
induces cell cycle arrest or apoptosis (Ocker and Schneider-Stock, 2007).     
IP6K2 is found situated in the 3p21 chromosomal region that is prone to allelic lose and 
are spotted in various human cancers. Also, IP6K2 is found situated close to tumour 
suppressor genes such as NPRL2, FUS1, RASSF1A, SEMA3B and SEMA3F (Shames and 
Minna, 2008; Zabarovsky et al., 2002). It is possible that a copy of the gene is lost along 
with the other suppressor genes in human cancers. Although IP6K2 might eventually turn 
out to be a tumour suppressor, there is no direct evidence to prove this. 
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1.1.4d Chromatin remodelling 
Gene expression in eukaryotes is regulated by chromatin-remodeling. The effect of InsP6 
on adenosine triphosphate (ATP)-dependent chromatin-remodeling has been examined in 
vitro. In this investigation InsP6 was shown to inhibit nucleosome mobilization by NURF, 
ISW2 and INO80 remodelling protein complexes. The inhibition appeared to happen via 
modulation of ATPase activity of the complexes. Controls used in the experiments such as 
InsS6, InsP3, InsP4, EDTA and EGTA failed to show such an effect. However, a slight 
inhibition was noted with InsP5. Nucleosome mobilization by the yeast complex SWI/SNF 
was shown to be stimulated by Ins(1,4,5,6)P4 and InsP5 but not by Ins(1,3,4,5)P4 and InsP6. 
These events did not appear to be due to ATPase activity of the protein complex. These 
complexes control the expression of ino1 which is involved in the production of inositol-1-
phosphate synthase protein. Northern analysis of mRNA for ino1 in yeast showed absence 
of ino1 mRNA in plc and arg82 but showed decreased levels (41% reduction) in the 
ipk1 strains. This suggests a role for InsP4, InsP5, InsP6 and IDPs (particularly InsP7 and 
InsP8, with some rescue from PP-InsP4) for the reduced mRNA levels in ipk1 in 
transcription in vivo (Shen et al., 2003). This data was in accordance with investigation on 
the induction of pho5, a gene that is induced by phosphate starvation, in yeast knockouts 
lacking arg82, hence InsP4-InsP8. The study showed the inability of arg82 strains to 
recruit SWI/SNF and INO80 complexes to pho5 promoter region for chromatin 
remodelling and related gene transcription (Steger et al., 2003). Both the reports mentioned 
here support the role of IPs in chromatin remodelling and the importance of relative 
levels/ratios of InsP4, InsP5 and InsP6 in these processes.   
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1.1.5 Roles of IDPs in DNA repair 
DNA damage can trigger variety of responses, of which DNA repair is a crucial one. 
Careful repair of the damaged DNA is essential for the upkeep of genomic stability and 
integrity. Errors in the repair process may result in genetic alterations and subsequent 
induction of cancer and other genetic diseases. Although there are numerous DNA repair 
pathways, this study will focus on the following three well-characterized pathways: non-
homologous DNA end-joining (NHEJ), homologous recombination (HR) and base 
excision repair (BER). HR has been reported to accurately repair double-strand DNA 
breaks (DSDBs) without loss of genetic information, whereas NHEJ can be potentially 
mutagenic (Lieber et al., 2003).  
1.1.5a NHEJ 
In mammals, DSDBs are mended through NHEJ, a process that involves recognition of 
damage and binding of Ku70/80 protein to the broken ends. This binding is followed by 
recruitment of DNA-PKCS (DNA-dependent protein kinase catalytic subunit), a 
serine/threonine kinase whose precise substrate is unknown. The binding of Ku and DNA-
PKCS to DNA results in DNA-PK holoenzyme which helps in protecting DNA ends from 
nuclease attacks. This large complex also recruits DNA ligase IV heterodimer and prepares 
the damaged DNA ends for repair. Besides the above mentioned factors, a ‘stimulatory 
factor’ such as InsP6 was reported to be necessary for the formation of the complex and 
efficient end-joining (Hanakahi et al., 2000). This action was not restricted to InsP6 as it 
was found that InsP4 and InsP5 were also capable of stimulating end-joining, though to a 
less extent and InsS6 was found inactive. However, the possibility that the DNA repair may 
actually have been due to InsP7 or InsP8 was not completely ignored as the reactions could 
have been contaminated with IP6K (Kcs1) (Hanakahi et al., 2000). InsP6 was subsequently 
shown to directly bind Ku70 and this apparently increased the recruitment of DNA-PKCS 
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(Hanakahi and West, 2002; Ma and Lieber, 2002). However, this was not the case with S. 
cerevisiae homologue yKu70 (Hanakahi and West, 2002). The recombinant Ku70 used for 
this experiment is unlikely to have InsP6 kinase activity associated with it, but it is equally 
possible that the commercial InsP6 has InsP7 or InsP8 in it. 
1.1.5b HR 
In the eukaryote yeast, DSDBs are thought to be predominantly repaired through high-
fidelity HR mediated by the Rad52 epistasis group (Ozenberger and Roeder, 1991). The 
key DNA intermediates or stages in the HR process include (a) resection, where the 5′-
ends of the break are chopped off, (b) strand invasion, where the overhanging 3′ single-
stranded (ss) tail makes contact with an identical DNA by pairing complimentarily with the 
unbroken strand, and (c) Holliday junctions, where the ligation of broken strands forms a 
loop which further is cleaved and annealed to result in non-crossover products. Rad52 is a 
prerequisite for the efficient HR in yeast (Bai and Symington, 1996) and is often 
considered a genetic marker to define this process (Lisby et al., 2001). Though its structure 
and properties are conserved from yeast to humans (Sung et al., 2000), studies suggest a 
possibility of an alternative Rad52-independent repair pathway in higher eukaryotes 
(Yamaguchi-Iwai et al., 1998). The importance of Rad52 in HR process has been attributed 
to its ability to look for and facilitate annealing of homologous DNA strands. Also, 
efficient strand exchange process in vitro was observed only when Rad52 offered a bridge 
between ss-DNA binding replication protein complex and the Rad51 recombinase (Lisby 
et al., 2001). 
In yeast, green fluorescent protein (GFP) –tagged Rad52, followed by DSDBs, showed 
relocalization from a diffused nuclear distribution state to formation of distinct foci at the 
region of genomic insult. These foci represent the sites of active DNA repair in vivo. 
Interestingly, the Rad52 were found forming DNA repair and recombination centres solely 
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during S phase of mitotic cells (Lisby et al., 2001). Such coupling of repair process to S 
phase can be beneficial to cells as the DSDBs formed can be automatically spotted during 
the replication process and repaired through checkpoints before moving to G2/M phase.    
Reports suggest that IDPs such as InsP7 and InsP8 are required for hyper-recombination 
events in yeast lacking protein kinase C (Huang and Symington, 1995; Luo et al., 2002). A 
recent study regarded IDPs to be novel regulators of HR signalling in mammals (Jadav et 
al., 2013). In this study, cells lacking IP6K1 showed decreased viability and reduced 
recovery following treatment with hydroxyurea, a replication stress inducer, or 
neocarzinostatin, a radiomimetic antibiotic. Although HR-mediated repair was initiated in 
these cells, an efficient repair of damaged DNA failed to occur. As a result, IP6K1 mutant 
cells underwent death while some survived with build-up of chromosomal aberrations.  
Reports also suggest that DSDB recognition in yeast is mainly performed by Mec1 and 
Tel1 [S. cerevisiae homologue of mammalian ataxia telangiectasia and Rad3-related 
protein (ATR) and Ataxia telangiectasia mutated (ATM), respectively] (Craven et al., 
2002). Once stimulated, these sensors allegedly initiate a phosphorylation cascade that in 
turn activates Rad53. IDPs are reported to downregulate Tel1, which apart from playing a 
role in DSDBs response, also regulate telomere length in yeast (York et al., 2005). IDP 
such as PP-InsP4, but not InsP7 or InsP8, has been identified to regulate telomere length in 
yeast. Also, loss or gain of function of kcs1 was found to result in either shortened or 
elongated telomeres. These examples suggest that IDPs play a crucial role in telomere 
length (York et al., 2005) and thus, serve a protective role against DNA damage and/or 
involvement in cellular senescence. 
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1.1.6 Examples for DNA damage induced repair    
Many of the commonly used chemotherapeutic cytotoxic compounds or ionising radiations 
(IR) cause high levels of DNA damage, that activate cell cycle checkpoints, leading to cell 
cycle arrest and/or cell death (Swift and Golsteyn, 2014). DSDBs, which are considered as 
the most fatal form of DNA damage, can be caused by agents such as radiomimetic 
chemicals (bleomycin and neocarzinostatin), antimetabolites 5-fluorouracil (5FU), IR, 
topoisomerase inhibitors (camptothecin), and chemicals that generate reactive oxygen 
species (Mahaney et al., 2009; Swift and Golsteyn, 2014). However, innate or acquired 
resistance of tumours to some of these chemotherapeutics, e.g. 5FU (Jette et al., 2008) and 
bleomycin (Ramotar and Wang, 2003), have caused therapeutic failures. DNA repair 
following chemotherapy insult is often associated with such tumour resistance. The 
understanding of how the cells respond to the DNA damage causing agents and/or manage 
to repair the lethal lesions becomes the key to increasing the efficacy of the anticancer 
agents. In this study, the focus will be on understanding of mechanism of action of two 
anticancer treatments: 5FU (Fig. 1.1.3) and bleomycin (Fig. 1.1.4). The contribution of the 
activated repair pathways to these agents’ resistance are also discussed herein. 
 
 
Figure 1.1.3 Structure of antimetabolite 5FU 
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Figure 1.1.4  Structure of anticancer drug bleomycin. Adapted from (Ramotar and 
Wang, 2003) 
1.1.6a 5FU-induced DNA damage 
5FU is one of the widely used antimetabolite drug for treating malignancies including 
colorectal, breast, stomach, pancreatic, oesophageal and head and neck cancers. 5FU has 
been reported to work both by inhibiting vital biosynthesis processes and by integrating 
themselves into DNA and RNA, and preventing normal function. Evidence suggests a 
more complex mechanism for 5FU involving pyrimidine nucleotide balances, DNA repair 
processes and disruption in RNA metabolism (Longley et al., 2003; Seiple et al., 2006).  
Intracellular enzymatic conversion of 5FU results in active metabolites: 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) 
and fluorouridine triphosphate (FUTP). The mechanism of 5FU involves inhibition of 
thymidylate synthase (TS) covalently by the active metabolite FdUMP. TS is a vital 
enzyme needed for the catalysis of deoxythymidine monophosphate (dTMP) from 
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deoxyuridine monophosphate (dUMP) (Fig. 1.1.5) (Santi et al., 1987). The binding of 
FdUMP to TS, blocks the access of dUMP to nucleotide binding site and inhibits synthesis 
of dTMP and subsequent deoxythymidine triphosphate (dTTP). Depletion of dTTP through 
various feedback mechanisms is reported to influence and disrupt the normal levels of 
dATP, dGTP and dCTP (Longley et al., 2003). The imbalances particularly dATP/dTTP 
ratio is believed to interrupt DNA synthesis and repair and, result in fatal DNA damage 
(Houghton et al., 1995). Additionally, TS inhibition and depletion of dTMP levels results 
in the accumulation of dUMP and subsequent deoxyuridine triphosphate (dUTP), which 
can be misincorporated into DNA. In S. cerevisiae the processing of such DNA requires 
base excision repair (BER) pathway to step in and remove the uracil from the DNA.  
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Figure 1.1.5  5FU toxicity and damage to RNA and DNA.  5FU is believed to interfere 
with nucleic acid structure and function by directly incorporating fluoronucleotides into 
DNA and RNA, and through inhibition of thymidylate synthase by the active metabolite 
generated by 5FU, which leads to imbalance in the nucleotide pool. Adapted from Seiple et 
al. (2006). 
 
BER pathway begins with the excision of the uracil base from the DNA by the enzyme 
uracil-DNA glycosylase (UDG) (Ung1 in yeast) and creating an abasic site or 
apurinic/apyrimidinic (AP)-site. This is followed by cleavage of the DNA backbone at the 
abasic site by AP endonuclease enzyme (APE) (Apn1 or Apn2 in yeast). Further, Flap 
endonuclease, a DNA polymerase and DNA ligase (RAD27p, Polβ and cdc9p, respectively 
in yeast) insert the correct base in the nicked DNA and complete the repair process (Fig. 
1.1.6). However, increase in the levels of dUTP by 5FU could elevate the probability of 
deoxyuridine being incorporated into DNA again (Fig. 1.1.6). Studies suggest that such 
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repeated cycles of uracil BER and incorporation of deoxyuridine results in permanent 
damage to DNA, replication fork failure and cell cycle arrest (Hoskins and Scott Butler, 
2007; Ladner, 2001; Seiple et al., 2006).  
 
Figure 1.1.6  Uracil BER mediated 5FU toxicity. Attempts to remove misincorporated 
uracil by BER may result in lethal intermediates along this pathway. Possible intermediates 
in this process (clockwise) are the mutagenic 5FU base itself, AP-site containing strand 
(abasic DNA) generated as a result of Ung1 activity. Adapted from Seiple et al. (2006)
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The importance of the mechanism involving 5FU induced-cytotoxicity was highlighted in 
experiments using yeast. According to this study, ung1 showed significant protection 
against 5FU whereas deletion of the major gene, apn1, encoding for AP endonuclease 
increased the sensitivity of the yeast cells to 5FU (Seiple et al., 2006). Such results suggest 
that the intact-abasic intermediate created during the repair pathway, if not processed by a 
BER mechanism, can lead to inherent toxicity. Several backup pathways have been 
proposed to repair the abasic and 5′dRP groups in the absence of Apn1. Pathways 
involving Apn2 and other BER enzymes such as AP lyase are reported to account for 
efficient removal of abasic sites and successful repair in Apn1 mutant strains of yeast 
(Seiple et al., 2006). 
The reaction pathway involving production of dTMP from dUMP provides the single de 
novo source of thymidine precursors which is necessary for DNA synthesis and repair. 
Both of these processes are severely disrupted due to thymidine starvation (raise of dUTP 
that overwhelms dUTPase) and misincorporation of uracil in DNA (raise in nucleotide 
pool imbalance) following 5FU insult and therefore result in what is commonly referred to 
as ‘thymine-less death’ (Ladner, 2001; Longley et al., 2003). 
5FU induced disruption of RNA synthesis by FUTP is a less understood mechanism (Fig. 
1.1.5). Unlike thymidine-based 5FU toxicity in DNA, toxicity in RNA has been found to 
be induced by uridine. Cytotoxicity due to misincorporated 5FU into RNA has also been 
reported. The proposed effects of 5FU on RNA include mRNA splicing blockage, 
polyadenylation, base modification in ribosomal-RNA, small nuclear-RNA, and transfer-
RNA, ribosomal-RNA processing and, self-splicing of group I introns. However, 
contribution of these effects to the cytotoxicity of 5FU remain unclear (Hoskins and Scott 
Butler, 2007).    
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1.1.6b Bleomycin-induced DNA damage 
Radiomimetic drugs and IR are two of the anticancer treatments that induces tumour 
killing via DNA strand breaks. Bleomycin, a radiomimetic glycopeptide antibiotic, is used 
in the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer and 
cancers of head and neck. Bleomycin is less heavily used, and often causes impaired lung 
functions as a result of lipid peroxidation (Ramotar and Wang, 2003).  Bleomycin is 
believed to induce DNA damage similar to that of IR but different to 5FU. IR generates 
numerous types of damaged bases, abasic sites and other fragmentary products in addition 
to ss-breaks with 3′-phosphoglycolate (3′-PG) esters (Fung and Demple, 2011). However, 
bleomycin causes much more restricted lesions such as 4′-oxidised abasic sites and direct 
strand breaks resulting in 3′-PG adducts and, 5′-abasic ends (Fig. 1.1.7). The ss- breaks 
produced initially may further affect the opposite strands leading to DSDBs directly or 
through incision by DNA repair enzymes (Fung and Demple, 2011).  
Bleomycin is reported to generate DNA base loss and cause ss- and ds- DNA damage in 
the presence of Fe(II) and oxygen (Chen and Stubbe, 2005). Extraction of a hydrogen 
molecule from the deoxyribose and formation of a free radical is believed to enable 
Bleomycin-Fe(II)-O2 complex to break the DNA molecule (Lim et al., 1995). This 
complex is also reported to cleave yeast tRNA
Phe
, signifying that bleomycin oxidises RNA 
and as well as DNA (Huttenhofer et al., 1992). Furthermore, the redox status of a given 
cell type is stated to influence the kind of lesions that bleomycin generates. Under low 
oxygen levels, bleomycin forms primarily AP-sites while in the presence of oxygen, it 
produces largely DNA strand breaks (Fig. 1.1.7) (Ramotar and Wang, 2003).  
Removal of the 3′-PG adduct requires APE1 enzyme in mammals whereas it requires 
Apn1, Apn2, Mdt1 or tyrosyl-DNA phosphodiesterase (Tdp1) in yeast. Mdt1 mutants are 
reported to be sensitive to bleomycin, while single apn1, apn2 and tdp1 mutants are not 
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sensitive requiring the triple apn1apn2tdp1 knockout to confer sensitivity (Liu et al., 
2004). Whether it is the repair of the oxidised abasic site or the removal of unsaturated 
abasic residues generated by AP lyase activity, it requires APE1. Moreover, APE1 is also 
involved in the conversion of the 3′-PG (at oxidative breaks) to 3′-OH prior to gap 
filling/ligation process of DNA repair (Fung and Demple, 2011).  
 
 
Figure 1.1.7  Bleomycin-induced DNA damage. The types of lesions induced by 
bleomycin are dependent on the oxygenation conditions. In the presence of oxygen, 
bleomycin produces primarily DSDB, such as 3′-PG, whereas in the absence of oxygen, 
bleomycin generates largely an oxidised AP-site. Adapted from Ramotar and Wang 
(2003). 
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Reports suggest that APE1 deficient cells are more sensitive to bleomycin than to IR. 
APE1 knockdown in TK6 lymphoblastoid cells and HCT116 colorectal cancer cells was 
found to make them sensitive, more greatly towards bleomycin than to IR (Fung and 
Demple, 2011). An explanation for this could be that: APE1 exhibits opposing effects in 
IR-induced cytotoxicity, one involving increased tumour killing through de novo DSDB 
formation (dual cutting of closely opposed AP-sites) and the other a protective role 
involving removal of 3′-PG containing AP-site. Removal of 3′-PG by bleomycin is thought 
to be a rate limiting step in the repair process. The 3′-PG diesterase activity of APE1 is 
proposed to be 100-fold slower than it’s nicking of AP-site or C4′-oxidised residues in 
mammals (Xu et al., 1998). Such narrower role of APE1 in repair of bleomycin-induced 
damage explains the high sensitivity of the cells and build-up of unrepaired DSDBs in 
APE1 deficient cells. In the absence of APE1, other enzymes that are capable of cleaving 
3′-PG at DSDB lesions include polynucleotide kinase (removes 3′-P using ATP as a 
cofactor) (Xu et al., 1998), Tdp1 (Zhou et al., 2009) and Artemis (Povirk et al., 2007).  
In yeast, the repair of DNA lesions is not just restricted to enzymes that cleave AP-sites or 
3′-PG groups but also involves Rad52 and Rad6 proteins, which represent the 
recombination and post-replication DNA-repair pathways, respectively (Ramotar and 
Wang, 2003). Ku, an important member of NHEJ pathway, has been reported to participate 
in the repair of bleomycin-induced damage mostly via telomere-specific 
functions/”chromosome healing” rather than NHEJ-dependent functions in yeast (Tam et 
al., 2007). Furthermore, phleomycin (selective antibiotic of the bleomycin family) has 
been shown to activate Mec1-induced direct phosphorylation of Ser129 of histone H2A 
similar to methyl methane sulfonate (MMS). Failure to phosphorylate H2A has been found 
to attribute to hypersensitivity of cells to both phleomycin and MMS (Downs et al., 2000). 
A more recent study suggested that increased translocation of HR proteins, Rad51 and 
Rad52, to short telomeres and not to single cut sites elicits a Mec1-dependent 
25 
 
hypersensitivity to bleomycin in telomerase deficient cells. This presents a potential 
mechanistic basis for the reduced DSDB processing in organisms with defective telomeres 
( Lin et al., 2009). 
1.1.7 BER pathway 
Most of the complex ds-DNA damages are repaired by NHEJ and HR mechanisms (Lieber, 
2010), whereas the majority of small lesions such as deamination of cytosine residues to 
uracil, single oxidised base, AP-sites and ss- breaks are repaired primarily by BER 
pathways (Fung and Demple, 2011). BER pathway, comprising of multiple repair 
enzymes, is an evolutionarily conserved pathway (Kim and Wilson, 2012). Regardless of 
any differences in the BER theme, the core pathway shares a set of common components 
and usually initiates five distinct enzymatic steps: (i) recognition and excision of 
incorrect/damaged base by DNA glycosylases to generate an abasic or AP-site 
intermediate, (ii) AP-site incision by an APE enzyme or AP-lyase, (iii) removal of 
fragmented sugar residues by a lyase or phosphodiesterase, (iv) correct base incorporation 
by a DNA polymerase and, (v) sealing the repaired ends by a DNA ligase. Defects in any 
of these BER components leads to increased mutations, reduced cell viability, and 
hypersensitivity to DNA-damaging agents (Kim and Wilson, 2012). Moreover, the 
pathway is stated to play a vital role in identifying cellular responses to relevant anticancer 
agents, such as nucleoside analogues (e.g. 5FU), alkylating agents (e.g. temozolomide) and 
IR (Kim and Wilson, 2012).  In this study I will deal with only the initial two key enzymes 
of BER pathway i.e., DNA glycosylases (UDG specifically) and APE that are involved in 
the repair of 5FU- and bleomycin-induced damage.    
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1.1.7a UDG 
A search for the mechanism underlying the repair of uracil in E. coli DNA led to the 
discovery of UDG and thereby the discovery of the BER pathway (Lindahl, 1974). The 
first step in BER is typically UDG catalysing the cleavage of the N-glycosidic bond 
between the 2′-deoxyribose and the substrate base to generate an AP-site (Kim and Wilson, 
2012). Ung1 (coded by ung1 gene) which is part of the UDG family is found to be highly 
conserved in herpes viruses, bacteria, yeast and human (Olsen et al., 1989). An amino-acid 
sequence similarity of 40.3% was observed for UDG/Ung1 in humans and yeast (Krokan et 
al., 1997). However, mammalian cells have been found to contain several additional 
glycosylases, such as thymine DNA glycosylase (TDG), single-strand-specific 
monofunctional uracil DNA glycosylases-1 (SMUG1), 8-oxoG DNA glycosylases 
(OGG1), methyl-CpG binding domain, 3-methyl-purine glycosylase and endonuclease 
VIII-like (Nei-like or NEIL), which are capable of excising the damaged DNA (Jacobs and 
Schar, 2012). In eukaryotes, Xeroderma pigmentosum, complementation group C (XPC) 
homologue in yeast, RAD4, has been reported to play UDG-like role in cells i.e., 
recognising structurally diverse DNA lesions (Sugasawa and Hanaoka, 2007).  
In yeast, the Ung1 protein-coding gene (approximately 40 kDa) is found located on 
chromosome 13 (SGDatabase). The gene encodes for notably two isoforms; mitochondrial 
Ung1 and nuclear Ung2 in both human and yeast. Although the two isoforms have a 
common catalytic domain, they differ in their N-terminal sequences (Krokan et al., 2002) 
and hence the difference in their locations. Ung1 are highly selective to uracil and their 
removal from U:G mismatches are considered to be faster than removal from U:A, 
although the preference is dependent on the DNA sequence around the particular mismatch 
(Slupphaug et al., 1995). Ung2, besides repairing U:G mismatch in nucleoplasm of the 
cell, are also reported to interact with proliferation cell nuclear antigen and trimeric 
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replication factor A to induce long patch BER as well as replication (Otterlei et al., 1999). 
In the absence of Ung, back-up repair mechanisms are reported to be activated among 
which SMUG1 may have a leading role (Nilsen et al., 2000). 
AP-site 
AP-sites are the intermediates formed during the course of BER and can also be generated 
spontaneously as a result of hydrolytic cleavage of N-glycosidic bonds (Khodyreva et al., 
2010). Following excision and release of substrate base, DNA glycosylases were reported 
to bind to AP-site with high affinity (Waters et al., 1999). Thus, separation of these two 
units is considered to be rate limiting step in the BER process. Since AP-site is an unstable 
intermediate, the binding of the glycosylases is thought to help protect cells from their 
toxic and mutagenic effects (Jacobs and Schar, 2012). Further, release of glycosylases is 
coordinated with the entry of downstream acting BER enzyme such as APE1. APE1 has 
been reported to stimulate the turnover rate of Ung2, TDG and OGG1, and similar effect 
was also seen with the XPC protein on TDG and SMUG1 (Jacobs and Schar, 2012; 
Shimizu et al., 2010). 
Dissociation of glycosylases from AP-site can also be regulated by means of 
posttranslational modification including conformational changes to the enzyme bound to 
the DNA. Increased ability to dissociate from AP-site and associate with replicating 
chromatin was observed when Ung2 were cell cycle specifically phosphorylated at serine-
23. Such modifications apparently enables efficient repair of the misplaced uracil during 
ongoing DNA replication (Hagen et al., 2008). 
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1.1.7b APE 
The resulting AP-site from the DNA glycosylase activity is incised by a highly conserved 
repair enzyme, APE (Wang et al., 2014). The Exo III family of APE comprises of two 
isoforms APE1 and APE2, which have homologues in several organisms including S. 
cerevesiae (Daley et al., 2010). APE1, an essential enzyme, performs key functions such as 
DNA/RNA repair and transcriptional regulation activities. APE2 has been recently 
reported to play a role in ATR-Chk1 checkpoint activation caused by oxidative stress 
(Wang et al., 2014; Willis et al., 2013).  
The yeast Apn1 protein-coding gene (41.4kDa), a homologue of APE1, is found located at 
chromosome 11 followed by rad27 gene (Dyakonova et al., 2012). Apn1, unlike APE1, 
does not regulate any essential function under normal growth settings (Popoff et al., 1990). 
In DNA repair, APE1 cleaves the phosphodiester bond between 5′-phosphate of the AP-
site and the preceding nucleotide, leaving a 5′-deoxyribose phosphate (5′dRP) moiety and a 
free 3′-hydroxyl group at the end. Polymerase β (polβ) hydrolyses 5′-dRP and fills in the 
single nucleotide gap, which is followed by subsequent sealing of the nick using DNA 
ligase III-XRCC1 (X-ray repair cross-complementing protein 1) complex.  
In addition to the above, APE1 possess three distinct functions: (a) 3′-phosphodiesterase 
activity, to clean-up the DNA lesions with 3′ blocked termini such as 3′-phosphoglycolate 
(3′-PG) and 3′-phosphate, (b) non-specific 3′-5′ exonuclease activity, which may serve as 
an autonomous proof-reading function during synthesis step of BER to prevent 
misincorporation of damaged/mismatched nucleotides by DNA polymerases, and (c) 
nucleotide incision repair activity that removes the oxidised DNA bases by creating a nick 
containing 3′-OH group and 5′-base residue (Wang et al., 2014). Thus, APE1 is capable of 
repairing diverse DNA lesions.  
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APE1 is believed to exploit a common active site mechanism involving amino-acid 
residues Glu96, Asp210 and His309 to coordinate Mg
2+
 binding and catalyse breakdown of 
the phosphodiester bond (Mol et al., 2000; Wang et al., 2014). Glu96 and Asp210 are also 
considered to be crucial for APE1 reactions. Double mutation of these residues is reported 
to slow down the dissociation of APE1 from AP-site, while eliminating AP-site incision 
activity (McNeill and Wilson, 2007). Furthermore, the mutants were observed to exhibit 
increased sensitivity and accumulation of fatal AP-site damage with MMS treatment, 
whereas they failed to show sensitivity to bleomycin. In contrast, downregulation of APE1 
level has been shown to increase cellular sensitivity to MMS and bleomycin (Fung and 
Demple, 2011). APE1 depleted cells have also shown to accumulate high levels of AP-
sites, which when left unrepaired can threaten to be mutagenic and can induce apoptosis 
(Fung and Demple, 2005). He et al. (2001) reported A549 lung epithelial cells expressing 
Apn1 to exhibit significantly reduced DNA damage even in the presence 100 µg/ml of 
bleomycin.   
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1.2 Diphosphoinositol polyphosphate phosphohydrolases (DIPPs) 
1.2.1 Introduction to DIPPs 
The implication of IDPs (1-InsP7, 5-InsP7 and InsP8) in crucial processes such as cell 
signalling and metabolic homeostasis has drawn particular attention to these high-energy 
signalling molecules lately. Understanding metabolic regulation of IDPs turnover appears 
essential to unveil how this signalling cascade is controlled. In fact, no metabolic pathway 
can claim to  be complete or meaningful without the knowledge of the kinetic parameters 
of the participating enzymes (Rohwer, 2012). However, modelling of IDPs metabolism is 
complicated by there being two parallel kinase pathways from InsP6 to InsP8 (named I and 
II in (Padmanabhan et al., 2009); Fig. 1.2.1), and by diphosphoinositol polyphosphate 
phosphohydrolases (DIPPs). A further confounding factor is that humans express five 
DIPP isoforms: type 1 (DIPP-1), types 2α/2β (DIPP-2α/DIPP-2β)  and types 3α/3β (DIPP-
3α/DIPP-3β)  (Caffrey et al., 2000; Hidaka et al., 2002; Leslie et al., 2002; Safrany et al., 
1998). However, Saccharomyces cerevisiae expresses only one: the diadenosine and 
diphosphoinositol phosphohydrolase (Ddp1). 
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Figure 1.2.1  Metabolic interconversions of InsP6, InsP7 and InsP8. Diphosphoinositol 
polyphosphate phosphohydrolases represented as DIPP (Ddp1 in yeast); Inositol 
hexakisphosphate kinase represented as IP6K (Kcs1 in yeast); Diphosphoinositol 
pentakisphosphate kinase represented as PPIP5K (Vip1 in yeast). Pathways I and II are 
named as in Padmanabhan et al. (2009). 
 
The DIPP that dephosphorylate IDPs are as important as kinases to cell functions (Shears 
et al., 2013). DIPPs are held responsible for rapid turnover of IDPs inside cells and are also 
the reason why mammalian cells mostly show low steady-state concentration of these 
molecules (Menniti et al., 1993). Overall, the levels of InsP7 range between 1-5 µM 
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(Shears, 2004), of which mammalian cells are reported to have mostly 5-isomer form 
(Albert et al., 1997). In yeast and mammalian cells, the levels of PP-InsP4 and InsP8 are 
each recorded to be about 10-20% of those of InsP7 (Safrany, 2004; Safrany et al., 1998; 
Shears et al., 2013).  
1.2.2 DIPP isoforms 
1.2.2a DIPP-1  
The first DIPP form, DIPP-1 [also known as Nudix-type 3 (NUDT3)], that metabolises 
both InsP7 and InsP8 was purified, characterised and sequenced from rat liver by (Safrany 
et al., 1998). InsP6 is not a substrate of DIPP, but it is found to inhibit dephosphorylation 
of both InsP7 and InsP8. DIPP sequences of rat and human are reported to show 
considerable conservation. The human DIPP cDNA sequence greatly matched the regions 
of chromosome 6 and within the region is minimum four exons identified for the candidate 
gene.  The DIPP-1 form is found expressed largely in brain, heart, pancreas and liver, with 
some degree of expression in all the tissue type tested (Safrany et al., 1998). This study 
also found that physiologically relevant conditions such near neutral pH and Mg
2+
 
concentration of 1-2 mM, can add to optimal hydrolysis of IDPs by DIPP. Also, fluoride 
was found to potently inhibit of DIPP-1 activity on both InsP7 and InsP8. 
A site-directed mutagenisis study revealed the importance of several catalytically crucial 
residues in human DIPP-1 (Yang et al., 1999), namely (i) Glu66 and Glu70 within Nudix-
type (NudT) domain, (ii) the glycine repeat regions, GR1 and GR2, where GR1 consists of 
tripeptide (G50, G51 and G52) at the N-terminus of NudT catalytic motif, and glycine 
residues (G72, G75 and G82) within a consensus sequence, GX2GX6G at the C-terminus of 
the motif and (iii) His
91
 and Phe
84
 that are vital largely for InsP8 than InsP7 hydrolysis.  
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1.2.2b DIPP-2  
A 21 kDa human isoforms, DIPP-2α and DIPP-2β, with a 76% identity to DIPP-1 was 
characterized by Caffrey et al. (2000). The catalytically essential residues seen in DIPP-1 
along with the predicted secondary structure are conserved in DIPP-2α. DIPP-2 (also 
known as NUDT4) form is most highly expressed in heart compared to other tissues and 
the gene coding for it is located on chromosome 12 (Caffrey and Shears, 2001). The two 
isoforms of DIPP-2 differ from each other merely by DIPP-2β containing of an extra 
amino acid (Gln
86
) (Caffrey et al., 2000). Possible reasons that may contribute to the 
coexistence of the two isoforms are: nucleotide polymorphism in the gene or product of 
two different genes or variants produced as a result of alternative splice sites. DIPP-2β is 
considered less active than DIPP-2α against InsP7. Moreover, DIPP-2α is reported to hold 
high activity on InsP7, although it is considered less active than DIPP-1. Report by Caffrey 
et al. (2000) also suggests involvement of an array of alternative (canonical and non-
canonical) polyadenylation signals in the synthesis of multiple mRNAs for DIPP-2α. These 
messenger molecules have identical α and/or β open reading frames but differ in the length 
of the 3′-UTR region (Caffrey et al., 2000). The 5′-UTR region has high GC content (84%) 
and accommodates six CAG repeats. This feature of human DIPP-2 is considered unusual, 
as most of the eukaryotic transcription process involves only a single polyadenylation 
signal (Edwalds-Gilbert et al., 1997). Such feature also suggests that expression of these 
proteins is regulated by several molecular processes. 
1.2.2c DIPP-3 
The two 19 kDa DIPP isoforms, namely DIPP-3α and DIPP-3β, which exhibits 90% 
identity to DIPP-2 (residues 2-165) and 74% identity to DIPP-1 (residues 2-164) were 
characterised by (Hidaka et al., 2002). DIPP-3 has been shown to express in high levels in 
pancreas and heart (Leslie et al., 2002). The genes NudT10 encoding DIPP-3α and NudT11 
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encoding DIPP-3β are found just 152 kbp apart on chromosome X. Besides the 
resemblance in coding regions, the two DIPP-3 forms show high similarity in predicted 
intron/exon structure, aligned introns sequences and 5’-non-translated sequence, 
suggesting that the two genes encoding the isoforms might have arose as a result of gene 
duplication event. Such duplication event in human genome often emphasizes that the 
expressed protein serves some function and are not entirely redundant (Otto and Yong, 
2002). A 33-residue active site region, Nudix-type catalytic motif, found in DIPP-3α 
showed strong conservation with DIPP-1 and -2. The motif was found flanked on either 
side (N-terminal GGG tripeptide and C-terminal GX2GX6G sequence) by short Glycine-
rich sequences (Hidaka et al., 2002).  
The two isoforms of DIPP-3 was observed to differ from each other solely by DIPP-3β 
containing Arg-89 in the place of Pro-89 amino-acid, which is seen in the DIPP-3α form 
(Hidaka et al., 2002). This Arg residue, which is also conserved in DIPP-1 and -2 forms, 
serves a catalytic role (Yang et al., 1999) and thus makes DIPP-3β ~2-fold more active in 
vitro (Hidaka et al., 2002). The specificity constants (Kcat/Km) for hydrolysis of InsP7 by 
DIPP-3 was similar to that with DIPP-2β, however, it was 9-25-fold lower than the value 
for DIPP-1 (Safrany, Ingram, et al., 1999) and -2α (Caffrey et al., 2000). Previous work 
has shown the ability of DIPP family to metabolise diadenosine hexaphosphate (Ap6A), 
another Nudix substrate (Leslie et al., 2002; Safrany, Ingram, et al., 1999). However, 
kinetic study of DIPP-3 has found IDPs to be the more physiologically relevant substrate 
compared to less efficiently metabolised substrate, Ap6A (Hua et al., 2003). A decline of 
35% to 45% in the steady-state levels of InsP7 and InsP8 was observed with overexpression 
of either of the DIPP-3 forms (Hidaka et al., 2002). This was the first report to show 
altered expression of DIPP in intact cells to affect the IDP concentrations in vivo. Both 
DIPP-3 forms require an optimum alkaline pH in vitro and also demand for the presence of 
divalent cations such as Mn
2+
 over Mg
2+ 
for their activity (Leslie et al., 2002). Although 
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role of these cations in these reactions is not clear, it is possible that they are required to 
neutralise the negative charges carried by substrate’s phosphate groups or they may be 
directly involved in the catalytic act (Thomas and Potter, 2014).   
1.2.2d Ddp1 
The Ddp1 of S. cerevisiae, located on chromosome 15, encodes for a 21 kDa protein that 
hydrolyses IDPs and diadenosine polyphosphates (ApAs) (Cartwright and McLennan, 
1999; Safrany, Ingram, et al., 1999). Ddp1 is a member of MutT family of hydrolases 
which is conserved from yeast to humans (Cartwright and McLennan, 1999). Ddp1, as an 
IDP phosphatase hydrolyses InsP7 and InsP8 to InsP6 whereas, as an ApA phosphatase, it 
much readily dephosphorylates Ap6A and is also capable of dephosphorylating diadenosine 
pentaphosphate (Ap5A), adenosine pentaphosphate (p5A) and adenosine tetraphosphate 
(p4A). Ddp1p, which is considered as the yeast homologue of NUDT3 or DIPP-1 isoform 
of humans, has been found to have control over the evolutionarily conserved activity of 
mRNA decapping in vitro (Song et al., 2013). Similar to DIPP-1 (Safrany et al., 1998), 
Ddp1 activity was also found to be severely affected in the presence of fluoride (Lonetti et 
al., 2011).    
A recent report demonstrated Ddp1 to hydrolyse pyrophosphate group in the 1-position of 
1-InsP7 completely, but, failed to do the same with 5-isomer of 5-InsP7 under the same 
conditions (Lonetti et al., 2011). This was proposed to be due to 5-InsP7 acting as a 
competitive inhibitor for Ddp1, especially when used in combination with Ap5A substrate 
(Wu et al., 2013).   
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1.2.3 Structure of a DIPP   
All the mammalian DIPP isoforms are fairly small proteins with a molecular weight just 
about 20 kDa (Hua et al., 2003; Leslie et al., 2002; Safrany et al., 1998). The binding site 
of each protein is usually dependent on the Nudix domain, which often has characteristic 
amino acid sequence Gx5Ex5[UA]xREx2EExGU (where U signifies an aliphatic, 
hydrophobic residue) . This domain is more often found conserved in proteins with 
functions restricted to hydrolysis of substrates such as nucleoside di- and triphosphates, 
dinucleoside polyphosphates and nucleotide sugars [McLennan (2007) in Shears et al. 
(2013)]. A site-directed mutagenesis study by Yang et al. (1999) revealed that the residues, 
His(91) and Phe(84), found outside the Nudix domain to greatly influence the catalytic 
activity of human DIPP-1 towards IDPs. So far only one DIPP structure, human DIPP-1, 
has been presented (Thorsell et al., 2009). 
The human DIPP-1 structure has been reported to contain a canonical nudix fold 
comprising of two β-sheets flanked by short helices. The nudix domain, unlike the usual 
loop-helix-loop fold, exhibits a strand-loop-helix configuration in DIPP-1. This variation is 
due to insertion of six residues in the place of five between the N-terminal Gly and the first 
Glu in the domain (Thorsell et al., 2009). Also, the first three residues of the nudix domain 
are found tightly associated with the neighbouring β-strand.  
InsP8 was not fully characterised when the DIPP-1 structure was published. However, 
Thorsell et al. (2009) managed to model both 1,5 and 3,5 alternative isomers of InsP8 into 
the active site of  DIPP-1 structure. This in turn led them to speculate that 3,5-InsP8 form 
was most preferred of the two to form strong interactions with the active site residues of 
DIPP-1. However, it was later found out to be the 1,5-InsP8 isomer by Wang et al. (2012). 
Structure of DIPP-1 is shown in Fig. 1.2.2. 
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Figure 1.2.2  Structure of Homo sapiens-DIPP-1. Residues of nudix domain are 
represented as sticks and coloured beige. Magnesium ions are in grey, fluoride ions in 
green and water molecules in red. Adapted from Thorsell et al. (2009). 
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1.3 Effects of aspirin analogues on oesophageal cancer 
1.3.1 Oesophageal cancer  
Oesophageal cancer is considered as one of the deadliest cancers worldwide because of its 
aggressive nature and low survival rate.  It is the 8
th
 most common cancer seen worldwide 
and is the 6
th
 most common cause of death from cancer [CRUK(b)]. According to 
incidence and mortality statistics by CRUK(b), oesophageal cancer is the 13
th
 most 
common cancer and is the 6
th
 most common cause of death in the UK.  Cancer of the 
oesophagus usually occurs in one of two forms, squamous cell carcinoma (SCC) arising 
from the stratified squamous epithelial lining of oesophagus and adenocarcinomas (ADC) 
from the columnar glandular cells lining the oesophagus (Conteduca et al., 2012). These 
two cancer types vary in occurrence, geographical distribution, ethnic difference, aetiology 
and nutritional intake/deficiencies (Kamangar et al., 2009). The factors that differentiate 
oesophageal SSC from ADC, including the genetic alterations and potential tumour 
targets/markers are described in Table 1.3.1. Other rare variants of oesophageal cancer 
include sarcomas (~2%) and small cell carcinoma (0.05- 4%) (Yun et al., 2007; Zhang, 
2013). Additionally, a tumour occurring at less than 5 cm above or below the oesophagus-
stomach juncture is classed as gastro-oesophageal junction (GOJ) cancer. Though GOJ act 
different to cancers of stomach and oesophagus, doctors’ stage and treat GOJ tumours as 
oesophageal cancer [CRUK(a)]. 
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Factors oesophageal squamous cell carcinoma (SCC) oesophageal adenocarcinoma (ADC) 
Origin  
 
Stratified squamous epithelial lining of oesophagus. Columnar glandular cells lining the oesophagus. 
Region of 
occurrence 
Evenly distributed between the middle and lower third of 
the oesophagus (Enzinger and Mayer, 2003). 
Three quarters occur in the distal oesophagus (type I ADC) 
(Enzinger and Mayer, 2003). Other types include type II 
(true carcinoma of the cardia/cardiac carcinoma) and type 
III (subcardial gastric cancer infiltrating the distal 
oesophagus) (Rudiger Siewert et al., 2000). 
Risk 
factors 
Tobacco and alcohol abuse lead to 20-fold increased risk of 
developing SCC (Lee et al., 2005). 
-Precancerous and asymptomatic Barrett’s oesophagus 
(BO, or Barrett’s metaplasia) (Conteduca et al., 2012). 
-BO related dysplasia, oesophagitis and gastro-oesophageal 
reflux disease (GORD). 
-Distal oesophageal irritation due to achalasia, hiatus 
hernia, scleroderma or chemical injuries [CRUK(a)].  
Family 
history and 
associated 
risk 
Molecular alterations at phospholipase C epsilon 1 and 
C20orf53 (Wang et al., 2010), down-regulation of TGF-
β signalling (SMAD1) (Chattopadhyay et al., 2009) , loss 
of heterozygosity (LOH) of chromosome 13 regions in 
Chinese patients (Hu et al., 2003), aberrant methylation on 
the promoter p16 (Abbaszadegan et al., 2005). 
Family history of BO, oesophagogastric junctional 
adenocarcinoma and ADC (Chak et al., 2002), hiatal hernia 
and prostate cancer (Jiang et al., 2014). 
Geographic
al 
distribution 
Developing countries, spreads out from northeast China to 
Middle East (Melhado et al., 2010). 
Developed countries, increased occurrence in US and 
western Europe (Conteduca et al., 2012).  
Racial 
group/gend
er 
In the US, it affects four times more blacks than whites 
(Cook et al., 2009) and more in men than women (Melhado 
et al., 2010). 
Occurs most often in whites. In the US, it affects five times 
more whites than blacks and eight times more men than 
women (El-Serag et al., 2002). 
Survival 
rate 
5-year survival rates with 37.1% for primary cancer, 18.5% 
for regionally spread cancers, and 3.1% for metastatic 
cancer (Wong et al., 2011). 5-year survival rates were 46% 
after tumour resection (Mariette et al., 2005). 
5-year survival rates were 45% after tumour resection 
(Mariette et al., 2005).  
Prognostic 
biomarkers 
and genetic 
alterations  
-Expression of Metastasis suppressor-1  (Xie et al., 2011). 
-Down-regulation of gene deleted in oesophageal cancer 1 
(DEC1) (Leung et al., 2008). 
-Up-regulation of COX-2 (Zimmermann et al., 1999), ß-
catenin levels (Kimura et al., 1999), NFκB (Yang et al., 
2005). 
-Altered expression of apoptosis related genes including B-
cell lymphoma 2, caspase 3, TNF-related apoptosis-
inducing ligand, EGFR, Fas-L and Fas (Chang et al., 2005). 
-Frequent LOH on human chromosome 1p, 3p, 4, 5q, 9, 
11q, 13q, 17q and 18. These chromosome changes lead to a 
loss of putative tumour suppressor function (Stoner et al., 
2007). 
-Single nucleotide polymorphism (SNP) in alcohol 
dehydrogenase 1B, acetaldehyde dehydrogenase 2 (Cui et 
al., 2009) and cytochrome p450 1A1 (Zhuo et al., 2009). 
-Mutations of p53 (Gao et al., 1994; Dulak et al., 2013), 
NOTCH1 (Forde and Kelly, 2013). Epigenetic silencing of 
RAS association domain family 1A and fragile histidine 
triad genes (Kuroki et al., 2003). 
-Low expression of miR-223 is associated with poor 
prognosis (Mathe et al., 2009). 
-Elevated miR-21 and reduced miR-375 expression levels 
(Mathe et al., 2009). 
-GORD, oesophagitis, BO are important biomarkers. BO 
develops in 10% of patients with GORD (Gorecki, 2001). 
-11-fold increase in risk for ADC in BO patients compared 
to people without the condition (Hvid-Jensen et al., 2011). 
-Overexpression of cyclin-D1 in BO cells (Arber et al., 
1996; Barrett et al., 1996). 
-Hypermethylation and mutation of CDKN2/p16 (Barrett et 
al., 1996; Klump et al., 1998; Dulak et al., 2013).  
-Increase in aneuploidy or tertraploid cell fraction and 
inactivation of p53 in BO (Galipeau et al., 1996). 
-LOH on chromosomes 17p, 18q, 5q (Wu et al., 1998) and 
9p21 (Barrett et al., 1996). 
-Polymorphisms in glutathione S-transferase M1, T1 and 
P1 (Kala et al., 2007). 
-Low levels of serum-selenium correlates with increased 
risk of high-grade dysplasia, tertraploid fractions and 
TP53LOH in persons with BO (Rudolph et al., 2003). 
-Low expression of miR375, miR233 is associated with 
poor prognosis (Mathe et al., 2009). 
-Elevated level miR-21, miR-223, miR-192, and miR-194 
but reduced miR-203 expression (Mathe et al., 2009) and 
miR-196a (Luthra et al., 2008). 
Table 1.3.1 Factors that differentiate oesophageal SSC from ADC 
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1.3.2 Treatment 
With the increasing incidences of oesophageal cancer worldwide, arises the urgent need for 
effective treatments and new approaches to combat this disease. Chemotherapy has been a 
moderately effective treatment option for locally advanced and metastatic oesophageal 
cancer (Forde and Kelly, 2013). Recent focuses on the potential oncogenic targets in 
oesophageal cancer have resulted in the emergence of number of promising and efficient 
targeted therapies. Brief notes on the current therapies and future strategies are listed 
below.  
1.3.2a Targeted therapy 
Besides the advancements with combination therapies for oesophageal cancer, survival 
and/or cure rates have been low (17.5% surviving 5 years, SEER statistics as of 2004-
2010). Targeted therapy which has been successful with cancers such as colon could prove 
useful for oesophageal cancer (Forde and Kelly, 2013). Molecular level knowledge on 
cancer signalling pathways have shed light on the potential targets in oesophageal cancer 
including nuclear factor-κB (NF-κB), CDKs, cyclooxygenase (COX)-2 inhibition, matrix 
metalloproteinases (MMPs), epidermal growth factor receptor (EGFR) and vascular 
endothelial growth factor (VEGF) (Campbell and Villaflor, 2010). A brief description on 
the most promising targets at present are stated below and some of the clinical trials carried 
out based on these targets are mentioned in the Table 1.3.2.      
1.3.2a(i) EGFR 
EGFR is at least of four types: EGFR (EGFR-1, HER-1), HER-2, HER-3 and HER-4. 
EGFR, a proto-oncogene, plays an important role in regulating cell proliferation, invasion, 
metastasis and apoptosis (Tabernero et al., 2005). EGFR proteins are reported to be 
overexpressed in 30-70% of oesophageal SCC and ADC and their overexpression are often 
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correlated with poor prognosis (Itakura et al., 1994; Wang et al., 2007). In an effort to 
target EGFR in oesophageal or GOJ cancer, numerous clinical trials have been initiated 
with key agents like monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). 
The most common mAbs used currently for treatments and in clinical trials include 
cetuximab (IgG1), panitumumab (IgG2) (Table 1.3.2). Trastuzumab (Herceptin) and T-
DM1 are HER-2 receptor-targeted mAbs that are involved in current clinical trials. T-DM1 
with its promising outcome as moved on to phase III trial whereas multimodality 
neoadjuvant treatment with trastuzumab is unclear because of its suspected cardiotoxicity 
in patients (Table 1.3.2). Studies of EGFR TKIs to date has been unsatisfactory, with 
comparatively high toxicity rates and limited signs of activity due to low incidence of 
activating mutations of EGFR in oesophageal cancer (Forde and Kelly, 2013).   
1.3.2a(ii) VEGF 
VEGF, an angiogenesis regulator is also considered a potential target to tackle oesophageal 
cancer. Similar to EGFR, overexpression of VEGF has also been reported in 28%-64% of 
oesophageal cancer and is likewise associated with poor prognosis (Forde and Kelly, 
2013). In addition, evidences of increased expression of VEGF during chemotherapy and 
radiotherapy have made it an attractive target for multimodality neoadjuvant therapy 
(Campbell and Villaflor, 2010; Kulke et al., 2004). Despite the hype, VEGF-targeted 
therapy is yet to yield a satisfactory response in case of oesophageal cancer. Although 
trials showed signs of efficiency with VEGF-targeted therapy in unselected populations, 
the efficacy failed to stand out in phase III randomised trials. However, a recent phase III 
trial (REGARD) with ramucirumab appears to be promising with a 1.4 month survival 
advantage (Forde and Kelly, 2013) (Table 1.3.2).   
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1.3.2a(iii) MET/hepatocyte growth factor (HGF) and Fibroblast growth factor 
receptor (FGFR) 
Gene amplification of MET proto-oncogene has been reported in 2%-10% of oesophageal 
ADC but only 1% in SSC (Forde and Kelly, 2013; Kato et al., 2013; Lennerz et al., 2011). 
MET induced cancers are of higher grade and are usually diagnosed at an advanced stage.   
Phase III MET inhibitors trials including Onartuzumab and Rilotumumab are ongoing at 
the moment (Table 1.3.3). Promising results from phase II trial with Rilotumumab 
combined with chemotherapy in patients with overexpressed MET has given hope that 
these agents may exhibit efficacy and give an added optional treatment for patients (Forde 
and Kelly, 2013).  
Increased expression of FGFR-2, observed in 4% of oesophageal cancer, has been again 
associated with poor prognosis (Matsumoto et al., 2012). Preclinical study by Yashiro et 
al., (2010) suggests that FGFR-2 inhibitors may yield synergistic anticancer effect with 
chemotherapy in gastric cancers (Yashiro et al., 2010).  Cediranib, an FGFR-2 oral 
inhibitor, despite of good tolerability outcome in phase I study in GOJ and ADC is yet to 
undergo further clinical investigation.  A selective oral potent inhibitor of FGFR-1, FGFR-
2, and FGFR-3 called AZD4547 is undergoing phase II trial for FGFR-advanced 
oesophageal GOJ. Amongst the various pathway-specific anticancer agents known, FGFR-
tyrosine kinase inhibitors appears to be a more wise strategy that is likely to show 
clinically relevant benefits (Forde and Kelly, 2013).  
1.3.2b Novel targets 
Several other carcinogenic cellular pathways, molecular strategies and tumour targets are 
currently under clinical investigation for oesophagus related cancers (Table 1.3.3). 
Efficacy of everolimus which targets mTOR and inhibits downstream signalling is 
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currently being investigated. Synergistic effects of poly (adenosine diphosphate-ribose) 
polymerase (PARP) family of inhibitory proteins in combination with radiation are being 
tried in a phase I trial for locally advanced oesophageal and GOJ tumours (Forde and 
Kelly, 2013).  Novel immune-based treatments are also being launched in clinical trials, 
including ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody and adjuvant 
tumour vaccine following tumour resection. Next-generation immunomodulatory 
antibodies such as anti-programmed death-1 and anti-programmed death ligand-1 are also 
under clinical investigation for oesophageal and solid tumours. Chemotherapeutic 
treatments based on the methylation status of forkhead-associated and ring finger domains 
(CHFR) are also being experimented in clinical trials (Forde and Kelly, 2013).   
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Table 1.3.2 Some of the oesophageal cancer targeted therapies in clinical trials. 
Adapted from (Forde and Kelly, 2013). Abbreviations: BSC, best supportive care; CRT, 
chemoradiation; GOJ, gastro-oesophageal junction; NCT, clinicaltrials.gov identifier; 
ORR, overall response rate; OS, overall survival; pCR, pathologic complete response; PFS, 
progression-free survival; SWOG, Southwest Oncology Group; T-DM1, trastuzumab 
emtansine; TKI, tyrosine kinase inhibitor. 
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Targeted 
therapies 
NCT 
identifier 
Patient population Treatment(s) Results/status 
 
 
 
Cetuximab 
(mAb 
targeting 
EGFR) 
NCT00445861 
 
 
 
NCT00509561 
 
 
 
NCT00109850 
(SWOG 0414) 
Stage IIB-IIIC resectable 
esophageal/GOJ tumour 
 
Stage IA-IIIC 
oesophageal/GOJ (type I) 
tumours not candidates for 
surgery  
 
Stage III oesophagus/GOJ 
tumours not candidates for 
surgery 
Preoperative 
cisplatin/docetaxel/cetuxi
mab 
 
Cisplatin/capecitabine/ra
diation ± cetuximab 
 
 
Cisplatin/Irinotecan 
(IR)/cetuvimab/radiation 
Phase(IB/II) completed; promising with 
pCR and near pCR rates of 68%  
 
 
Phase II/III completed; increased 
toxicity and poor survival 
 
 
Phase II closed early because of poor 
accrual; among 21 patients treated, 2 
died 
Panitumumab 
(mAb 
targeting 
EGFR) 
NCT00757172 
(ACOSOG 
Z4051) 
Stage IIB-IV (M1a)  
oesophageal/GOJ 
adenocarcinoma 
Preoperative 
cisplatin/docetaxel/radiat
ion/panitumumab 
Phase II completed; promising with 
pCR and near pCR rate of 55.2%. Trial 
closed for lack of efficacy 
 
Trastuzumab 
(mAb 
targeting 
HER-2 
 
NCT01041404 
 
First-line HER-2-positive 
stage IV GOJ/gastric 
adenocarcinoma 
 
Cisplatin/fluorouracil or 
cisplatin/capecitabine ± 
trastuzumab 
Phase III results show 2.7 month OS 
advantage with addition of: 
trastuzumab/chemotherapy, 13.8 month; 
chemotherapy alone, 11.1 month 
(p=0.0046). No increase in significant 
toxicity 
Lapatinib 
(TKI targeting 
HER-2 and 
EGFR) 
 
NCT00680901 
 
First-line stage IV HER-2-
positive 
oesophageal/GOJ/gastric 
adenocarcinoma 
 
Capecitabine and 
oxaliplatin ± lapatinib 
 
Phase II trial completed accrual; 
awaiting  results 
T-DM1 (mAb-
drug 
conjugate 
targeting 
HER-2) 
 
NCT01641939 
 
Second-line stage HER-2-
positive GOJ and gastric 
cancer  
 
T-DM1 versus taxane 
 
Remarkably well tolerated in studies to 
date. Currently accruing for Phase III 
trial 
Bevacizumab 
(mAb 
targeting 
VEGF-A) 
NCT00354679 
 
 
 
 
 
NCT00450203 
(ST03,MAGIC-
B trial) 
Stage IIA-IIC resectable 
oesophageal/GOJ 
adenocarcinoma 
 
 
 
Stage II-IV (M1a) resectable 
oesophageal/GOJ or gastric 
adenocarcinoma 
Preoperative 
irinotecan/cisplatin/radiat
ion plus bevacizumab 
 
 
 
Preoperative 
epirubicin/cisplatin/cape
citabine ± bevacizumab 
for 3 cycles followed by 
postoperative 
epirubicin/cisplatin/cape
citabine ± bevacizumab 
for 3 cycles 
Phase II trial showed prolonged survival 
compared to historical standards (pCR: 
15%); median time to tumour 
progression:8.3 months; no increase in 
PFS or OS 
 
Currently accruing for Phase II/III trial 
Ramucirumab 
(mAb 
targeting 
VEGF-R2) 
NCT01246960 
 
 
 
NCT00917384 
(REGARD) 
First-line oesophageal/GOJ or 
gastric adenocarcinoma 
 
 
Second-line GOJ or gastric 
adenocarcinoma 
5FU 
/leucovorin/oxaliplatin ± 
ramucirumab 
 
BSC ± ramucirumab 
Completed accrual for phase III trial 
 
 
 
Phase III results showing median OS: 
ramucirumab + BSC, 5.2 month; BSC, 
3.8 month (p= 0.04753) 
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Targeted 
therapies 
NCT identifier Patient population Treatment(s) 
MET/HGF 
targeted therapy 
NCT01611857 
  (phase I/II) 
 
 
NCT01662869 
(phase III) 
 
NCT01697072 
(phase III) 
First-line stage IV molecularly unselected 
oesophageal/GOJ/gastric adenocarcinoma 
 
First-line stage IV HER-2-negative, MET-
positive GOJ tumours 
 
First-line stage IV MET-positive GOJ or 
gastric tumours 
5FU/leucovorin/oxaliplatin plus tivantinib (c-MET 
inhibitor) 
 
 
Modified 5FU/leucovorin/oxaliplatin 6 ± 
onaruzumab 
 
Epirubicin, cisplatin, and Capecitabine + placebo or 
rilotumumab 
 
mTOR targeted 
therapy 
NCT01490749 
(phase I/IIB 
Locally advanced oesophageal tumours Capecitabine plus oxaliplatin/carboplatin/radiation 
± everolimus (inhibitor of mTOR) 
 
Immune-directed 
therapies 
NCT01258868 
(phase I) 
 
NCT01284231 
(phase I) 
 
NCT01375842 
(phase I) 
 
NCT01585987 
(phase II) 
Following resection of oesophagus tumours 
 
Advanced gastrointestinal adenocarcinoma, 
including GOJ tumours 
 
Solid tumours, including oesophageal cancer 
 
Following first-line chemotherapy for stage 
IV GOJ gastric tumours 
Adjuvant ISCOMATRIX autologous tumour 
vaccine and celecoxib 
 
MEDI-565 (CEA/CD3 bispecific antibody T-cell 
activator) 
 
MPDL3280A (PD-L1 antibody) 
 
 
Ipilimumab 
PARP NCT01460888 
(phase I) 
Locally advanced oesophagus /GOJ tumours Radiation with concurrent olaparib 
Hedgehog 
signalling 
targeted therapy 
NCT00982592 
(phase II) 
First-line unresectable or metastatic 
GOJ/gastric adenocarcinoma 
5FU/leucovorin/oxaliplatin ± vismodegib 
Akt  NCT01260701 
(phase II) 
Second-line stage IV GOJ/gastric 
adenocarcinoma) 
 
MK2206 (Akt inhibitor) 
FGFR NCT01457846 
(phase II) 
Second-line stage FGFR-amplified 
oesophageal /GOJ/gastric adenocarcinoma  
 
AZD4547 (FGFR inhibitor) versus paclitaxel 
CHFR 
methylation 
NCT01372202 Locally advanced oesophageal/GOJ tumours Chemotherapy chosen based on CHFR methylation 
status 
 
Claudin-18 NCT01671774 CLDN18.2 expression-positive stage IV 
oesophageal/GOJ or gastric cancer 
iMAB362 (antibody targeting CLDN18.2 cell 
surface antigen) + zoledronic acid  
 
Table 1.3.3 Novel targeted therapies for oesophageal cancer in clinical trials. Adapted 
from (Forde and Kelly, 2013). Abbreviations: CHFR, checkpoint with forkhead-associated 
and RING finger domains; PD-L1, programmed death-ligand 1. 
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1.3.2c Non-steroidal anti-inflammatory drugs (NSAIDs) and their role in cancer 
NSAIDs are a class of drugs commonly used for treatment of fever, pain-related and 
inflammatory conditions such as headaches, menstrual cramps, mild-to-moderate pain 
from inflammation of tissue or injury and arthritis. The most prominent members of this 
group of drugs include aspirin, ibuprofen, naproxen, indomethacin, sulindac and piroxicam 
(Gurpinar et al., 2013).  
Epidemiological, clinical and preclinical studies provide substantial evidence that NSAIDs 
(including COX-2 selective inhibitors) possess potent antitumorigenic properties (Gurpinar 
et al., 2013). The anticancer effect of NSAIDs against colorectal cancer (CRC) is 
particularly well-known. Several cohort studies have shown significantly reduced risk of 
colorectal adenomatous polyps and CRC in long-term users of NSAIDs than non-users 
(Chan, 2002; Giardiello et al., 1995; Thun et al., 2002). Reduction of precancerous 
colorectal polyps in patients with Garner’s syndrome with the use of NSAID sulindac 
(Clinoril
®
) was the first clinical evidence to be reported in a case study (Waddell and 
Loughry, 1983). Furthermore, several randomized controlled trials (RCTs) reported that 
sulindac strongly inhibits the development of adenomatous polyps and causes regression of 
existing polyps in patients with familial adenomatous polyposis (FAP) (Giardiello et al., 
1993; Winde et al., 1995). A study which compared the efficiency of several NSAIDs on 
UV-induced non-melanoma skin cancer in SKH-1 hairless mice reported sulindac to be the 
most potent NSAID in reducing skin cancer (Mikulec et al., 2013). Suppression of 
adenoma formation in FAP patients was also reported with the use of the COX-2 selective 
inhibitor, celecoxib (Celebrex
®
) (Steinbach et al., 2000). This led to the FDA approval of 
celecoxib treatment for FAP patients in 1999, but was later withdrawn due to drug related 
vascular and upper gastrointestinal (GI) side effects (Gurpinar et al., 2013; Solomon et al., 
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2005). Regular Ibuprofen intake was also found to reduce risk of breast cancer by about 
50% in a cohort study (Harris et al., 1999).           
1.3.3 Aspirin  
Acetylsalicylic acid, commercially known as aspirin, is one of the most widely used anti-
inflammatory drug to date. The active metabolite of aspirin, salicylic acid, was first 
discovered by Greek physician Hippocrates more than 2000 years ago from the bark of the 
willow tree. However, aspirin was first synthesized in its stable form by Felix Hoffmann in 
1897 at Bayer & Co laboratory (Gensini and Conti, 2009). Aspirin is a non-opioid 
analgesic with antipyretic and antiplatelet properties with a half-life of 15-20 min in the 
blood (Bruno et al., 2012).  Aspirin does not only act as an effective anti-inflammatory 
drug but also can prevent stroke and other cardiovascular diseases. A number of RCTs are 
still trying to address the issue of the safe use of prophylactic aspirin for the primary 
prevention of cardiovascular diseases (Sutcliffe et al., 2013).  
1.3.3a Aspirin as a chemopreventative drug  
In the last few years the attention has been towards the potential role of aspirin in the 
prevention and possibly treatment of various cancers. Several studies have reported that 
continued use of aspirin can result in lesser incidence of cancers or deaths from cancers 
arising from various tissues. These include cancers such as breast (Harris et al., 1999), lung 
(Muscat et al., 2003), prostate (Jacobs et al., 2005), ovarian (Cramer et al., 1998), 
oesophagus, stomach, colon and rectum (Thun et al., 1993). However, the possible 
chemoprotective benefit with the administration of aspirin was comparatively significant 
with digestive tract related cancers than others mentioned above (Thun et al., 1993). 
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1.3.3b Aspirin and CRC 
Of several chemotherapeutic strategies that are being pursued to combat CRC, use of 
aspirin is one of the most promising. In animal models, aspirin was found to reduce the 
initiation and progression of aberrant crypt foci in the colon (Liu et al., 2008). Recent 
meta-analysis data with large number of patient studies indicates that daily use of aspirin at 
treatment dose for 5 years or more reduces the risk of developing multiple cancer types 
including CRC (Algra and Rothwell, 2012). In addition, the review indicated aspirin’s 
ability to suppress the risk of cancer metastasis. Also, in a RCT of patients with Lynch 
syndrome (CAPP2 study), administering 600 mg dose of aspirin daily for ~2 years resulted 
in substantial decline of CRC incidence (Burn et al., 2011). A recent study also reported 
significant decrease of CRC incidences in Scotland with only 75 mg daily-dose of aspirin 
for a period of 5 years (Din et al., 2010). Regular use of aspirin post-diagnosis of non-
metastatic CRC has also been reported to reduce CRC-specific mortality, an association 
that was strongest when the cyclooxygenase-2 (COX-2) was overexpressed in primary 
tumour (Chan et al., 2009). Overexpression of COX-2 in majority of the oesophageal 
cancers has also been reported (Zimmermann et al., 1999). Since inhibition of this enzyme 
is claimed by some to be the reason behind NSAIDs/aspirin’s chemotherapeutic properties, 
it is possible that these drugs hold promising anticancer effects against oesophageal 
cancers.  
1.3.3c Aspirin and oesophageal cancer 
Multiple studies have suggested that aspirin and other NSAIDs protect against oesophageal 
cancer. According to a meta-analysis study based on exposure type, aspirin was found to 
have greater protective effect than non-aspirin NSAIDs (Corley et al., 2003). Several 
epidemiological studies have reported that intake of aspirin and other NSAIDs could 
protect against oesophageal ADC by either preventing the development of precursor BO or 
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by reducing the possibility of BO advancing to ADC. A study reported 33% reduction in 
the risk of developing oesophageal ADC with the use of NSAIDs (Corley et al., 2003). 
Furthermore, BO patients using NSAIDs exhibited significantly reduced risk of developing 
oesophageal ADC (6.6%) compared to non-users (14.3%) (Vaughan et al., 2005). Reports 
suggest that such reduced cancer risk in BO patients using NSAIDs could be due to 
decreased rate of acquisition of somatic genomic abnormalities in individuals (Kostadinov 
et al., 2013). In contrast, a cohort study found no substantial correlation between use of 
aspirin or non-aspirin NSAIDs and oesophageal ADC (Abnet et al., 2009). Aspirin use was 
also associated with reduced risk (90%) of developing squamous cell carcinoma of head 
and neck (Ahmadi et al., 2010). Liu et al. (2009) found that use of aspirin following an 
oesophagectomy for SSC patients improved the 5-year survival rate to about 49.8% 
compared to placebo (42.2%) and no tablet (41.2%) ( p = 0.26).  
1.3.3d  Anti-metastatic property of aspirin   
Aspirin not only reduces the risk of cancer death but also reduces the risk of metastasis in 
certain cancers. A review on daily aspirin against no aspirin for the prevention of 
cardiovascular diseases in five large UK trials showed that aspirin reduced (a) risk of 
distant metastasis by 30-40% and, (b) risk of metastatic adenocarcinoma by almost half 
(Rothwell, Wilson, et al., 2012). Adenocarcinoma patients who did not have metastasis to 
start with but still continued to use daily aspirin up to or after diagnosis showed reduced 
risk of metastasis (by about 70%) on subsequent follow-up. Such effect was seen with a 
low-dose (75 mg), slow-releasing formulation of aspirin that had only little systemic 
bioavailability (Rothwell, Wilson, et al., 2012). The mechanism behind the anti-metastatic 
effect of aspirin was shown to be inhibition of platelet formation or thrombocytosis (Gasic 
et al., 1972; Langley et al., 2011). However, aspirin’s ability to decrease invasiveness in 
COX-2 negative colon cancer cells was attributed to up-regulation of NM23 (a metastatic 
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suppressor gene) and down-regulation of carcinoembryonic antigen and CD44v6 
(metastasis inducer) expression (Yu et al., 2002).  
1.3.3e Side effects of aspirin use 
Besides the beneficial anticancer property of aspirin, there is the issue of serious side 
effects with its use. Long-term use of aspirin is reported to carry the risk of adverse 
gastrointestinal bleeding. Regular use of NSAIDs was found to cause ulcers in 15%-30% 
and annual incidence of upper GI clinical events in 2.5%-4.5% of patients (Laine, 2002). 
Dyspepsia, an upper GI symptom, was also found to occur in 15%-60% of NSAID users.    
Whether the risk of aspirin related side effects balances against its benefits is still 
debatable. However, the side effects profile of aspirin use is relatively small compared to 
adverse effects of most cancer treatments. Analysis by Rothwell, Price, et al. (2012) also 
showed that extended use of aspirin can reduce risk of major extracranial bleeds in 
patients. A meta-analysis study found aspirin use, at a low dose of 75-325 mg, to increase 
the risk of major bleeding by ~70%, but the absolute annual increase was limited at 0.13% 
for major bleeding, 0.12% for gastrointestinal bleeding and 0.03% for intracranial bleeding 
(McQuaid and Laine, 2006).  
1.3.3f Adjuvant aspirin therapy 
Several clinical and pre-clinical studies have been carried out to see whether aspirin in 
combination with an anti-acid reflux drug can reduce the side effects during the treatment. 
Examples of such studies are as follows: 
1.3.3f(i) Aspirin with Proton-Pump Inhibitor esomeprazole 
Aspirin along with an acid suppression drug called esomeprazole is being tried out in a 
randomised phase III AspECT trial in the UK (Das et al., 2009). This study aims to find 
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the benefits of low or high dose of acid suppression drug with or without aspirin in 
decreasing the risk of BO and related ADC.  
1.3.3f(ii) Ursodeoxycholic acid with aspirin 
An in vivo study by Rizvi et al. (2010) reported that Urso in combination with aspirin 
reduces risk of oesophageal ADC in animals with reflux. The novel target of Urso-aspirin 
combination was proposed to be GLI1, a hedgehog-regulated transcription factor. The 
urso-aspirin combination was suggested to exert chemopreventative effect by 
downregulating pro-oncogenic gene GLI1 which in turn regulates activation of cell cycle 
regulator, CDK2 (Rizvi et al., 2010). 
1.3.3f(iii) Statin with aspirin 
A meta-analysis study stated that prolonged use of statin in combination with 
aspirin/NSAIDs could provide greater protective effect against oesophageal ADC (Singh 
and Singh, 2013).  According to a recent study, endometrial cancer patients under statins 
and aspirin treatment had an 84% decreased threat of death compared to non-users and 
statin or aspirin users (Spoozak et al., 2013). The toxicity profiles of statins by itself and its 
effect on aspirin induced gastropathy is unknown. Epidemiological data suggests that use 
of NSAIDs in combination with statins, 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors, appear to have an added protective effect in patients with BO 
(Kastelein et al., 2011). 
1.3.4 Molecular mechanisms involved in anticancer effects of aspirin  
Increasing evidences in support of aspirin’s anticancer role has raised the demand for an 
insight into the biological mechanism underlying it. Although many mechanisms of actions 
are postulated for aspirin so far, it still remains an area of much debate. Studies suggest 
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that aspirin mainly exerts its anticancer effects through COX-dependent or/and through 
COX-independent pathways.  
1.3.4a COX-dependent mechanisms 
Prostaglandin (PG) H-synthases or COX enzymes exists as two isoforms COX-1 and 
COX-2. COX is a bifunctional enzyme exhibiting both COX and peroxidase activity. The 
COX component of the enzyme coverts arachidonic acid (AA) to hydroperoxy 
endoperoxide prostaglandin G2 (PGG2), and the peroxidase part reduces the PGG2 to 
corresponding alcohol (PGH2) which acts as the precursor of prostanoids [i.e., 
prostaglandins, prostacyclin (PGI2), and thromboxane A2 (TXA2)] (Hamberg and 
Samuelsson, 1973). Prostaglandins, regarded as vital messenger molecules,  in their active 
state influences a number of pathophysiological processes such as cell growth, 
angiogenesis,  invasion, apoptosis, immune response and thrombosis in an array of tissues 
(Langley et al., 2011).  
COX-1, which is expressed in most tissues, is thought to regulate a number of 
‘housekeeping’ functions such as vascular homeostasis, renal blood flow and glomerular 
functions. COX-2, expressed in restricted tissues in physiological levels especially in 
endothelial cells, is thought to contribute to COX-2-dependent-PGI2 effects such as anti-
thrombosis and vasodilation (Fig. 1.3.1) (Hennan et al., 2001). However, overexpression 
of COX-2 in tissues has been associated with pathological condition such as cancer 
(Seibert et al., 1997; Williams et al., 1999).  Prostaglandin E2 (PGE2), a major prostanoid 
produced by COX-2 variant in the cancer cells, has been found to be the key agent 
promoting cell proliferation, metastasis, angiogenesis and resistance to apoptosis 
(Greenhough et al., 2009). Studies have also reported a role for COX-1 in pathological 
process such as atherosclerosis and cancer (Daikoku et al., 2005; McClelland et al., 2009). 
An immunohistochemical study by Zimmermann et al. (1999) found COX-2 expression in 
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91% of oesophageal SCC and 78% of oesophageal ADC. This study also showed 
overexpression of COX-2 variant in cancerous tissue as opposed to normal oesophageal 
squamous epithelium. However, COX-1 expression in this study was found to be at 
physiological levels in both normal and cancerous tissues. 
Cancer of SCC, BO and ADC are all associated with increased COX-2 expression 
(Shirvani et al., 2000; Zimmermann et al., 1999). Several studies have reported increased 
expression of COX-2 in oe33 (Abdalla et al., 2005; Jimenez et al., 2010), oe21 (Abdalla et 
al., 2005) and flo-1 (Aggarwal et al., 2000) cells. However, a latter study also found flo-1 
to express only trace levels of either COX isoforms (Aggarwal et al., 2000). 
 Most hypotheses have centred round aspirin’s ability to modulate AA metabolism by 
COX inhibition. Unlike other NSAIDs, aspirin’s capability to irreversibly inhibit COX 
enzymes is well known. Irreversible acetylation of serine molecule (i.e., Ser529 in human 
COX-1, and Ser516 in human COX-2) by aspirin results in blockade of the COX channel 
and thereby prevents access of AA to the active site of the enzyme (Chan and Detering, 
2013). Preferential inhibition of COX-1 than COX-2 by aspirin is well established. 
Considering aspirin’s short half-life in the blood and inclination to inhibit COX-1 variant 
>100-fold more than COX-2 (Dovizio et al., 2012), it appears ideal for aspirin to act on 
COX-1 platelets and irreversibly block TXA2-dependent platelet function (Fig. 1.3.1) 
(Clarke et al., 1991). In contrast, a higher dose of aspirin in shorter intervals (because 
nucleated cells are quick to resynthesize the COX enzymes while platelets cannot) is 
required for inhibition of COX-2-dependent pathophysiological processes. In vitro studies 
show varying IC50 values for COX-1 and COX-2 inhibition by aspirin: in chondrocyte 
cells, COX-1 IC50=3.57 µM and COX-2=29.3 µM (Blanco et al., 1999); in intact cells, 
COX-1=4.3 µM and COX-2=714.3 µM (Botting, 2006; Mitchell et al., 1993). However, 
55 
 
all the above studies reported aspirin to be highly selective for COX-1 compared to COX-
2. 
 
 
Figure 1.3.1 Anticancer effects of aspirin-triggered lipoxins. Aspirin acetylates COX-1 
enzyme and irreversibly blocks TXA2-dependent platelet functions to produce the 
beneficial cardiovascular effects. Contrarily, acetylated COX-2 participates in the 
transformation of free arachidonic acid to 15R-HETE, which is then metabolised by 
leukocytes (or monocytes) to 15-epilipoxinA4 in the presence of the enzyme 5-
lipoxygenase (5-LO). Adapted from Baker et al. (2009); Bruno et al. (2012). 
 
The antiplatelet property of aspirin does not only reduce incidences of myocardial 
infarction but also is thought to partly contribute to aspirin’s anticarcinogenic effect. 
Increased platelet activation or thrombocytosis is observed in 10-57% of cancer patients 
(Sierko and Wojtukiewicz, 2004). An increase in platelet count was associated with tumour 
progression and poor survival rate in oesophageal carcinoma patients (Shimada et al., 
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2004). Oesophageal ADC patients were reported to show significantly higher platelet 
activation compared to SCC patients (Aminian et al., 2011). Moreover, thrombocytosis has 
been reported to be involved in crucial stages of cancer development (Bambace and 
Holmes, 2011). Thrombocytosis promotes tumour driven platelet aggregation, release of 
cytokines (interleukin (IL)-1, IL-6), proteolytic enzymes (heparanase, MMPs), and platelet 
microparticles which can aid in cell proliferation, angiogenesis and metastasis. It is also 
proposed that aspirin-induced-thrombocytosis may promote COX-2 expression and 
metastasis development through the production of key factors such as IL-1β, platelet 
derived growth factor and transforming growth factor beta (TGF-β) in colorectal adenoma 
and CRC (Sciulli et al., 2005).  
Aspirin shows an incomplete allosteric inhibitory effect on COX-2 compared to COX-1 
(Sharma et al., 2010). Acetylation of COX-1 suppresses the enzyme activity, whereas 
acetylation of COX-2 alters the enzyme hampering its ability to form PGG2 and thus 
produces an alternative product, 15R-hydroxyeicosapentaenoic acid (15R-HETE) from AA 
(Fig. 1.3.1). Further, 15R-HETE are metabolized to the epi-lipoxins (also known as 
aspirin-triggered lipoxin) by the action of 5-LO in monocytes and leukocytes (Gilroy, 
2005). Epi-lipoxins are shown to be potent inhibitors of cell proliferation and angiogenesis 
(Baker et al., 2009). A recent study in a rat model with gastroesophageal reflux revealed 
low levels of PGE2 and increased levels epi-lipoxin4 at oesophageal tissue levels with 
aspirin treatment (50 mg/kg/day) compared to non-treated (Esquivias et al., 2014). 
However, epi-lipoxin4 was found ineffective in preventing the induction of oesophageal 
ADC in their study. 
Yet another proposed mechanism of aspirin that helps protects against cancer is by the 
inhibition of sphingosine-l-phosphate (S1P) from human platelets, even in the presence of 
stimulated potent peptide agonist of the thrombin receptor PAR-1 (protease-activated 
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receptor-1) (Ulrych et al., 2011). Expression of S1P from platelets, a regulatory molecule 
in cancer development (Kawamori et al., 2009), is dependent on the activation of COX-1 
dependent TXA2.  
1.3.4b COX-independent mechanism 
Besides aspirin’s ability to inhibit COXs, several other COX-independent mechanisms 
have been proposed to contribute to pharmacological effects of aspirin in CRC. NSAIDs 
and aspirin are reported to affect major cancer signalling pathways that are involved in cell 
proliferation and/or induce apoptosis.   
1.3.4b(i) Induction of Apoptosis 
Numerous reports suggest that the primary mechanism behind the anticancer effect of 
NSAIDs/aspirin is apoptosis. Sulindac sulphide was the first NSAID to be reported to 
exhibit a COX-independent antineoplastic effect on cancer cells (Shiff et al., 1995). 
Administration of non-COX-inhibitory sulindac sulfone was found to result in induction of 
apoptosis selectively in rectal polyps of FAP patients but not in normal rectal mucosa 
(Stoner et al., 1999). Such a feature of selective effect is not obvious even with the 
conventional chemotherapeutic drugs that are designed to act by inducing apoptosis 
(Gurpinar et al., 2013). A study by Shureiqi et al. (2001) found that NSAIDs induce 
apoptosis in both oesophageal ADC and SCC cells by up-regulating expression of 15-
lipoxygenase-1 (a tumour suppressor gene). Aspirin-induced apoptosis was also observed 
by Li et al. (2000) in oesophageal cancer cell lines. However, aspirin has been reported to 
induce cell cycle arrest and necrosis at higher concentrations in vitro in CRC (SW 620 and 
HT-29) cell lines (Subbegowda and Frommel, 1998).  
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Many mechanisms and targets have been associated with the NSAID’s induction of 
apoptosis. Although a particular NSAID may have its own specific COX-independent 
target, it is possible that a combination of effects triggered by NSAIDs in different 
signalling pathways through direct or indirect target may contribute to induction of 
apoptosis. Major direct cellular targets that induce NSAID-mediated apoptosis are 
mentioned below.   
1.3.4b(ii) IKKβ/NF-κB 
Several studies have shown that NSAIDs may exert their apoptotic effect through direct 
modulation of NF-κB signalling pathway. NF-κB transcriptional factors such as p50 and 
p65 (Rel A) components remain in an inactive form in the cytoplasm when in association 
with IκB inhibitory regulatory protein (Gurpinar et al., 2013). However, ubiquitination and 
proteasomal degradation events during phosphorylation of IκB by the cGMP-dependent 
protein kinase IKKβ results in release of free NF-κB. The free NF-κB then enters nucleus 
and binds to DNA, resulting in transcriptional activation (Fig. 1.3.2) (Brown et al., 1995; 
Gurpinar et al., 2013). Anti-apoptotic property of NF-κB is exhibited by activation of 
apoptosis inhibitors such as TRAF1/2 and c-IAP1/2, or c-myc (cell survival promoters). 
NF-κB mediated apoptosis has been evident in both in vivo and in vitro models of CRC 
i.e., HT29 xenograph model and Apc
Min+/- 
mice. Aspirin (5 mM), sodium salicylate (5 
mM), sulindac (1 mM), and its analogues sulindac sulphide (200 µM) and sulfone (1 mM) 
were all reported to directly bind and inhibit recombinant IKKβ and regulate NF-κB 
signalling in COS cells transfected with an NF-κB-responsive expression vector 
(Yamamoto et al., 1999). Aspirin has been reported to inhibit cancer progression by 
induction of apoptosis in oesophageal SCC cells by inhibition of NF-κB signalling (Liu et 
al., 2005). In this study, the induction of apoptosis was associated with down-regulation of 
COX-2 expression, prostaglandin synthesis and up-regulation of cytoplasmic IκB. 
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Figure 1.3.2 COX-independent mechanisms of aspirin. Aspirin has been associated with several off-target effects. Some, but not all, 
proposed pathways are shown above. Adapted from (Bruno et al., 2012; Gurpinar et al., 2013). 
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1.3.4b(iii) Wnt/β-Catenin pathway 
An increase in the accumulation of cytoplasmic β-catenin and activation of Wnt/β-catenin 
pathway has been implicated in CRC cases (Munemitsu et al., 1995). Activation of this 
pathway is a result of mutation in adenomatous polyposis coli (APC) gene (Fig. 1.3.2). 
Mutated apc gene is reported to result in a truncated non-functional form of the protein 
which fails to form the complex that downregulates β-catenin (Munemitsu et al., 1995). 
This translates into abnormally high level of cytoplasmic β-catenin which then translocate 
to the nucleus and binds to members of T-cell factor (TCF)/lymphoid enhancer factor 
family transcription factors and activates cyclin D and Myc transcription (Wnt targeted 
genes) (Shtutman et al., 1999). A study by Bos et al. (2006) demonstrated that treating 
CRC cell lines with aspirin inhibits protein phosphatase 2A enzyme activity, a protein that 
influences phosphorylation of the β-catenin. Furthermore, increase in the level of 
phosphorylated β-catenin results in its degradation and thereby inactivation of the Wnt/β-
catenin pathway.  
1.3.4b(iv) ERK signalling 
A higher concentration of aspirin in vitro has been reported to modulate COX-independent 
biological responses through differential regulation of kinases involved in the extracellular 
signal-regulated kinases pathway (ERK 1/2) [also known as, Ras-Raf-MEK-ERK pathway 
or mitogen activated protein kinase (MAPK) pathway] (Fig. 1.3.2) (Seger and Krebs, 
1995). Activation of the ERK pathway by various extracellular stimuli in diverse tissue 
types result in phosphorylation of various downstream substrates that are involved in 
regulation of key processes such as cell cycle progression, cell migration, differentiation, 
proliferation, metabolism and transcription (Seger and Krebs, 1995). Mutations in the key 
kinases and/or aberrant activation of ERK pathway are reported in many types of cancer. A 
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study by Zheng et al. (2011) reported the expression and activation of ERK/MAPK 
cascade in an oesophageal SCC cell line (i.e., EC9706). The study also found ERK 2 to be 
more important than ERK 1 in the proliferation of SCC cells. It was recently shown that 
several NSAIDs including aspirin down-regulates ERK/MAPK cascade by inhibiting the 
binding of oncogene Ras to c-Raf which otherwise would activate ERK pathway leading to 
carcinogenesis (Pan et al., 2008).   
1.3.4b(v) AMPK/mTOR 
Adenosine monophosphate-activated protein kinase (AMPK) is an energy-sensing enzyme 
capable of detecting and reacting to AMP:ATP variations during hypoxia, exercise, 
ischemia and glucose deprivation (Hardie, 2011). In order to live up to the energy 
demands, AMP inhibits ATP-consuming processes and in turn generates more ATP by 
initiating β-oxidation of fatty acids. Recent studies have reported that AMPK plays a 
pivotal role in regulating diverse oncogenes involved in cancer progression, such as p53, 
fatty acid synthase (FASN) and mechanistic target of rapamycin (mTOR) (Luo et al., 
2010). A study using CRC cells found that mM concentrations of aspirin was adequate to 
(a) down-regulate mTOR pathway by inhibiting mTOR effectors S6K1 and 4E-BP1 and 
(b) alter nucleotide ratio and activate AMPK pathway (Din et al., 2012). In fact, AMPK 
activation and autophagy as a result of mTOR inhibition was greater when aspirin was 
given in combination with metformin (an AMP activator) treatment (Din et al., 2012).    
1.3.4b(vi) Acetylation of proteins by aspirin 
Aspirin has been shown to acetylate several plasma constituents (hormones and enzymes), 
biomolecules (DNA and RNA) and proteins (haemoglobin and histones) in vitro (Alfonso 
et al., 2009; Pinckard et al., 1968). A study found aspirin (100 µM) to acetylate the key 
tumour suppressor protein p53 in human breast cancer cell line (Alfonso et al., 2009). An 
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increase in acetylation of p53 by aspirin has been associated with increased p53 binding to 
DNA and expression of its two targeted genes, p21
CIP1
 (protein involved in cell cycle 
arrest) and Bax (Bcl-2-associated X protein, a mitochondrial pro-apoptotic protein). 
According to a study, treating oesophageal cancer cell lines with aspirin reduced B-cell 
lymphoma 2 (Bcl-2) expression, whereas no changes were noted with expression of Bax 
and p21 (Li et al., 2000).  
1.3.4b(vii) Akt/PDK-1 
3-phosphoinositide-dependent-kinase-1 (PDK-1), a kinase crucial in the activation of Akt 
pathway, is implicated in the progression of several cancers (Vivanco and Sawyers, 2002). 
Phosphoinositide 3-kinase (PI3K) indirectly regulates PDK-1 by phosphorylation of 
PtdIns(4,5)P2, co-recruiting PDK-1 and its substrate Akt, leading to phosphorylation and 
activation of Akt, a critical regulator of cell growth, proliferation, motility and survival. 
Anti-apoptotic property of Akt is exerted by phosphorylated inactivation of pro-apoptotic 
protein BAD (Bcl-2 associated death promoter), direct phosphorylation of proteins that 
down-regulates β-catenin levels, phosphorylation of caspase 9 to prevent its cleavage to 
active form of caspase 9 (Fig. 1.3.2) (Hanada et al., 2004). Several studies have reported 
that the apoptotic effect of celecoxib is through inhibition of PDK-1 and Akt (Gurpinar et 
al., 2013). The ability/efficiency of the drug celecoxib to induce apoptosis in HT-29 colon 
cells was found to be dependent on mutational or expression status of PDK-1 and/or Akt 
(Arico et al., 2002).    
1.3.4b(viii) Specific protein (Sp) regulated anticancer effect of aspirin 
Sp or zinc transcription factor are key proteins involved in various cellular processes such 
as cell differentiation, growth, apoptosis and immune responses. A study indicated that use 
of aspirin-like nitro-NSAID ie., GT-094 exerted anticancer effect on CRC through a 
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reactive oxygen species-dependent regulation of Sp transcription factors and Sp-regulated 
genes. Sp regulated genes include key apoptosis-control genes like Bcl-2, survivin, 
hepatocyte growth factor receptor (c-MET), VEGF and its receptors VEGFR1 (Pathi et al., 
2011). Moreover, anticancer effect of aspirin on CRC was found to be through induction of 
apoptosis and down-regulation of Sp-regulated genes involved in CRC carcinogenesis 
(Pathi et al., 2012). In the same study, the anticancer effect of aspirin was found to be 
similar to that of salicylate and thus they proposed that the chemotherapeutic effect of 
aspirin may primarily be due to salicylate metabolite.  
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 MATERIALS and METHODS 2.
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2.1 Materials 
2.1.1 Reagents  
Unless otherwise stated all chemicals were standard reagent grade or higher and purchased 
from Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK. Tissue culture media and 
supplements were all purchased from Life Technologies Ltd (Gibco), Inchinnan Business 
Park, Paisley, UK. 
Amersham Pharmacia Biotech, Buckinghamshire, UK 
-pGEX6P-1  
-Glutathione Sepharose-4 Fast-Flow column 
 
Calbiochem (EMD Chemicals), San Diego, CA, USA 
-Bleomycin sulphate, Streptomyces verticillus (Cdk1 inhibitor III) 
-Protease inhibitor cocktail set I 
-InsP6 
 
Cayman Chemical Company, Ann Arbor, Michigan, USA 
-Colorimetric COX (ovine) inhibitor screening assay kit. Cat No. 760111 
 
Calbiochem/Novagen (EMD Chemicals), San Diego, CA, USA 
-KOD hot start DNA polymerase kit 
 
Fisher Scientific Ltd, Bishop Meadow Road, Loughborough, UK  
-Acrylamide 40% solution (Acrylamide : Bis-acrylamide, 29 : 1) 
 
ForMedium™, Hunstanton, Norfolk, UK 
-Yeast nitrogen base without amino acids  
-Yeast synthetic drop-out media supplement without histidine  
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Geneflow Ltd, Lichfield, Staffordshire, UK 
-50x TAE buffer 
 
Invitrogen Ltd, Paisley, Scotland, UK (incorporating Gibco, Life Technologies) 
-Geneticin G-418 sulphate 
 
Meridian Biotechnologies Ltd, Chessington, Surrey, UK 
-ProFlo+ scintillant (custom preparation for high phosphate) 
 
New England Biolabs Ltd, Hitchin, Hertfordshire, UK 
-Uracil-DNA Glycosylase (UDG)  
-AP endonuclease (APE-1) 
-T4 DNA ligase 
 
Oxoid Ltd (Thermo Scientific), Basingstoke, Hampshire, UK 
-Bacteriological peptone 
 
Promega Corporation, Madison, WI, USA 
-1kb DNA ladder 
 
QIAGEN Ltd., Crawley, West Sussex, UK 
-MinElute pcr purification kit  
-QIAquick gel extraction kit  
-Q solution 
-MinElute gel extraction kit 
-Miniprep kit 
-pQE30 
Roche Diagnostics Operations Inc., Indianapolis, IN, USA 
-Annexin-V-Fluos staining kit (flowcytometer) 
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Thermo Fischer Scientific Inc., Rockford, IL, USA 
-4',6-diamidino-2-phenylindole (DAPI) 
 
VWR International Ltd, Lutterworth, Leicestershire, UK 
-Tris-(hydroxymethyl) aminomethane 
 
Dr Tim Underwood, University of Southampton, UK 
Kindly provided oesophageal cancer cell lines- oe21, flo-1 and oe33  
 
Dr. Stephen K Dove’s lab, University of Birmingham, UK 
Vector pFA6a-GFP(S65T)-HIS3MX6 (Longtine et al. 1998) ( (Fig.2.2.2) 
 
University of Wolverhampton, UK 
Aspirin analogues: PN508, PN510, PN511, PN512, PN514, PPN517, PN524, PN525, 
PN526, PN527, PN528 and PN529 prepared by Dr Chris Perry. 
 
Professor A.G. McLennan 
Kindly gifted Ddp1p 
 
 
Dr S.B. Shears (NIEHS, NIH, RTP, NC, USA) 
Radiolabeled and non-radiolabeled 1-InsP7, 5-InsP7 and InsP8 
2.1.2 Strains, nucleotide and primer sequences 
Sigma-Genosys, Sigma custom product, Suffolk, UK 
-Fluorescein tagged DNA strands – JJC, JJU and 16PG. Untagged reverse complements 
JJG and a hairpin loop (HP). Complete sequences are listed in the Table 2.1.1.  
-List of primers used in this study and their sequences are mentioned in the Table 2.1.3. 
Primers SSW6-15 were adapted from (Longtine et al., 1998). 
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Euroscarf, Frankfurt, Germany 
Wild-type S. cerevisiae strain was used for the experiments. All the other yeast strains used 
in the study are given in the Table 2.1.2. 
2.1.3 Media composition and solutions 
Ingredients used for the solutions are listed in the Table 2.1.4 
 
 
Sequence 
name 
Nucleotide sequence (5′--3′) 
JJC Fluorescein-
CGGAATTCGTCTAGGTTTGAGGTCGACATCGGATCCATGGTACCTCGAGGG
CAATGTCTA 
JJU Fluorescein-
CGGAATTCGTCTAGGTTTGAGGTUGACATCGGATCCATGGTACCTCGAGGG
CAATGTCTA 
JJG TAGACATTGCCCTCGAGGTACCATGGATCCGATGTCGACCTCAAACCTAGA
CGAATTCCG 
16PG Fluoroscein-CAATAGAGTAACACGG-PG 
 
HP pCGACCAGTCCCTGCCTTTTGGCAGGGACTGGTCGGCCGTGTTACTCTATTG 
 
 
Table 2.1.1 List of nucleotide sequences used in this study 
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Strain name Genotype source 
BY4741 MATa; his3∆1; leu2∆0; met15∆0; ura3∆ Euroscarf 
plc1 BY4741; plc1::kanMX4 Euroscarf 
arg82 BY4741; arg82::kanMX4 Euroscarf 
ipk1 BY4741; ipk1::kanMX4 Euroscarf 
kcs1 BY4741; kcs1::kanMX4 Euroscarf 
vip1 BY4741; vip1::kanMX4 Euroscarf 
rad51 BY4741; rad51::kanMX4 Euroscarf 
rad52 BY4741; rad52::kanMX4 Euroscarf 
ku70 BY4741; ku70::kanMX4 Euroscarf 
adk1 BY4741; adk1::kanMX4 Euroscarf 
pho80 BY4741; pho80::kanMX4 Euroscarf 
pho81 BY4741; pho81::kanMX4 Euroscarf 
pho85 BY4741; pho85::kanMX4 Euroscarf 
ipk1/kcs1 Prepared by Dr. Steve Safrany        - 
 
Table 2.1.2  List of S. cerevisiae  strains used in this study
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ID no. 
 
Primer name Primer sequence (5′--3′) 
SSW6 Ung1-GFP 
(forward)(no stop) 
GGAGGCAAATGCTCGCTTAGAGTCAGAATCAAAGG
ACCCTCGGATCCCCGGGTTAATTAA 
SSW7  Ung1-GFP (reverse) AGAGTTTGGAAATCGAGACCTGCATATGCAATAGTA
ATATGAATTCGAGCTCGTTTAAAC 
SSW8 Apn1-GFP 
(forward)(no stop) 
CTTGTCACAAATGACAAAGAAGAGGAAGACTAAGA
AAGAACGGATCCCCGGGTTAATTAA 
SSW9 Apn1-GFP  
(reverse) 
CAAAAATTGATTACGTATTTAAAATTCTTCTCGCTTC
TCA GAATTCGAGCTCGTTTAAAC 
SSW10 Apn2-GFP (forward) 
(no stop) 
AAATAATACAGAATCATCTTGTGGGTTTTTTCAGTGG
GTTCGGATCCCCGGGTTAATTAA 
SSW11 Apn2-GFP (reverse) GTGTTTTATTCTCCCAAAATATCAGCTGACGTTTTCA
TATGAATTCGAGCTCGTTTAAAC 
SSW12 Rad51-GFP (forward) 
(no stop) 
CTATGAAGATGGTGTTGGTGACCCCAGAGAAGAAGA
CGAGCGGATCCCCGGGTTAATTAA 
SSW13 Rad51-GFP (reverse) GTAAACCTGTGTAAATAAATAGAGACAAGAGACCA
AATACGAATTCGAGCTCGTTTAAAC 
SSW14 Rad52 GFP (forward) 
(no stop) 
AAGACCAAAGATCAATCCCCTGCATGCACGCAAGCC
TACTCGGATCCCCGGGTTAATTAA 
SSW15 Rad52-GFP (reverse) AATGATGCAAATTTTTTATTTGTTTCGGCCAGGAAGC
GTTGAATTCGAGCTCGTTTAAAC 
SSW21 Ung1 (~50bp upstream 
of junction) 
AACGATTGGCTATACAATACCCGCGGAGAG 
 
SSW22 Apn1 (~50bp upstream 
of junction) 
AAGTTTGAGGTTAAACAAAAGAAGCGAGCT 
 
SSW23 Apn2 (~50bp upstream 
of junction) 
GAATCCATGCTGAAAACATCGAAAACTTCG 
 
SSW24 Rad51 (~50bp 
upstream of junction) 
CAAAAAGGGTAAGGGATGTCAAAGATTATGC 
 
SSW25 Rad52 (~50bp 
upstream of junction) 
GCCGCCTTCTAAGGTAGTACATCCTAATGG 
 
SSW26 GFP (reverse) CCTTCACCCTCTCCACTGACAG 
SSW27 Kcs1-upstream GTACATCTTTCTGTCTTCTC 
SSW28 Kcs1-downstream CGGACTGAAATAAGCGCAGC 
SSW29 Ipk1-upstream CGTGATATGCTACCAGTCG 
SSW30 Ipk1-downstream GTATGTGCATCTGCCAGTAC 
SSW31 Arg82-upstream GATATGTGCATACGTGTGCC 
SSW32 Arg82-downstream CAAGGTAAACTTCACCTCTC 
                                     
Table 2.1.3 List of primers used in this study 
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Table 2.1.4 Media composition and solutions 
 
 
 
 
 
 
 
 
 
Media/solutions Composition 
Luria Bertani (LB) + 
antibiotics 
Yeast Extract (0.5%, w/v), tryptone (1%, w/v), NaCl (1%, 
w/v) + ampicillin (100 μg/ml) or/and Geneticin (G418) (200 
μg/ml) 
LB agar + antibiotics LB + Bacto agar (2%, w/v) 
 
Yeast Extract Peptone 
Dextrose (YPD) + 
antibiotic 
Yeast Extract (1%, w/v), Bacto peptone (2 %, w/v), glucose 
(2 %, w/v) + ampicillin (100 μg/ml) or/and G418 (200 
μg/ml) 
YPD agar + antibiotics YPD + Bacto agar (2%, w/v) 
 
Yeast synthetic drop-out 
media supplement 
without histidine (DO-
His) agar (1L) + 
antibiotics 
Yeast nitrogen base without amino acids (0.67%, w/v), yeast 
synthetic drop-out media supplement without histidine 
(0.192%, w/v), Bacto agar (2%, w/v). 
The media was autoclaved for 15 min at 121°C. Media was 
cooled down to 55-60 ºC before adding glucose (2%, w/v) 
(from a 40% w/v stock) and ampicillin (100 μg/ml) or/and 
G418 (200 μg/ml). 
10X DNA gel 
electrophoresis sample 
loading buffer [for urea-
polyacrylamide gel 
electrophoresis (urea-
PAGE)] 
Glycerol (100%, v/v), bromophenol blue (0.1%, w/v) 
For every 20µl of sample, 2µl of the above sample buffer 
was used. 
5X DNA gel 
electrophoresis sample 
buffer 
Glycerol (30%, v/v), xylene cyanol (0.25%, w/v), 
bromophenol blue (0.25%, w/v). 
For every 10µl of sample, 3µl of the above sample buffer 
was used. 
1X PAGE running buffer Tris (25 mM), glycine (192 mM) 
Phosphate buffered 
saline (PBS) 
Sterile PBS was prepared using PBS tablets and filter-
sterilized via a 0.22 μm filter or autoclaved. 
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2.2 Methods 
2.2.1  Yeast strains and culturing requirements  
Haploid strains of S. cerevisiae (BY4741) and deletion strains were obtained from 
Euroscarf. All the strains except for ipk1/kcs1 were BY4741 with a background of 
MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0, utilizing the kanMX4 deletion strategy, unless 
specified otherwise. KanMX4 plasmid contains the G418 cassette which makes the strains 
resistant to antibiotic Geneticin (G418) (Brachmann et al., 1998). ipk1/kcs1 double 
knockouts were prepared by mating a kcs1 BY4741 MATa with a ipk1 BY4742 MATα - 
causing sporulation, and pulling  tetrads (by Dr Steve Safrany). Sporulation was of 
particularly low efficiency. Tetrads were only considered when four colonies grew from 
any particular tetrad. Once colonies were established, a polymerase chain reaction (PCR) 
based analysis was performed to determine whether kcs1, ipk1 or kanMX genes were 
present. All the mutants were tested by PCR using primers encompassing the relevant 
genes individually (Fig. 2.2.1). 
 S. cerevisiae strains were grown in standard Yeast extract–Peptone-Dextrose (YPD) or 
Synthetic dropout media supplemented with essential amino acids. All the strains were 
grown in the presence of an antibiotic i.e., ampicillin to avoid contamination. Strains were 
generally cultured at 30 ºC in a shaking incubator. ipk1/kcs1 and kcs1 are temperature 
sensitive and thus required an ideal temperature of 30 ºC and not above.  All the yeast 
strains used in this study are listed in Table 2.1.2. 
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Figure 2.2.1 Verification of mutants using PCR. DNA was obtained from each of the 
strains e.g. wild-type, kcs1, ipk1 and arg82 by following lyticase-sorbitol treatment as 
mentioned in Section 2.2.19.  Following heat treatment, 1µl of this mixture was used as 
template DNA for each PCR reaction. Primers for specific genes were used; these flanked 
the gene of interest, beyond the region where the kanMX4 cassette should have been 
inserted. The example shows primers for Kcs1, Ipk1 and Arg82 testing wild-type, kcs1, 
ipk1 and arg82 for the presence of the gene (varied sizes) or kanMX4 cassette (~2 kb). 
When genes were of a similar size to the kanMX4 cassette the PCR product was diagnosed 
using restriction enzyme mapping. DNA amplification was achieved using the following 
PCR setting: 95
 
ºC, 7 min, followed by 40 cycles of 95
 
ºC, 1 min; 45
 
ºC, 1 min; 72
 
ºC, 4 
min. Finally the incubations were held at 72 ºC for 10 min. 
Length of the G418 resistance marker product: ~2.0 kbp. 
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kcs1: length of the kcs1 product: 3274 bp.  
ipk1: length of the ipk1 product: 953 bp.   
arg82: Length of the arg82 product: 1135bp.  
2.2.2  Polymerase chain reaction 
All PCRs were performed with Labnet International’s TC020A MultiGene II thermal 
cycler. KOD hot start DNA polymerase kit was used for PCR reactions. For all the 
standard PCR reaction setup in this study, following components were used: 10X buffer 
diluted to 1X final concentration, 1.5 mM magnesium sulphate (MgSO4), 200 µM 
Deoxyribonucleotide triphosphate (dNTPs) (each) and 0.02 U/μl KOD  polymerase were 
mixed in one “master mix” made up to 40 μl total volume with ddH2O. To this master mix, 
appropriate upstream primer (300 nM) and downstream primer (300 nM) were added. 
Total reaction volume remained constant at 50 μl for all the reaction setup. In addition, a 
plasmid DNA template (pFA6a-GFP(S65T)-HIS3MX6) at a concentration of 10 ng was 
included for PCR reactions involving amplification of template DNA. The temperature 
cycling profile was as is shown in Table 2.2.1. A single step PCR program was used for all 
PCR reactions with varying annealing temperature. The annealing temperature  was 
calculated by presuming that all the bases in the primer sequence were complimentary to 
those on the target DNA. 
 
Table 2.2.1 PCR cycling profile 
 
Polymerase 
activation 
Denaturation Annealing Extension Final 
extension 
Soaking 
temperature 
96 °C 96 °C 50 °C   70 °C 70 °C 10 °C 
2 min 0.33 min 0.33 min 1.5 min 5 min/kb 12 h 
1 cycle 30 cycles 1 cycle 
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2.2.3  Drug sensitivity assay of yeast mutants 
Spot assay for yeast was employed to examine the sensitivity of anticancer drugs such as 
bleomycin and 5FU on wild-type and yeast mutants lacking IDPs or repair enzymes.  Stock 
solution of 10 mg/ml of 5FU was prepared by dissolving in dimethyl sulfoxide (DMSO). 
Bleomycin was dissolved in water to give a stock concentration of 10 U/ml. YPD agar + 
ampicillin (to avoid bacterial contamination) plates were treated with bleomycin (10 
mU/ml) and 5FU (2 µg/ml) respectively overnight prior to the addition of yeast strains. 
Yeast strains (wild-type, kcs1, arg82, ipk1, ku70, rad52, adk1, vip1, rad51, 
mdt1, ung1, apn1, apn2, pho80, pho81, pho85 and imp2) were grown to 
exponential phase and serially diluted to achieve half-log dilutions from 10,000 to 3 
cells/l. Serially diluted strains (1 µl/spot) were then pin-frogged/spotted onto drug-free 
(control) and drug-treated YPD agar-ampicillin plates. After 48 h of incubation at 30 ºC, 
growth was assessed and plates photographed. 
2.2.4 Preparation of DNA oligonucleotide working solution 
Double stranded oligonucleotide sequences as previously described by Owen et al. (2007); 
Sartori et al. (2001) were used as substrates for the experiments. Oligonucleotide 
sequences JJU and JJC used in this study are both 60 bp long and contain a fluorescein 
molecule tagged at 5′-terminus. Oligonucleotide JJG is a 60 bp long untagged reverse 
complement sequence. The ds- sequence employed have a matching pair of 
oligonucleotides containing a C:G (JJC/JJG) or a specific U:G mismatch (JJU/JJG). The 
oligonucleotide sequences are given in Table 2.1.1. The oligonucleotide working solution 
was prepared in the presence of annealing buffer comprising of 10 mM tris at pH 7.8, 50 
mM NaCl and ddH2O. Two oligonucleotide working solutions: (a) fluorescein-labelled ss-
DNA (JJU; JJC) (0.5 µM) and (b) ds-DNA made of labelled ss-DNA (0.5 µM) and 
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unlabelled reverse strand (1 µM) (JJU+JJG; JJC+JJG) were prepared by heating the 
oligonucleotides at 95 ºC for 5 min in the presence of annealing buffer and then cooling 
them slowly down to room temperature.     
In a similar way, F-16PGmer plus hairpin (HP) was prepared by annealing fluorescein-
tagged 16PGmer (3′-PG) to 5′ phosphate HP loop at 95 ºC for 5 min in the presence of 
annealing buffer (same as above). The solution was slowly cooled to room temperature.  
2.2.5 Urea-PAGE for separation of DNA oligonucleotide substrates 
Separation of substrate and the product was achieved using urea-PAGE. The assay 
protocols mentioned in the literature (Owen et al., 2007) were found to be inadequate and 
resulted in poor product resolution. Hence, assay conditions such as: a) presence of SDS, 
b) urea concentration (Table 2.2.2), c) presence of stacking gel d) temperature at which gel 
was run, e) loading buffer and f) running buffer were altered to optimise the assay to our 
research needs.   
In general, resolving gel was prepared by using relevant concentration of urea and 
acrylamide (Table 2.2.2) along with 45 mM tris at pH 8.8, 0.02 mg/ml of ammonium 
persulphate and 0.1% TEMED.  The resolving gel was casted first into the PAGE 
equipment and iso-propyl alcohol was pipetted on top to remove air bubbles and even-out 
the surface. After polymerisation of the gel, iso-propyl alcohol was removed by washing 
with ddH2O.  A stacking gel, where required, was prepared by using appropriate 
concentration of urea and acrylamide (Table 2.2.2) along with 125 mM tris at pH 6.8, 0.02 
mg/ml of ammonium persulphate and 0.1% TEMED. The stacking gel was casted on top of 
the resolving gel holding the combs in place and was left to polymerize.  
For all the experiments, fluorescein-tagged DNA strands (ss- or ds-) were used at a final 
concentration of 50 nM. Oligonucleotide substrate samples were prepared by heat treating 
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labelled ss- or/and ds-DNA for 5 min at 96 
o
C in the presence of 10X sample loading 
buffer (10% glycerol containing 0.01% bromophenol blue). Equal quantity of samples 
were then loaded onto the gel and subjected to electrophoresis at 100 V/gel for 2 h at room 
temperature or for 1 h at 60 ºC in the presence of tris-glycine buffer.  
Reaction products were visualised using a Storm 840 phosphorimager using ImageQuant 
software. A blue-excited fluorescence (520-nm long-pass) filter was chosen to scan the 
gels at 800 V (photomultiplier tube voltage) with a pixel size of 100 microns.  
Urea gel 
concentration 
Acrylamide final concentration 
Resolving gel Stacking gel 
0 M 38% 4% 
0.5 M 36% 4% 
1 M 36% 4% 
3 M 32% 4% 
5 M 30% 4% 
7 M 25% 4% 
 
Table 2.2.2 Table outlining the acrylamide concentrations used in correspondence to 
urea concentrations in urea-PAGE gels. Acrylamide concentration for stacking gel 
remains constant at 4% regardless of urea concentration whereas acrylamide concentration 
for resolving gel differs with concentration of urea as outlined above. 
2.2.6  Denaturants for separation of DNA oligonucleotide substrates 
Fluorescein-labelled DNA strands, JJC (ss-DNA) and JJC+JJG (ds-DNA) were used as 
substrates for this experiment. APE1-buffer/NE-buffer-4 at a concentration of 1X (50 mM 
potassium acetate, 20 mM tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 
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7.9 at 25 ºC) was added to all samples to avoid changes in the pH. Both, ss- and ds- DNA 
substrates were treated with denaturants – glycerol, formaldehyde, formamide and DMSO 
individually at varying concentrations and incubated for 30 min at 30 ºC. The final 
concentrations of the denaturants ranged from 20% - 80%.  The samples were then heat 
treated in the presence of 10X sample loading buffer for 5 min at 96 
o
C before loading it 
onto urea-PAGE gel. A 7 M urea-PAGE gel was opted for this experiment. Gel was run at 
100 V/gel for 2 h at room temperature or for 1 h at 60 
o
C. Substrate-product separation was 
visualised using a Storm 840 phosphorimager with the help of ImageQuant software. Scan 
settings were same as mentioned in Section 2.2.5. 
2.2.7  Recombinant enzymes on single and double stranded DNA 
Catalytic activity of recombinant enzymes, UDG and APE1, on ss- and ds- DNA substrates 
were tested using this experiment. Labelled DNA strands, JJU (ss-DNA) and JJU+JJG (ds-
DNA) were used as substrates for this purpose. 1X NE-buffer-4 was added to all the 
samples. Initially, both ss- and ds-DNA (50 nM) were treated with 10 U/assay of human 
UDG enzyme (except for the control). Then, varying concentrations of human APE1 
enzyme (half-log dilutions from 10 U/assay) was added to the samples and incubated for 
30 min at 30 
o
C. A control, containing just the substrate and NE-buffer-4 was included in 
the experiment for comparison. The samples were heat treated for 5 min at 96 
o
C in the 
presence of 10X sample loading buffer before loading it onto 7 M urea-PAGE gel. The gel 
was run at 100 V/gel for 1 h at 60 °C. Substrate-product separation was visualised using a 
Storm 840 phosphorimager with the help of ImageQuant software (Section 2.2.5). 
Similarly, to examine UDG activity on ss- and ds-DNA, fluorescein-tagged substrates were 
treated with varying concentrations of UDG enzyme (half-log dilutions from 10 U/assay) 
(except for control). The mixture was incubated for 30 min at 30 
o
C and then heat treated 
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in the presence of 10X sample loading buffer. Samples were loaded onto a 7 M urea gel 
and run at 100 V/gel for 1 h at 60 °C. Gels were scanned using phosphorimager. 
2.2.8 Protein extraction from yeast 
Yeast strains were grown overnight at 30 °C in sterile YPD medium supplemented with 
ampicillin to minimize the chances of bacterial infection. The yeast strains were sub-
cultured next morning and allowed to grow (3-4 h) until cells attained log-phase. Number 
of cells in the culture was determined and equal number of cells for each of the yeast 
strains was obtained. Cells were spun down (3000 rpm, 3 min) and washed with ddH2O to 
remove traces of medium. The cell pellet was treated with 0.5 ml of the lysis buffer 
containing 1X protease inhibitor cocktail I (500 µM serine proteases, 150 nM serine 
proteases and esterases, 1 µM cysteine proteases, 0.5 mM metalloproteases, 1 µM cysteine 
proteases and trypsin-like proteases). The lysis buffer consists of 400 mM tris at pH 7.6, 2 
M NaCl, 0 mM or 1 mM or 100 mM EDTA, and the presence or absence of 2% Tween-20. 
Cell lysates were prepared by sonicating the cells for 1 min; cycle-1×10%; power-65%; 
using tapered tip (KE76) probe (Bandelin electronic). Supernatant was collected and stored 
at -20 
o
C for further use. The concentration of the protein was estimated using Bradford 
assay as described in Section 2.2.13. 
2.2.9 Identification of UDG-like enzyme in yeast extracts (Glycosylase assay) 
Both wild-type and kcs1 yeast extracts were prepared as described in Section 2.2.8. These 
extracts were tested for the presence of UDG-like enzyme. For this experiment, 
fluorescein-tagged JJU+JJG ds-DNA was used as substrate. 1X NE-buffer-4 was added to 
all the samples to avoid pH changes. The substrate (50 nM) was individually treated with 
wild-type yeast extract and kcs1 extract and incubated for 30 min at 30 ºC. A negative 
control containing untreated substrate and a positive control for UDG activity containing 
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substrate treated with UDG enzyme (10 U/assay) was included in the experiment for 
comparison. Following incubation, the samples were heat treated at 96 ºC for 5 min in the 
presence of 10X sample loading buffer. Samples were loaded onto 7 M urea-PAGE gel and 
run at 60 ºC for 1 h with 100 V/gel. Gel was visualised using Storm 840 phosphorimager 
(Section 2.2.5). 
2.2.10 Borohydride-trapping assay 
Sodium borohydride (NaBH4) has been previously shown to protect AP-sites in DNA from 
heat-treatment (Petronzelli et al., 2000). Thus, NaBH4 was used in this experiment to 
protect the AP-site, created by UDG enzyme, from heat treatment. Fluorescein-tagged 
JJU+JJG (50 nM) was used as substrate for this experiment. 1X NE-buffer-4 was included 
in all samples to avoid pH changes. To confirm the presence of UDG-like and APE1-like 
activity in both wild-type and kcs1 yeast extracts, the following conditions were included 
in the experiment.  
To determine APE1 activity, the substrate was treated with relevant yeast extract in 
combination with (i) UDG, (ii) UDG+NaBH4, and (iii) NaBH4. To determine UDG 
activity, the substrate was treated with relevant yeast extract in combination with (i) APE1, 
and (ii) NaBH4. A positive control for NaBH4 containing substrate with UDG+ NaBH4 was 
included for comparison. A negative control containing untreated substrate and positive 
controls for recombinant enzymes (i) UDG, (ii) APE1, (iii) UDG+APE1 (each enzyme at 
10 U/assay) were also included for comparison. 
The samples following addition of yeast extracts and/or recombinant enzymes were 
incubated for 30 min at 30 ºC. And then, where required, NaBH4 was added to the samples 
at a final concentration of 100 mM and was further incubated at room temperature for 15 
min. (NaBH4 was freshly prepared in ddH2O just before the start of the experiment). All 
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the samples were heat treated at 96 ºC for 5 min in the presence of 10X sample loading 
buffer. Samples were then loaded onto 7 M urea-PAGE gel and run at 60 ºC for 1 h with 
100 V/gel. Gel was visualised using Storm 840 phosphorimager (Section 2.2.5). 
2.2.11 EDTA inhibition assay 
In this study, to ensure efficient extraction of protein from yeast, an extraction buffer 
containing high concentration of EDTA was employed. However, EDTA has been reported 
to inhibit DNA strand cleavage (Ason and Reznikoff, 2004). Thus, an experiment was 
conducted to check whether EDTA is involved in the catalysis of DNA substrate cleavage. 
For this experiment, yeast extracts prepared in the absence of both Tween-20 and EDTA 
was used. The fluorescein-tagged JJU+JJG ds-DNA was first treated with the relevant 
yeast extracts and then with increasing concentration of EDTA i.e., 0, 12.5, 25, 50 and 100 
mM final concentration. Samples were incubated for 30 min at 30 ºC and were heat treated 
for 5 min at 96 ºC in the presence of 10X sample loading buffer. Samples were loaded onto 
7 M urea gel and electrophoresed at 100 V/gel for 1 h at 60 ºC. Gel was scanned using 
Storm 840 phosphorimager (Section 2.2.5).   
2.2.12 Phosphoglycolate repair assay 
Reports suggest that APE1 is not only involved in nicking of the DNA at AP-site, but is 
also involved in the removal of 3′-PG (Parsons et al., 2004; Z. Wang et al., 2014). In this 
study, an oligonucleotide substrate (16mer) blocked with a 3′-PG moiety and 
complimentary 5′-phosphate HP were used to check for the ability of yeast extracts (wild-
type and kcs1) to remove the blocking 3′-PG moiety and perform repair in the presence of 
T4 ligase. 
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In this experiment, F-16PGmer along with HP (250 fmol/reaction) was incubated with 
either APE1 enzyme or relevant yeast extract for 1 h at 37 ºC in the presence of 1X NE-
buffer-4. To this mixture, 800 U/assay of T4 ligase along with T4 buffer was added and 
were further incubated for varying lengths of time (15, 30, 45 and 60 min) at 37 ºC. 
Following incubation, the samples were heat treated at 96 ºC for 5 min in the presence of 
10X sample loading buffer. Samples were loaded onto 7 M urea-PAGE gel and run at 60 
ºC for 1 h with 100 V/gel. Gel was visualised using Storm 840 phosphorimager using same 
settings as mentioned in Section 2.2.5. 
2.2.13  Estimation of protein concentration 
Protein concentrations were determined using an adaptation of methods previously 
described by Bradford (1976). Coomassie brilliant blue G-250 solution (Bio-Rad) was 
diluted 1:4 with ddH2O. Assays were performed by adding 100 ul of this diluted reagent 
with 10 ul of known standard or unknown sample in a 96-well plate. The samples were left 
for at least 5 min at room temperature and the absorbance was determined at 595 nm. The 
standard curve was created using bovine serum albumin (BSA) each time. The protein 
concentration was calculated with reference to this standard curve of BSA.  
2.2.14  Isolation of plasmid DNA from Escherichia coli   
E. coli (strain DH5) containing plasmid DNA pFA6a-GFP(S65T)-HIS3MX6 (Longtine et 
al., 1998) (Fig. 2.2.2) were grown on LB agar plates supplemented with 100 µg/ml 
ampicillin. LB broth containing ampicillin antibiotic was inoculated with E. coli and was 
cultured overnight at 37 ºC. The bacteria were spun down and the plasmid was isolated by 
following Qiagen’s Miniprep protocol. Steps followed in the plasmid isolation include 
sequential lysis, precipitation and elution using Miniprep kit.  
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Figure 2.2.2 Plasmid pFA6a-GFP(S65T)-His3MX6 map obtained from SnapGene 
resources webpage (SnapGene).  
 
2.2.15 GFP-tagging yeast proteins 
A modified version of green fluorescent protein (GFP) from the jellyfish Aequorea victoria 
is expressed in various organisms and it represents a good tool for determination of the 
subcellular localisation of proteins (Cubitt et al., 1995). In contrast to other bioluminescent 
systems, GFP works without exogenously added proteins, substrates or co-factors, 
allowing expression to be monitored in vivo (Chalfie et al., 1994). Tagging of 
chromosomal genes of budding yeast was done by HR via transforming corresponding 
PCR fragments into the desired strains. 
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For the chromosomal GFP tagging at 3′-terminal of target DNA repair genes, the knock-in 
fragment was amplified from the plasmid pFA6a-GFP(S65T)-HIS3MX6 (Longtine et al., 
1998) by PCR using primers that included the sequences for annealing to the template 
plasmid, flanked by sequences complementary to the 40 nucleotides immediately before 
and after the stop codon of the target gene. All primer sequences used for the above 
purpose are listed in Table 2.1.3. PCR reaction mixture preparation and the thermocycler 
settings used were same as described in Section 2.2.2 and Table 2.2.1. To check if the PCR 
was successful and whether it yielded correct size products, the PCR products were 
visualised using agarose gel electrophoresis (Section 2.2.16). Fig. 2.2.3 represents the gel 
showing the PCR products. The products were then excised from the gel, extracted 
(Section 2.2.17) and used to transform wild-type and kcs1 yeast strains. 
 
 
Figure 2.2.3 Gel showing PCR products. Primer pairs were used to insert GFP into the 
C-terminus of each protein using selected primer pairs (SSW6 and 7 for Ung1; SSW8 and 
9 for Apn1; SSW10 and 11 for Apn2; SSW12 and 13 for Rad51; SSW14 and 15 for 
Rad52) and plasmid pFA6a-GFP(S65T)-His3MX6 as template. PCR products were 
purified on an agarose gel before transformation into either wild-type or kcs1 mutant 
yeast. 
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2.2.16 Agarose gel electrophoresis 
1% w/v agarose gels were prepared by dissolving appropriate amount of ultra-pure 
electrophoresis grade agarose in 1X TAE buffer containing 0.5 µg/ml of ethidium bromide. 
The solution was heated to dissolve the agarose and was left to cool down to ~50 
o
C. The 
molten agar was poured into the casting tray with a plastic comb in place to form the 
loading wells. The gel was immersed in the gel tank containing 1X TAE buffer with 0.5 
µg/ml of ethidium bromide. 
Appropriate volume of 5X DNA loading buffer (3 µl for every 10 µl sample) was added to 
the samples before loading into the wells. The gel was run at 100 V for 45 min. The gel 
was removed and the fluorescing ethidium bromide with DNA was observed under 
ultraviolet (UV) light. The gel image was captured using GeneSnap software (Syngene) for 
further reference. 
2.2.17 Extraction of DNA from agarose gel 
The DNA bands were viewed using a UV trans-illuminator. Desired band was excised 
from the gel using a sterile scalpel with minimal exposure to the DNA. The excised slice of 
gel was transferred to a microfuge tube and the DNA was extracted using the Qiagen’s 
MinElute Gel Extraction Kit following the manufacturer’s protocol. Extracted DNA was 
eluted in ddH2O. 
2.2.18 Transformation of S. cerevisiae with plasmid DNA 
Yeast strains (wild-type and kcs1) were grown overnight at 30 °C in sterile YPD medium 
supplemented with 100 µg/ml ampicillin. The yeast strains were sub-cultured next morning 
and were allowed to grow (3-4 h) until cells attained log-phase. Yeast cells were spun 
down (3000 rpm, 3 min) and washed with ddH2O to remove traces of medium. Cells were 
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spun down and the pellet was re-suspended in 1 ml of 100 mM LiAc for 5 min at room 
temperature. Cells were pelleted and the reagents – 32% PEG, 0.1 M LiAc, 0.27 mg/ml 
carrier DNA (salmon sperm DNA), approximately 10 μg of relevant PCR product (refer 
Section 2.2.15 and Fig. 2.2.3) were added in the same order mentioned as above. The 
contents were vortexed vigorously after each reagent was added. The suspension was then 
subjected to heat shock at 42 °C for 90 min. The cells were spun down (8000 rpm, 3 min) 
and the pellet was re-suspended in sterile YPD medium containing ampicillin. The yeast 
cells were allowed to recover at 30 °C for 3 h. Cells were pelleted (5000 rpm, 3 min) and 
washed with distilled water to remove traces of medium. Cells were pelleted (5000 rpm, 3 
min) and re-suspended in sterile ddH2O. The yeast cells were then plated on DO-His 
(plasmid pFA6a-GFP(S65T)-HIS3MX6 has a ‘histidine’ marker) agar plates containing 
100 µg/ml ampicillin (Sambrook et al., 1989). The plates were incubated for 3-4 days at 30 
°C until clones appeared on the plate. Once colonies grew on the selective media, the 
plates were stored at 5 ºC  
2.2.19 Extraction of genomic DNA from yeast 
Single yeast colonies were picked from the DO-His agar plates (refer Section 2.2.18) and 
suspended in buffer (10 µl) containing lyticase (200 U/assay) and 1.2 M sorbitol (lyticase-
sorbitol treatment). Samples were incubated at 37 ºC for 1 h and then heat treated at 94 ºC 
for 1 min. 1 µl of this sample/DNA was used for further amplification of the desired 
fragment using PCR.  
For GFP-tagged proteins in yeast: A gene-specific upstream primer (SSW21-25) along 
with a GFP/common downstream primer (SSW26) was used (Table 2.1.3) for 
amplification of desired fragment. PCR was carried out with the same settings as described 
in Section 2.2.2 and Table 2.2.1. The resultant product was electrophoresed in agarose gel 
(Section 2.2.16) and visualised (Fig. 2.2.4). A DNA marker was run alongside the samples. 
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The products/bands were checked for the right size and purity. Desired bands were 
excised, extracted (Section 2.2.17) and were sent for sequencing (Source BioScience 
LifeSciences sequencing service, Nottingham, UK).  
The samples were screened for the presence of a GFP-tag downstream of the gene of 
interest and putative knock-in strains were to be confirmed by sequencing the appropriate 
locus of genomic DNA recovered from transformed cells. 
 
 
Figure 2.2.4 PCR amplification of genomic DNA of successful GFP-tagged yeast 
clones. Lanes 1-2: wild-type-GFP-Ung1, lane 3: wild-type-GFP-apn1, lanes 4-5: wild-
type-GFP-apn2, lanes 6-7: wild-type-GFP-rad51, lanes 8-9: wild-type-GFP-rad52, lanes 
10-11: kcs1-GFP-apn2, lane 12: kcs1-GFP-Ung1, lanes 13-14: kcs1-GFP-apn1. Lanes 
1-11 show successful incorporation of the GFP-kanMX4 cassette, whereas lanes 12-14 
show unsuccessful colonies.  
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2.2.20  Subcellular localization of GFP-tagged protein 
GFP-tagged (GFP-Ung1, GFP-Rad51, GFP-Rad52 and GFP-Apn1) successful wild-type 
and kcs1 yeast clones were grown to exponential phase in YPD medium supplemented 
with ampicillin. Using confocal microscopy, images of the live yeast cells constitutively 
expressing GFP-tagged protein were captured. Leica microsystems TCSSP5 system 
confocal microscope with an argon laser set at 488 nm and a 63x oil objective was used to 
capture live images of the yeast cells.  At first, images of untreated live yeast cells (control) 
were captured by placing them on a glass slide covered with a glass coverslip.  Next, the 
clones were individually treated with 5 mU/ml bleomycin (bleomycin was diluted in YPD 
medium) for 90 min at room temperature. Localisation of GFP-tagged protein in wild-type 
and kcs1 was visualised. Further, the medium containing the drug was removed by 
pelleting the yeast cells (5000 rpm, 3 min). The cells were re-suspended in drug-free YPD 
medium containing ampicillin and were allowed to recover for 1 h at room temperature. 
Localization of GFP-tagged proteins post recovery was examined.  
2.2.21 Glutathione S-transferase (GST)-tagging of recombinant proteins  
GST-tagging of DIPP-3α (hAps2) and DIPP-3β (hAps1) was performed exactly as 
described by Leslie et al. (2002). The GST-tagged DIPPs 1, 2α and 2β plasmids (Caffrey et 
al., 2000; Safrany et al., 1998) were prepared by subcloning the relevant DIPP from 
pQE30 into pGEX6P-1 using BamHI and SalI. All clone sequences were verified. 
Expression plasmids based on pGEX6P-1 were transformed into E. coli strain BL21, and 
induced at 26 ºC overnight with 100 µM isopropyl β-D-1-thiogalactopyranoside. Cells 
were then harvested and disrupted by sonication (3 × 15 s) in the presence of buffer A 
containing 20 mM Tris, 150 mM NaCl, 2 mM dithiothreitol, 0.1 mM EGTA, pH 7.5, 
supplemented with 5 μg/ml leupeptin and 1 μg/ml aprotinin. Floating particles were 
removed by centrifugation. The supernatant containing GST-DIPPs were subsequently 
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purified using a 5 mm × 5 cm Glutathione Sepharose-4 Fast-Flow column at a flow rate of 
1 ml/min. Using buffer A, the column was washed for 5 min. Proteins bound to the column 
was eluted using a gradient generated by the mixing of buffer A and buffer B (buffer A 
plus 25 mM glutathione, pH 7.5) as follows: 0-10 min, 0-50% buffer B; 10-13 min, 100% 
buffer B. The eluted proteins were stored at -80 ºC in 10% v/v glycerol.  
2.2.22 Enzymatic synthesis and purification of IDPs  
Three IDPs, both radiolabeled and non-radiolabeled (1-InsP7, 5-InsP7 and InsP8) were 
enzymatically-prepared, purified by PAGE-based technique as described (Loss et al., 
2011; Weaver et al., 2013) and provided by Dr S. B. Shears. Samples from “blank” gels 
i.e., no IDPs, processed in parallel, provided vehicle controls. Purity of [
3
H] 1-InsP7, [
3
H] 
5-InsP7 and [
3
H] InsP8 were assessed by HPLC and were found to be 95%, 86% and 94%, 
respectively. Such slight decomposition of the pyrophosphate groups have been reported to 
not affect assays of DIPP activity. All assays were corrected for the small proportions of 
products observed at “zero-time”.  
2.2.23 Enzyme Assay 
Phosphatase activity was investigated at 30 ºC for Ddp1p or at 37 ºC for human DIPPs in a 
reaction buffer (20 µl) that simulates intracellular conditions. The ingredients of the 
reaction buffer include 50 mM KCl, 50 mM HEPES (pH 7.2 with KOH), 4 mM CHAPS, 
0.05 mg/ml BSA, 1 mM Na2EDTA, 2 mM MgSO4. Appropriate [
3
H]-radiolabeled (Tritium 
or Hydrogen-3) and non-radiolabeled InsP7 or InsP8 were added to the assays containing 
the relevant enzyme. After 2-25 min, corresponding to approximately 20% substrate 
metabolism, reactions were quenched with 20 μl of ice-cold 2 M perchloric acid, 
centrifuged, and the supernatant was neutralized with 26.5 μl of 2 M K2CO3, 5 mM 
Na2EDTA. The potassium perchlorate precipitate was removed by centrifugation. Each 
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supernatant was further diluted in 100 μl Na2EDTA (1 mM) and then loaded onto a 
HiChrom 4.6 × 125 mm Partisphere 5 µM SAX column. The bound inositol phosphates 
were eluted at 1 ml/min using one of the two protocols generated by mixing buffer A (1 
mM Na2EDTA) with buffer B [A + 1.3 M (NH4)2HPO4, pH 3.85 with H3PO4]. Protocol 1, 
where 1 ml fractions were collected: 0-5 min, B = 0%; 5-10 min, B = 0-45%; 10-55 min, B 
= 45-100%. Collection started at 24 min. Protocol 2, where 0.5 ml fractions were collected: 
0-5 min, B = 0%; 5-10 min, B = 0-50%; 10-55 min, B = 50-100%. Collections started at 
24.4 min. Fractions were mixed 1:3 with ProFlo+ scintillant and the [
3
H]-labelled IDPs 
were assayed by liquid scintillation spectrometry. Km and kcat values were obtained by non-
linear regression analysis (GraphPad Prism 6).   
2.2.24  Mammalian cell culture 
All procedures and experiments requiring tissue culture were carried out aseptically in a 
laminar tissue culture hood using sterile reagents and equipment. Different cell lines were 
cultured separately to avoid cross contamination. An inverted phase contrast microscope 
(Nikon Eclipse TS100) was used to view the culture flask for cell morphology and 
confluency.  
2.2.24a  Culturing mammalian cells  
All solutions used for tissue culture were warmed to room temperature before use. Cells in 
culture were regularly split to maintain and to provide sufficient amount of cells for 
experiments. To perform this, cells were washed gently with 0.25% Trypsin-EDTA to 
remove trace of foetal bovine serum (FBS). Cells were detached from the substratum by 
further incubation with 0.25% Trypsin-EDTA. After the cells had completely detached, 
fresh medium containing FBS was added to inactivate trypsin. Depending on the cell 
density and the rate at which the cells grow, splitting ratio was decided. Cells were seeded 
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accordingly in a tissue culture flask with fresh medium and then incubated at 37 ºC in a 
humidified 5% CO2 atmosphere. The medium was changed every third day until cells 
reached confluency. 
2.2.24b  Oesophageal cancer cell lines and their requirements 
All the oesophageal cancer cell lines were a kind gift from Mr Tim Underwood, (Clinical 
scientist, Cancer Sciences Division, University of Southampton). Details and properties of 
the cell lines are given in Table 2.2.3 and morphology in the Fig. 2.2.5.  
Oesophageal cancer cell lines, oe21 (oesophageal squamous cell carcinoma) and oe33 
(oesophageal adenocarcinoma), were both cultured in vented culture flasks in the presence 
of RPMI-1640 medium supplemented with 10% (v/v) heat inactivated FBS, 200 mM L‐ 
glutamine and 1% antibiotic solution (10,000 U/ml penicillin/ 10 mg/ml streptomycin 
solution). The cells were incubated at 37 ºC with an atmosphere of 5% CO2.  
Flo-1 cell line (oesophageal adenocarcinoma) were cultured in vented culture flasks in the 
presence of Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat 
inactivated FBS, 200 mM L‐ glutamine and 1% antibiotic solution (10,000 U/ml penicillin/ 
10 mg/ml streptomycin solution). The cells were incubated at 37 ºC with an atmosphere of 
5% CO2. 
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Cell 
line 
Other 
names 
Biologic
al source 
Tissue Cell line origin Growth 
mode 
Morphology 
oe21 JROECL21 Human Oesophagus Squamous carcinoma of 
mid oesophagus of a 74 
year-old male patient. 
Adherent epithelial 
oe33 JROECL33 Human Oesophagus adenocarcinoma of the 
lower oesophagus 
(Barrett′s metaplasia) of a 
73 year old female patient 
Adherent epithelial 
flo-1 - Human Oesophagus primary distal oesophageal 
adenocarcinoma in a 68 
year-old Caucasian male 
Adherent epithelial 
 
Table 2.2.3 Details and properties of oesophageal cancer cell lines used in this study. 
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Figure 2.2.5 Morphology of oe21 (SCC), oe33 (ADC) and flo-1 (ADC) oesophageal 
cancer cell lines. Phase-contrast images showing characteristic phenotypic differences 
between the three oesophageal cancer cell lines. Images were captured at 100x 
magnification. 
  
oe33oe21
flo-1
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2.2.24c Cell counting 
Followed by detachment of cells (Section 2.2.24a), a small aliquot of cell suspension was 
pipetted onto a haemocytometer to count. The number of cells in a 16-square grid of the 
haemocytometer was recorded and then the number was multiplied by 10,000 to get the 
number of cells present in 1 ml of the solution.  
2.2.24d Cryopreservation of cell lines 
Cell line to be cryopreserved was grown to a confluency of 90%. The cells were harvested 
and centrifuged at 5000 rpm for 5 min. The supernatant was removed and the cells were re-
suspended in 2 or 3 ml of the freeze medium (90% (v/v) FBS and 10% (v/v) DMSO). The 
suspension was gently mixed and 1 ml aliquots of cell suspension were pipette into the 
labelled cryovials. The cryovials containing cells were frozen slowly in a -80 ºC freezer 
overnight and then were transferred to liquid nitrogen (-180 ºC) vessel for long term 
storage . 
2.2.24e  Resuscitation of frozen cell lines  
Cryovial containing frozen cells from liquid nitrogen storage was quickly thawed by 
placing in a 37 ºC water bath. Cells were then transferred to 25 cm
2
 flask containing pre-
warmed medium and allowed to recover overnight in a 37
 
ºC incubator with 5% CO2. After 
24 h, media was replaced to minimise the toxic effects of the cryoprotectant DMSO. From 
then after, cells were periodically sub-cultured and maintained as per requirements of each 
cell line. 
2.2.25 Preparation of aspirin and aspirin analogue stock solutions 
Aspirin and aspirin analogues were prepared as fresh stock solutions in DMSO, usually at 
a concentration of 0.25 M, before each experiment. A higher stock solution of 0.5 M was 
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used for working concentrations over 1 mM in order to keep the DMSO levels within the 
tolerable limit (~10%). Working concentration of a drug was prepared by diluting 
calculated amount of stock solution in the culture medium. This medium containing the 
drug was used to treat the cells.  
2.2.26  Cell viability assay 
Cell viability was measured by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) reduction assay. Oesophageal cancer cells were seeded at a density of 
2.5×10
3
 or 1×10
4
 cells/well in a 96-well plate and incubated overnight at 37
 
ºC with 5% 
CO2. After 24 h of seeding, the culture medium was replaced with fresh medium 
containing the drug at required concentrations and was further incubated for 72 h or any 
required length of time. A negative control consisting of cells treated with medium only 
and a vehicle control consisting of cells treated with medium containing DMSO (to 
determine any effects of solvent on the cells) was also included in these experiments. On 
the completion of incubation time (72 h), supernatant was aspirated from each well and 
300 μl of MTT substrate (0.5 mg/ml) prepared in the relevant medium was added to the 
cells. After 3 h incubation, the resultant formazan crystals were dissolved with 200 μl of 
DMSO. The quantity of formazan formed was measured by recording changes in 
the absorbance at 540 nm in a microplate reader (Microplate Reader Thermo Multiskan 
Ascent 96 & 384). A standard curve for formazan was constructed to examine the relation 
between formazan concentration and absorbance (Fig. 2.2.6). All experiments were 
performed in triplicates and the viable cells were expressed as a percentage relative to the 
negative control cells (formula used is shown below). 
% Cell viability =
Absorbance540 (treated cells − blank)
 Absorbance540 (control cells − blank) 
× 100 
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Figure 2.2.6 Standard curve for formazan. Formazan samples were diluted with 
increasing amounts of DMSO. This assay shows a remarkable linear range when 
comparing amount of formazan with absorbance [linear up to Absorbance (540 nm) of 4]. 
Linear regression analysis indicated R-squared value to be 0.99 and the data was shown to 
fit well with the model. This permitted absorbance to be linked directly to cell activity and 
number. 
2.2.27  Apoptosis assays 
Induction of apoptosis/necrosis in oesophageal cancer cells by aspirin and aspirin 
analogues were examined using flow cytometric analysis and fluorescence imaging.  
In case of both the assays, three controls were included:  (a) negative control consisting of 
cells treated with medium only, (b) positive control for apoptosis (irinotecan, 25 µM) and 
(c) positive control for necrosis (hydrogen peroxide or H2O2, 2 mM). Irinotecan, a 
topoisomerase I inhibitor used in the treatment of CRC, has been previously reported to 
demonstrate cytotoxic effect via induction of apoptosis (Deb et al., 2011; Rudolf et al., 
2012). Hence, irinotecan was used as a positive control for apoptosis in the experiments. 
Irinotecan was prepared as stock solution in DMSO and further diluted to a final 
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concentration of 25 µM in culture medium. Induction of necrosis by H2O2 at higher 
concentrations (500 µM and above) has been previously reported (McKeague et al., 2003). 
Hence, H2O2 was used as a positive control for necrosis at a final concentration of 2 mM in 
the experiments. Freshly prepared 0.25 M stock solutions of the aspirin compounds were 
used to prepare final drug concentration of 1 mM each. Since the drug exposure time is 
crucial for induction of apoptosis, different exposure time points (24, 48 and/or 72 h) were 
used in the experiment. 
2.2.27a   Flow cytometric analysis of apoptosis 
Annexin-V-Fluos staining kit was used for the purpose of detection and quantification of 
apoptosis in drug-treated cells as opposed to control cells. The staining kit comprises of 2 
dyes: (1) Annexin-V, a Ca
2+
 -dependent dye that binds to phosphotidylserine upon 
initiation of apoptosis (Vermes et al., 1995), and (2) Propidium iodide (PI), a membrane-
impermeant dye, stains the non-viable cells by intercalating into ds-DNA (Chou et al., 
1987).  
Oesophageal cancer cells were cultured in 25 cm
2
 vented flask until they reached 50% 
confluency. Cells were then incubated for 24, 48 and 72 h with aspirin and aspirin 
analogues at 1 mM concentration. Additionally, three controls: cell control, irinotecan (25 
µM) and H2O2 (2 mM) were included in the experiment. After incubation, the cells were 
harvested and washed in Hank’s balanced salt solution (HBSS) buffer. The cells were then 
incubated with labelling solution (100 µl incubation buffer with 2 µl Annexin-V-Fluos 
reagent and 2 µl of PI used for ~10
6
 cells) for 10-15 min at room temperature as per the 
manufacturer’s instructions. The cells were then diluted with 0.5 ml of HBSS buffer (per 
10
6
 cells) and analysed on a flow cytometer (BD Biosciences, Facscalibur).  
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Flow cytometer settings used are as follows. An excitation wavelength of 488 nm and 
bandpass filter of 530 nm was set for fluorescein (green) detection. For PI, a bandpass 
filter of 600 nm was employed. For detection of early apoptosis and late 
apoptosis/necrosis, cells were gated into four populations: Annexin
-
/PI
-
, Annexin
+
/PI
-
, 
Annexin
+
/PI
+
 and Annexin
-
/PI
+ 
(Fig. 2.2.7).   
 
 
 
Figure 2.2.7 Gating live cells undergoing apoptosis and necrosis using flow cytometer. 
Figure represents the quadrants drawn on a cytogram to distinguish different cell 
populations that are stained Annexin
+/-
 and PI
+/-
. Population (healthy cells) that shows 
negative staining for both Annexin and PI fall in the 1
st
 quadrant. Early apoptotic cells that 
take up only Annexin stain fall in the 2
nd
 quadrant. Late apoptotic cells that take up both 
Annexin and PI fall in the 3
rd
 quadrant. Cells or sometimes debris show positive staining 
for PI and move towards 4
th
 quadrant.  
2.2.27b  Fluorescence imaging of apoptosis  
Sigma’s Apo-TRACE cell staining kit was used for fluorescence imaging. Apo-TRACE 
dye selectively marks the cells undergoing apoptosis (Damianovich et al., 2006) and the PI 
stains the non-viable cells. Appropriate number of oesophageal cancer cells were seeded 
Annexin--/PI--
(healthy cells)
Annexin+/PI--
(early apoptosis)
Annexin--/PI+
(necrosis)
Annexin+/PI+
(late apoptosis/necrosis)
1 2
34
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on sterile cover slips placed in a 6-well plate and were incubated at 37
o
C, 5% CO2. Cells 
were grown until they reached 50-60% confluency and were then incubated with aspirin 
and aspirin analogues at 1 mM concentration for 24 and 48 h. After the treatment time, 
supernatant was aspirated carefully and the coverslip was gently washed with PBS. The 
staining medium (75 µg/ml Apo-TRACE and 75 µg/ml PI in assay medium), prepared 
according to manufacturer’s instruction, was added on to the cover slip and incubated at 
room temperature for 15-20 min protected from light. The coverslip was gently washed 
with PBS and laid cell-side down on a drop of mounting medium dotted on to a glass slide. 
The cell staining was observed using a fluorescence microscope (BX61; Olympus optical, 
UK) with filter settings - DAPI (excitation:350 nm; emission:470 nm) for Apo-TRACE 
and Texas red (excitation 596nm; emission 615nm) for PI staining. The images were taken 
at 200x magnification. 
2.2.28 Recovery of drug treated cells 
To examine if aspirin analogues had the ability to induce cytostasis, recovery experiments 
were performed on drug-treated oesophageal cancer cells. Cells were seeded at a density of 
5×10
3 
or 2×10
4
 cells/well and incubated overnight at 37
 
ºC, 5% CO2. Cells were then 
treated with aspirin and aspirin analogues at a final concentration of 1 mM each for 72 h. 
At the end of incubation, the medium containing drug along with dead floating cells were 
removed and the adherent cells were harvested and washed with sterile PBS. Cells were 
then reseeded at a density of 5×10
3 
or 2×10
4
 cells/well in a fresh plate with drug-free 
medium and allowed to recover for 72 h in a 37
o
C, 5% CO2 incubator. At the end of the 
experiment, cells were collected by trypsinization and counted using a Beckman Coulter 
Z1 cell counter with an orifice of 100 m and threshold size of 10 m.  
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All the three controls: non-treated cell control, irinotecan and H2O2 treatments were 
included in this experiment. All experiments were performed in triplicates and the 
total number of viable cells was expressed as a percentage relative to the non-treated 
control cells. 
2.2.29  COX inhibitor screening assay  
Colorimetric COX (ovine) inhibitor screening assay kit from Cayman Chemical was used 
to determine whether or not the aspirin compounds inhibited COX enzymes. This assay 
measures the peroxidase activity of COX colorimetrically by monitoring the appearance of 
oxidized N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD) at 590 nm. 
The compounds to be tested were prepared as stock solutions on the day of the experiment 
by dissolving in DMSO. Stock concentrations were prepared such that a final volume of 10 
µl was added to the assay.  
Assay was performed as described in the user’s manual in a 96 well plate. The final 
volume of the assay was fixed at 220 µl in all the wells. Wells were divided into 3 groups: 
(a) non-enzymatic/ background wells (in duplicate), (b) 100% enzyme activity wells (in 
duplicate) and (c) Inhibitory wells (each inhibitor assayed in duplicate). The background 
wells comprised of 160 µl of assay buffer (0.1 M Tris-HCl, pH 8) and 10 µl of the Heme 
provided. The 100% enzyme activity wells and inhibitory wells both comprised of 150 µl 
assay buffer, 10 µl Heme and 10 µl of enzyme (either COX-1 or COX-2). In addition to 
above, 10 µl of inhibitor (aspirin or aspirin analogues) was added to the inhibitory wells 
and 10 µl of solvent (DMSO) was added to the 100% enzyme activity wells and the 
background wells. The plate was carefully agitated for few seconds and incubated for 5 
min at 25 ºC. To all the wells 20 µl of colorimetric substrate (TMPD) was added. Quickly, 
20 µl of arachidonic acid (100 µM final concentration) was also added to all the wells. The 
101 
 
plate was carefully agitated for few seconds and incubated for ~2 min at 25 ºC. 
Absorbance of the samples was recorded at 590 nm using a plate reader.  
For calculations, average absorbance of the each sample was determined. Absorbance of 
the background wells (no COX enzyme) was subtracted from 100% enzyme activity wells 
(positive control for COX enzyme) and the inhibitor wells (with aspirin and aspirin 
analogues). Percentage inhibition was calculated using non-linear regression (GraphPad 
Prism 6.0) using a log-linear sigmoidal dose response curve with 4 parameter analysis 
(max, min, log IC50 and slope). 
2.2.30  Curve fitting and Statistical Analysis 
All data analysis and curve fitting was performed using GraphPad Prism (version 6.02 for 
Windows). Characterization of enzyme profiles was performed using non-linear 
regression. Michaelis-Menten kinetics were determined using a rectangular hyperbolic fit 
of data to determine the maximum velocity of the enzyme (Vmax) and Michaelis constant 
(Km). Vmax values were normally distributed and so mean ± SEM could be presented. Km 
values are not normally distributed, so pKm (-log Km) values were calculated and 
statistically manipulated, allowing parametric analyses to be performed. 
Growth inhibition values were determined using a log-linear sigmoidal plot with 4 variable 
parameters (Minimum, maximum, IC50 value and Hill slope were not fixed). pIC50 (-
logIC50), minimum, maximum and Hill slopes were treated as being normally distributed, 
allowing parametric analyses to be performed. 
Column statistics were performed using unpaired analyses assuming equal sphericity and 
normal distribution. Data sets were compared using one-way ANOVA corrected for 
multiple comparisons. The mean of control data was compared to results from drug-treated 
cells using a Dunnett’s post-hoc analysis.  
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 RESULTS - ROLES OF INOSITOL 3.
DIPHOSPHATES IN DNA REPAIR 
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3.1 Introduction 
DNA damage comes in many forms and can affect any aspect of the DNA molecule. The 
correct repair of these lesions is vital for the cell to prevent loss of genetic information, and 
genetic instability is one of the hallmarks for cancer and/or subsequent death (Zhivotovsky 
and Kroemer, 2004). The growing list of human genetic diseases due to defects in DNA 
metabolism makes it particularly important that we expand our knowledge on how these 
processes occur. Conversely, rapidly proliferating tumour cells can be targeted and 
destroyed using agents that cause DNA damage (Swift and Golsteyn, 2014). Tight control 
over DNA repair mechanisms following DNA insult appears more crucial than first 
thought, as overactive repair is a proposed mechanism for tumour resistance against 
several anticancer agents (Jette et al., 2008; Ramotar and Wang, 2003).    
5FU and bleomycin are the two oldest chemotherapeutics used today in the clinic. 
Although both the drug causes DSDB (Mahaney et al., 2009; Swift and Golsteyn, 2014), 
5FU does it by irreversibly inhibiting TS and causing imbalance in the deoxynucleotide 
pool whereas bleomycin causes oxidative DSDBs in the presence of free radicals and metal 
ions. Action of these two drugs on DNA results in intermediates such as AP-site or/and 3′-
PG adducts which when left unrepaired can threaten to be cytotoxic and mutagenic to cells. 
Whether acquired or innate, tumour cells have found ways to exploit cellular repair 
mechanisms to correct the lesions and gain resistance against the damage causing agents.  
NHEJ and HR are two of the well characterised primary pathways of DSDB repair. HR 
lead to accurate repair of DSDBs whereas NHEJ is potentially mutagenic (Lieber et al., 
2003). Higher eukaryotes employ both the repair mechanisms while HR-mediated repair is 
predominantly seen in yeast (Ozenberger and Roeder, 1991; Pfeiffer et al., 2004). 
Irrespective of the origin, it is widely accepted that the AP-site or/and 3′-PG removal 
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requires a BER downstream enzyme, APE1. APE2 exhibits a weak endonuclease activity 
but possess strong exonuclease and 3′-phosphodiesterase activity (Burkovics et al., 2006). 
Correspondingly APE1 appears to be the common enzyme that brings together the repair 
mechanisms of 5FU and bleomycin.  However, recent studies report that there is “division 
of labour between NHEJ and BER” in repair of AP-sites based on the DNA sequence 
around the particular mismatch. Ku, an NHEJ complex, has been reported to nick AP-sites 
near broken DNA ends, if they were to obstruct the progression of ligation of DSDB 
during NHEJ (Strande et al., 2012).  Furthermore, Li et al. (2013), has proposed a role for 
free Ku70 and free Ku80 in the BER process. Ku70 in particular has been found to bind to 
the AP-sites and downregulate BER process by inhibiting APE1 activity (Choi et al., 
2014). 
Of many cofactors that are necessary for efficient DNA repair, IPs are considered vital. 
InsP6, a precursor of IDPs, was found to be an essential ‘stimulating-factor’ for DNA-PK 
dependent NHEJ in vitro in cell extracts (Hanakahi et al., 2000). InsP6 was subsequently 
shown to bind Ku70 (Hanakahi and West, 2002; Ma and Lieber, 2002). In this study, these 
results have been reassessed using live yeast to determine whether such events are 
important in vivo. This study also tries to address whether the DNA repairs observed are 
actually mediated by IDPs rather than their precursors. IDPs which possess highly 
energetic pyrophosphate bonds in their structure have been long suggested to own defined 
dynamic functions in vital cellular processes and it is possible that IDPs could contribute as 
cofactors to the repair mechanism.     
A genetically tractable eukaryotic model: S. cerevisiae has been employed for experiments 
in this study. This unicellular eukaryotic organism was selected in particular because a) 
many processes seen in higher multicellular eukaryotes are also utilized in yeast, b) 
knockout and overexpression methodologies which are extremely time consuming and 
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difficult can be completed rapidly and easily in yeast and, c) gene function is highly 
conserved (Tugendreich et al., 1994), phenotypes seen in yeast can alert us to functions in 
higher organisms that one may not study in mice due to gene redundancy, functional 
sterility or death in utero. In addition, homologues of many yeast genes in human DNA, 
especially those that are involved in cell cycle regulation, meiosis and DNA repair are well 
established (Game, 2002). Mutation of these key genes in yeast and phenotypic study on 
them could lead to new and greater understanding of human genes that are vital in cancer 
and other diseases.  
In this study, a particular family of yeast knockout mutants with modulated levels of IPs 
(Fig.1.1.2 in chapter 1) were used as a model to investigate the role of IDPs in DNA repair. 
All mutants used herein are from the same BY4741 background, utilizing the KanMX4 
deletion strategy, unless specified otherwise. Family of S. cerevisiae strains, with deletion 
mutation in genes that controls the levels of IP, used in this study include kcs1, ipk1, 
arg82 and vip1 (refer Fig. 1.1.2). Additionally, a family of yeast mutants with 
modulated levels of various DNA repair enzymes involved in repair processes including 
rad51, rad52, ku70, ung1, apn1, apn2, mdt1, imp2, pho80, pho81 and 
pho85 were used for the experiments. In addition, adk1 was also tested as it appeared to 
have similar properties to IDP mutants. Two DNA damage-inducing anticancer agents, 
5FU and bleomycin were exposed to this panel of mutants to see if knockdown of some of 
the key IPs or repair enzymes led to increased sensitivity of the yeast cells.  
The sensitive mutants were chosen to study further the factors behind drug intolerance. 
Increased sensitivity of mutants to the drugs was speculated to be due to defects in DNA 
repair. The focus of this study was on the two key repair enzymes, Ung1/UDG and 
Apn/APE1, which brought together the 5FU and bleomycin repair pathways. We wished to 
know if these enzymes were responsible for the increased sensitization of mutants to the 
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drugs. More importantly, we were interested to know if IDPs or inorganic phosphates 
participated as cofactors in these repair reactions. To monitor repair enzyme activity, a 
fluorescein-tagged ds- oligonucleotide substrate containing a G:U  mismatch was used for 
the experiments. Denaturing urea-PAGE method was developed to suit the experimental 
needs and to achieve efficient and, clear separation of strands. Extracts from wild-type and 
the sensitive yeast mutant were checked for the activity of UDG-like and APE1-like 
enzymes. Presence or absence of these enzymes was judged based on the separation of the 
product from the substrate in the urea-PAGE gels (refer Table 3.1.1). Ability of extracts to 
remove 3′-PG moiety and further perform the end-joining repair process in the presence of 
T4 ligase was also investigated in this study using fluorescien-tagged-16PGmer (F-16PG) 
and a oligonucleotide containg hairpin-loop (HP, a 51mer). 
Our hypothesis is that the yeast mutants lack a functional enzyme due to the absence of 
essential IP cofactors. In circumstances where there is a functional enzyme and our initial 
hypothesis was wrong, then we planned to GFP-tag the candidate repair enzymes and track 
their movement and localization using confocal microscopy studies.  
 
UDG APE1 Action Result 
  No AP-site formation and no 
nicking of substrate 
No product formed 
  Removal of uracil and formation of 
AP-site 
Partially formed 
product 
  Formation of AP-site and nicking of 
the substrate at AP-site 
Completely formed 
product 
  No AP-site formation and therefore 
no nicking of the substrate 
No product formed 
 
Table 3.1.1 Activity of repair enzymes on mismatched DNA substrate 
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3.2 Strains lacking IDPs are sensitive to bleomycin and 5FU 
InsP6, a precursor of IDPs, was found to be an essential ‘stimulating-factor’ for DNA-PK 
dependent NHEJ in vitro in cell extracts (Hanakahi et al., 2000). Following this report, we 
wanted to reassess these results using live yeast to determine whether such events are 
important in vivo. We also speculated that the observed DNA repair might actually be 
mediated by high energy IDP molecules rather than their precursor. In this regard, a spot 
assay was conducted to examine the sensitivity of yeast to agents causing DSDBs. The 
agent used to cause such insult was bleomycin. When bleomycin did, indeed, selectively 
kill mutants lacking IDPs a screen of other anticancer drugs was undertaken. Before my 
starting this project, the IDP mutants had been shown to have wild-type sensitivity to the 
following drugs: actinomycin-D, caffeine, camptothecin, carboplatin, Congo Red, copper 
sulphate, cyclophosphamide, cytosine--arabinofuranoside, deferoxamine, doxorubicin, 
EDTA, EGTA etoposide, ferric chloride, hydrogen peroxide, hydroxyurea, methotrexate, 
methyl methanesulphonate (MMS), mimosine, 4-nitroquinoline-1-oxide, paclitaxel, 
tamoxifen, valinomycin and UVA or UVC irradiation (data not shown). However, in 
addition to bleomycin, these mutants were found to be sensitive to 5FU. 
The results of this assay clearly show that yeast mutants were over 1000-fold more 
sensitive to bleomycin and 100-fold more sensitive to 5FU than the wild-type (Fig. 3.2.1). 
Both kcs1Δ and arg82Δ showed extreme sensitivity to bleomycin, whereas ipk1Δ showed 
resistance equal to that of wild-type yeast cells. kcs1Δ and arg82Δ also showed high 
sensitivity to 5FU. rad52Δ were found to show similar sensitivity to bleomycin and 5FU. 
Interestingly, vip1Δ showed sensitivity equal to that of wild-type to both bleomycin and 
5FU (Fig. 3.2.1). adk1Δ were found to be highly sensitive to bleomycin, however, were 
less sensitive to 5FU. apn1Δ were severely affected with 5FU treatment but were found 
unharmed with bleomycin treatment.  
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Figure 3.2.1 Effect of bleomycin and 5FU on mutant yeast strains lacking (a) IDPs 
and (b) repair enzymes. Yeast strains were grown to log-phase in YPD medium at 30 ºC. 
The strains were serially diluted at 1/3 with YPD medium and spotted onto YPD agar 
plates (left to right; starting at 10,000 cells/spot) containing bleomycin at 10 mU/ml and 
5FU at 2 µg/ml concentrations (Section 2.2.3). A control, with yeast dilutions spotted onto 
a untreated YPD plate was also included. Plates were incubated at 30 ºC for 48 h and 
photographed. 
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3.3 Urea-PAGE for seperation of DNA 
To understand, at a molecular level, why the IDP mutants were sensitive to bleomycin and 
5FU,  extracts were tested for their ability to repair damaged DNA in vitro. In order to 
monitor such repair mechanisms PAGE was used. Previously published methods were 
found unsatisfactory as they permitted re-annealing of ds-DNA (Owen et al., 2007; 
Parsons et al., 2004). Thus, polyacrylamide gels with varying concentrations of urea and 
acrylamide were employed (Section 2.2.5). Concentrations of urea used in this experiment 
include 0 , 0.5, 1, 3, 5 and 7 M (Fig. 3.3.1). Corresponding acrylamide concentrations used 
for urea gels are outlined in the Table 2.2.2. A stacking gel containing urea was 
incorporated (unless specified otherwise) for all the experiments to maximise the 
resolution of DNA in the gel . SDS was omitted from all the gel and buffers as it reduced 
resolution (data not shown).  
Fluoroscein-tagged DNA strands, i.e., JJC (Fluoroscein-tagged 60-mer) and untagged 
reverse complement (JJG) were used for this experiment. The ss- (JJC) and ds-  (JJC+JJG) 
DNA sample mixtures were prepared as mentioned in Section 2.2.4 and run through 
different concentrations of polyacrylamide urea gels at room temperature (Section 2.2.5). 
As shown in Fig. 3.3.1 the ds-DNA ran above the ss-DNA in all cases. The differences 
between the amount of seperation can be accounted for by the difference in acrylamide 
concentration. In terms of resolution of the substrate and product seperation, 7 M urea gel 
comprising of both resolving and stacking gel was considered the best [Fig. 3.3.1(f)].  
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Figure 3.3.1 Urea-PAGE for separation of DNA. The ss (JJC) and ds (JJC+JJG) DNA 
substrates (50 nM each) were heat treated at 96 ºC for 5 min before loading it onto 
different concentrations of urea polyacrylamide gels: (a) 0 M urea; 38% acrylamide, (b) 
0.5 M urea; 36% acrylamide, (c) 1 M urea; 36% acrylamide, (d) 3 M urea; 32% 
acrylamide, (e) 5 M urea; 30% acrylamide, and (f) 7 M urea; 25% acrylamide. The gels 
were run at room temperature for 2 h with 100 V/gel. Gels were scanned using 
phosphorimager (Section 2.2.5).   
  
(a) (c)(b)
(d) (e) (f)
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3.4 Denaturing of DNA using denaturants   
In addition to urea, a denaturant was essential to dissociate ds- to ss-DNA. The denaturing 
agents assessed include glycerol, formamide, DMSO and formaldehyde. Denaturants were 
used at 20%, 40%, 60% and 80% concentrations, to determine the concentration at which 
there was clear dissociation of ds-DNA (Fig. 3.4.1). Untreated controls were included for 
comparison. The results showed that the JJC+JJG complex failed to dissociate even in the 
presence of denaturants glycerol, DMSO and formamide [Fig. 3.4.1(a), (c) and (e)] at room 
temperature. Denaturing of the ds-DNA was possible only when the gel was run at 60 ºC 
[Fig. 3.4.1(b), (d) and (f)].  
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Figure 3.4.1 Denaturing of DNA using glycerol, DMSO and formamide. Substrates (50 
nM) were incubated in the presence of varied concentrations of the denaturant for 30 min 
at 30 ºC. Samples were heat treated at 96 ºC for 5 min before loading it onto 7 M urea gel 
(Section 2.2.6). The gel was run either at room temperature [(a), (c) and (e)] for 2 h or at 
60 ºC [(b), (d) and (f)] for 1 h with 100 V/gel. Gel was scanned using phosphorimager. 
  
Formamide
(e) (f)
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3.5 Denaturing of DNA using formaldehyde 
Formaldehyde, a widely used denaturant, was also used to check for denaturation of ds-
DNA. Samples were similarly incubated with different concentrations of formaldehyde and 
heat treated at 96 ºC for 5 min before loading onto the gel (Section 2.2.6). The gel was run at 
both room temperature and 60 ºC. All samples treated with formaldehyde resulted in unclear 
bands as observed in the Fig. 3.5.1(c) and (d). Presuming that heating had an effect on the 
sample mixture, it was avoided and the samples were run without heat treatment. Although 
the resultant product was slightly better compared to previous result, the problem with clear 
differentiation between the bands still existed [Fig. 3.5.1(a) and (b)]. 
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Figure 3.5.1 Denaturing of DNA using formaldehyde. Substrates (50 nM) were 
incubated in the presence of varied concentrations of formaldehyde for 30 min at 30 ºC. 
Samples were either heat treated at 96 ºC for 5 min [(c) and (d)] or not [(a) and (b)] before 
loading it onto 7 M urea gel. The gel was run either at room temperature for 2 h or at 60 ºC 
for 1 h with 100 V/gel. Gels were scanned using phosphorimager.  
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3.6 Urea as a denaturing agent and influence of stacking gel on the 
resolution of urea-PAGE gels 
Though denaturants like glycerol, DMSO and formamide were useful in dissociating ds-
DNA, it was crucial to have urea in the gel. Gels prepared free of urea and run at room 
temperature resulted in ds-DNA undissociated even in the presence of other denaturants 
[Fig. 3.6.1(a)]. However, partial dissociation was witnessed when run at 60 ºC [Fig. 
3.6.1(b)]. Moreover, comparing Fig. 3.6.1 with Fig. 3.3.1(a), it is clear that the presence of 
stacking gel greatly aids in increasing the resolution of the bands. Gels prepared with 7 M 
urea and run at room temperature resulted in partial dissociation of ds-DNA even in the 
presence of denaturants [Fig. 3.6.2(a)]. However, complete dissociation of ds-DNA was 
observed when the gel was run at 60 ºC [Fig. 3.6.2(b)]. The resolution of bands in both the 
gels was again poor compared to previous result [Fig. 3.3.1(f)] due to the absence of 
stacking gel. 
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Figure 3.6.1 Denaturing of DNA using denaturants in urea free gel (without stacking 
gel). Substrates (50 nM) were incubated with appropriate denaturants at a final 
concentration of 20% each for 30 min at 30 ºC (Section 2.2.6). The mixture was heat 
treated at 96 ºC for 5 min before loading onto urea free gel (without stacking gel). The gel 
was electrophoresed (a) at room temperature for 2 h and (b) at 60 ºC for 1 h. Gels were 
scanned using phosphorimager. 
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Figure 3.6.2 Denaturing of DNA using denaturants in 7 M urea gel (without stacking 
gel). Substrates (50 nM) were incubated with appropriate denaturants at a final 
concentration of 20% each for 30 min at 30 ºC (Section 2.2.6). The mixture was heat 
treated at 96 ºC for 5 min before loading onto 7 M urea gel (without stacking gel). The gel 
was electrophoresed (a) at room temperature for 2 h and (b) at 60 ºC for 1 h. Gels were 
scanned using phosphorimager.  
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3.7 Recombinant enzymes on single and double-stranded DNA 
Recombinant enzymes involved in the DNA BER pathway are long thought to act on AP-
site/abasic site of only ds-DNA. A study by Marenstein et al. (2004) disproved this theory 
by presenting evidence that APE1 can also act on AP-site of ss-DNA. To check and 
reconfirm these results in our hands, catalytic activity and efficiency of recombinant 
enzymes, APE1 and UDG, on ss- and ds-DNA were tested (Section 2.2.7). Activity of 
these enzymes on ds-DNA was included for comparison. Fluoroscein-tagged JJU and 
untagged reverse complement JJG was used for this experiment. Results showed that 
recombinant UDG and APE1 act well on both ss- and ds-DNA [Fig. 3.7.2 and Fig. 3.7.1].  
The UDG enzyme added (10 U/assay) removes the uracil from the strand leaving an AP-
site, which is further cleaved by APE1. Higher concentration of APE1 (10 U/assay) in the 
presence of UDG nicks the DNA completely resulting in a product/band at the bottom of 
the gel [lanes 3,4 in Fig. 3.7.1(a)]. However, decreasing concentrations of APE1 (half-log 
dilutions from 10 U/assay) resulted in incomplete nicking of the substrate and therefore the 
bands are seen at the top of the gel [lanes 5,6,7 in Fig. 3.7.1(a)]. Under conditions tested 
ds-DNA was 10-times more sensitive to APE1 than ss-DNA.  
A high concentration of UDG enzyme (10 U/assay), in the absence APE1, was found to 
partially dissociate both ss- and ds-DNA [Fig. 3.7.2 (a) and (b)]. The dissociation of 
substrate to product decreased with decrease in UDG concentration (half-log dilutions 
from 10 U/assay) [lanes 2-7 in Fig. 3.7.2]. Under conditions tested ds-DNA was 10-times 
more sensitive to UDG than ss-DNA. 
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Figure 3.7.1 Effect of recombinant enzyme APE1 on (a) ss-DNA and (b) ds-DNA. 
Fluorescein-tagged ss- and ds-DNA (50 nM each) were first treated with 10 U/assay of 
UDG enzyme followed by addition of half-log dilutions of 10 U/assay of APE1 enzyme 
(Section 2.2.7). The mixture was incubated for 30 min at 30 ºC and heat treated at 96 ºC for 
5 min with 10% loading buffer.  Samples were loaded onto 7 M urea gel and run at 60 ºC 
for 1 h. In both the gels; lanes 2-7 contain substrates treated with UDG enzyme, lanes 3-7 
contain decreasing concentrations of APE1 enzyme and lane 1 contain untreated substrates 
(control). 
(a) (b)
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Figure 3.7.2 Effect of recombinant enzyme UDG on (a) ss-DNA and (b) ds-DNA. 
Fluorescein-tagged ss- and ds-DNA (50 nM each) were treated with half-log dilutions of 
10 U/assay of UDG enzyme. The mixture was incubated for 30 min at 30 ºC and heat 
treated at 96 ºC for 5 min (Section 2.2.7).  Samples were loaded onto 7 M urea gel and run 
at 60 ºC for 1 h. In both the gels; lanes 2-7 contain substrates treated with decreasing 
concentrations of UDG enzyme and lane 1 contain untreated substrate (control). 
3.8 Yeast extracts and their resemblance to UDG-like enzymes 
Both wild-type and kcs1 yeast extracts were prepared to check for the presence of DNA 
repair enzymes with properties similar to UDG. Yeast extracts were prepared in the 
presence or absence of detergent Tween-20 and with varying concentrations of EDTA (0, 1 
and 100 mM) (Section 2.2.8). Fluorescein-tagged JJU+JJG substrate was used in this 
experiment. The wild-type yeast extracts, regardless of EDTA concentration and presence 
or absence of Tween-20, showed UDG-like activity (creating AP-site) (lanes 2, 4, 6, 8, 10 
and 12 in Fig. 3.8.1). On the other hand, kcs1 extracts lacked UDG-like activity in the 
absence of Tween-20 and presence of 0 mM and 1 mM EDTA (lanes 3, 7 in Fig. 3.8.1). 
However, kcs1 extracts prepared in the absence of Tween-20 and presence of 100 mM 
(a) (b)
1      2       3      4       5      6       7      1      2     3     4      5      6       7     lanes
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EDTA showed UDG-like activity (lane 11 in Fig. 3.8.1). Further, inclusion of Tween-20 
into the yeast sonication buffer greatly increased UDG-like activity of the kcs1 extracts 
regardless of EDTA concentration (lanes 5, 9, 13 in Fig. 3.8.1). The cleaved product at the 
bottom of the gel, observed in extracts showing UDG-like activity, could be a resultant of 
either APE1-like activity (nicking of DNA at AP-site created by UDG) or heat-induced 
break.  
                   
Figure 3.8.1 Yeast extracts and their resemblance to UDG-like enzyme. Extracts of 
wild-type and kcs1 were prepared (Section 2.2.8) in the presence or absence of Tween-20 
and in the presence of 0, 1 and 100 mM EDTA. The ds-DNA (50 nM ) was incubated with 
relevant yeast extracts for 30 min at 30 ºC and heat treated at 96 ºC for 5 min (Section 
2.2.9). Samples were loaded onto 7 M urea gel and run at 60 ºC for 1 h. Gel was scanned 
using phosphorimager. Lane 1: untreated substrate (50 nM). Lane 2-5: substrates treated 
with wild-type and kcs1 extracts prepared in the presence or absence of Tween-20 (no 
EDTA). Lane 6-9: substrates treated with yeast extracts prepared in the presence or 
absence of Tween-20, with 1 mM EDTA. Lane 10-13: substrates treated with yeast 
extracts prepared in presence or absence of Tween-20, with 100 mM EDTA.  
k kk k k kww w www
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3.9 Yeast extracts and their resemblance to APE1-like enzymes 
Following identification of UDG-like enzyme in yeast extracts, experiments were 
conducted to check if they also possess APE1-like activity. As heat-treatment of DNA 
containing AP-site can cause cleavage (Ma et al., 2008), the presence or absence of APE1-
like activity in these extracts was uncertain. To ensure that nicking of the AP-site was 
through APE1-like activity and not through heat treatment at high temperature, 
borohydride-trapping assay was performed (Section 2.2.10). Fig. 3.9.1 shows the trapping 
assay performed with recombinant repair enzymes and yeast extracts prepared in the 
presence of Tween-20 and 1 mM EDTA (Section 2.2.8). From the Fig. 3.9.1(a) and (b), 
following conclusions can be reached: (a) wild-type and kcs1 extracts show UDG-like 
activity i.e., creating an AP-site for APE1 to act on it (lane 2 and 4 show low molecular 
weight band as a result of AP-site being nicked after heat treatment), (b) wild-type and 
kcs1 extracts show APE1-like activity i.e., nicking the DNA at AP-site  (lanes 2, 3, 8 and 
10 show low molecular weight band following heat treatment, even in the presence of 
NaBH4, which prevents thermal cleavage of AP-site) and (c) NaBH4 protects the AP-site 
from being cleaved when exposed to high temperatures (lane 9). Most importantly, lanes 8 
and 10 in Fig. 3.9.1 confirms that the dissociation of substrate to low molecular weight 
product is due to nicking of AP-site by APE1-like enzyme and not heat treatment. 
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Figure 3.9.1 Borohydride-trapping assay to determine APE1-like activity in (a) wild-
type yeast extracts and (b) kcs1 extract. Substrate JJU+JJG  was incubated for 30 min 
at 30 ºC with: no enzyme or yeast extract (lane 1) (control); with yeast extract (lane 2) 
(shows UDG- and APE1-like activity); with yeast extract and UDG enzyme (lane 3) 
(APE1-like activity); with yeast extract and APE1 enzyme (lane 4) (UDG-like activity); 
with APE1 and UDG enzyme (lane 5) (positive control for APE1 and UDG activity); with 
APE1 enzyme only (lane 6) (positive control for UDG activity); with UDG enzyme only 
(lane 7) (positive control for APE1 activity); with yeast extract, UDG enzyme and 100 mM 
NaBH4 (lane 8) (APE1-like activity); with UDG and NaBH4 (lane 9) (positive control for 
NaBH4); with yeast extract and NaBH4 (lane 10) (UDG- and APE1-like activity). Then, 
samples were heat treated at 96 ºC for 5 min and loaded onto 7 M urea gel and run at 60 ºC 
for 1 h (Section 2.2.10). Gels were scanned using phosphorimager. 
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3.10  Effect of EDTA on repair enzymes 
The clear effect of EDTA was unexpected (refer Section 3.8). Incorporation into the 
extraction procedure appeared to either release the sought activity or activate the enzymes 
once extracted. In order to distinguish between these two outcomes, both wild-type and 
kcs1 extracts prepared in the absence of Tween-20 and EDTA (Section 2.2.8) were 
chosen to examine the effect of EDTA on APE1-like and UDG-like activities. Substrate 
JJU+JJG was treated with yeast extracts as mentioned in Section 2.2.11  and was incubated 
with 0, 12.5, 25, 50 and 100 mM EDTA (final concentration) for 30 min at 30 ºC. The 
samples were heat treated and electrophoresed in a 7 M urea gel. Results showed that 
EDTA at a concentration of 50 mM partially inhibited DNA cleavage (lane 8 in Fig. 
3.10.1) and at 100 mM concentration completely abolished DNA cleavage (lane 10 in Fig. 
3.10.1) 
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Figure 3.10.1 Inhibition of UDG-like activity by EDTA. Fluorescein-tagged JJU+JJG 
substrate was first treated with yeast extracts prepared in the absence of Tween-20 and 
EDTA. To this reaction mixture increasing concentrations of EDTA (0, 12.5, 25, 50 and 
100 mM EDTA) were added and incubated for 30 min at 30 ºC (Section 2.2.11). Samples 
were heat treated at 96 ºC for 5 min and subjected to 7 M urea-PAGE. Lane 1: untreated 
substrate. Lane 2-12: substrate treated with relevant yeast extracts. Lane 2-3: no EDTA 
added. Lane 4-5: added 12.5 mM EDTA. Lane 6-7: 25 mM EDTA. Lane 8-9: 50 mM 
EDTA. Lane 10-11: 100 mM EDTA. Lane 12: substrate treated with UDG enzyme. The 
samples were heat treated at 96 ºC for 5 min and electrophoresed in a 7 M urea gel for 1 h 
at 60 ºC. Gel was scanned using phosphorimager.  
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3.11 Phosphoglycolate removal by APE1 
It is often debated that APE1 is involved in PG removal in addition to nicking of AP-
sites (Wang et al., 2014). APE1 is not only involved in nicking of abasic DNA 
following the removal of an inappropriately incorporated base such as uracil, it is also 
key in the removal of PG moieties caused when bleomycin damages DNA (Fung and 
Demple, 2011). F-16PG plus HP were incubated in the presence of extracts from both 
wild-type and kcs1 yeast and T4 ligase (800 U/assay) (Section 2.2.12). The rationale 
for this approach was that APE1 removes the 3′-PG group, decreasing the size of F-
16PGmer (lane 2 in Fig. 3.11.1). However, the resolution of this product from the 
starting material is poor. In order to determine the release of the PG moiety, HP was 
designed to covalently link to the F-16mer once the blocking PG group has been 
removed, producuing a high molecular weight product (lane 4 in Fig. 3.11.1). This is 
achieved by the T4 ligase present in most samples. There was no high molecular 
weight product with wild-type or kcs1 (lanes 5, 6, 7 and 8 in Fig. 3.11.1) except for 
in the presence of T4 ligase (lanes 9, 10, 11 and 12 in Fig. 3.11.1). However, the 
intensity of this band was not time-related. It is therefore suspected that the appearance 
of this band is merely due to the presence of some unphosphoglycolated starting 
material.  
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Figure 3.11.1 Removal of phosphoglycolate moiety by (a) wild-type yeast extract and (b)   
kcs1 extract. F-16PG plus HP was incubated with yeast extracts (lanes 5-12) for 30 min at 37 
ºC (Section 2.2.12) and was further incubated for 15, 30, 45 and 60 min at 37 ºC in the presence 
of T4 ligase enzyme (lanes 9-12). A positive control for PG removal followed by end-joining by 
APE1 enzyme and T4 ligase (lane 4), respectively, was included for comparison. A positive 
control for APE1 (lane 2) and T4 enzyme (lane 3), and an untreated substrate control (lane 1) 
was also included in the experiment. The samples were heat treated at 96 ºC for 5 min and 
electrophoresed in a 7 M urea gel for 1 h at 60 ºC. Gel was scanned using phosphorimager.   
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3.12 Subcellular protein localisation studies using confocal microscopy 
As it appears that the DNA repair enzymes with APE1- and UDG-like activities are present 
in kcs1 strain of yeast, but that extreme extraction methods are required to access these 
proteins, we decided to GFP-tag several proteins in order to see whether their cellular 
localisation was different in kcs1 when compared to wild-type yeast (Section 2.2.15). 
Rad52, Ung1 and Apn1 were successfully GFP-tagged in both wild-type and kcs1 
backgrounds. However, tagging Rad51 in kcs1 and Apn2 (Fig. 2.2.3) in both the 
backgrounds were unsuccessful. Confocal microscopy images of cells that are (i) non-
treated (control) (ii) bleomycin treated and (iii) recovery from bleomycin treatment 
(Section 2.2.20) showed no difference in the proteins studied. The GFP signal was too 
weak to image and to judge the exact localisation or movement of the tagged proteins. All 
the proteins roughly appeared to localise in the nucleus (Fig. 3.12.1). Rad51 in wild-type 
background was the only strain to show bright GFP signal [Fig. 3.12.1(c)]. Although not 
very clear from the images, Rad51 (wild-type background) [Fig. 3.12.1(c)] and Rad52 
(kcs1 background) [Fig. 3.12.1(d)] appeared to form foci after bleomycin treatment. Also 
from the images, it was noted that kcs1 contain large vacuole-like structures inside the 
cell [Fig. 3.12.1(a) and (d)]. The kcs1 has been previously reported to contain swollen 
and leaky vacuoles (Dubois et al., 2002; Saiardi et al., 2000). 
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Figure 3.12.1 Subcellular localisation of GFP-tagged proteins (i) Ung1, (ii) Apn1, (iv) 
Rad52 in wild-type and kcs1 backgrounds, and (iii) Rad51 in wild-type background. 
Confocal microscopic images of live yeast cells expressing GFP-tagged proteins; the green 
GFP fluorescence was overlaid onto a phase-contrast image of the cells. The GFP-tagged 
clones were treated with 5 mU/ml of bleomycin for 90 min and were visualised (Section 
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2.2.20). Following removal of the drug, the yeast cells were allowed to recover for 1 h in 
YPD medium and were visualised. GFP-tagged proteins appear to localise in the nucleus of 
yeast cells. A 63x oil objective was used to capture images. 
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3.13 Discussion 
Tumour resistance to anticancer agents like bleomycin and 5FU are often associated with 
the ability of cells to recover quickly through overactive cellular repair mechanisms. 
Moreover, drugs like bleomycin are less heavily used as it often causes impaired lung 
functions (Ramotar and Wang, 2003). Knowledge on the mechanisms and the factors that 
the tumour cells exploit to elicit resistance against chemotherapeutics would prove 
valuable to treat the disease much more effectively. We believe one such potential factor 
involved in the process of tumour resistance/DNA repair is IDPs.  
IDPs are regarded as novel regulators of HR signalling in mammals (Jadav et al., 2013). 
IDPs such as InsP7 and InsP8 are also reported to be crucial for hyper-recombination events 
in yeast lacking protein kinase C (Luo et al., 2002). In fact, the initial observations which 
have led us to determine the great importance of IDPs in DNA repair were found on the 
observation that InsP6 acts as a ‘stimulatory factor’ in NHEJ (Hanakahi et al., 2000). NHEJ 
in mammalian cells relies on a holoenzyme containing Ku70, Ku80 and DNA-PK, a 
complex that is activated in vitro by InsP6.  
In this study, a family of genetically modified yeast with modulated levels of IPs and repair 
enzymes were used as a model to investigate the role of IDPs in DNA repair. The results 
from the study suggest that IDPs are crucial in repair of DNA following insult with 
bleomycin and 5FU, but not of a myriad of other chemotherapeutics. The tested mutants 
were over 1000-fold more sensitive to bleomycin and 100-fold more sensitive to 5FU than 
wild-type yeast (Fig. 3.2.1). Three particular mutants- plc1 (data not shown), arg82 and 
kcs1, all lacking IDPs and reportedly inorganic polyphosphates (Auesukaree et al., 2005) 
were found to be hypersensitive to bleomycin and 5FU (Fig. 3.2.1) and not to other drugs 
like H2O2 (Onnebo and Saiardi, 2009). These findings clearly indicate that the enhanced 
sensitivity to bleomycin and 5FU cannot be due to the mutants being generally sick, or 
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having increased cell wall permeability. The increased sensitivity could be due to a range 
of toxic intermediates, such as complex DSDBs, or juxtaposed AP-sites and/or 3′ damage 
comprising ss- breaks, formed by bleomycin in particular (Chen and Stubbe, 2005). 
In our experiments, ipk1 showed resistance equal to that of wild-type yeast cells. The 
ipk1Δ mutants lack the enzyme responsible for the synthesis of InsP6 and InsP7, however 
are capable of synthesizing PP-InsP4 and (PP)2-InsP3 (Fig. 1.1.2) which supposedly can 
perform DNA repair alike InsP7 or InsP8 (Saiardi et al., 2002). The rad52 were found to 
show high sensitivity to both drugs. However, rad52 were also sensitive to IR, 
camptothecin, doxorubicin, hydroxyurea, MMS and UV. These differences would suggest 
that the mechanism of action of the IDP mutants is not through the Rad52 epistasis group.  
InsP7 kinase has recently been identified as Vip1 (Choi et al., 2007; Mulugu et al., 2007), 
although mutants have not been shown to lack the product (InsP8). The vip1 tested in the 
experiment was as sensitive as wild-type yeast, suggesting that the effects are not regulated 
by InsP8. Results from the screening experiment identified that only mutants lacking all 
IDPs are sensitive to bleomycin and 5FU. IDPs comprise below 5% of total IP pools, and, 
as such, removal of these from the general pool does not significantly alter the total IP 
levels. Therefore, the bulk phosphate effect can be excluded. Further, several other proteins 
that are involved in DNA repair including Rad, yKu, Msh, Cln and Sir family of proteins 
were all found to be less sensitive to bleomycin than the IDP mutants, and, therefore, were 
excluded as candidate proteins for which IDPs or inorganic polyphosphates act as cofactors 
(S.T. Safrany, personal communication). 
Pulsed-field gel electrophoresis studies performed previously in the group showed wild-
type, rad52, and kcs1 to have equal damage following treatment and therefore the 
increased sensitivity of the mutants have been correlated with a defect in DNA repair. The 
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rad52 were able, albeit slower than wild-type, to repair DSDB, whereas kcs1 failed to 
recover in these studies (U. Padmanabhan and S.T. Safrany, personal communication). 
Similarly, in comparing the wild-type, arg82, ipk1 and kcs1, only wild-type and ipk1 
were found to recover from the damage. Of all the preliminary studies done in the group, 
the most interesting finding was that, unlike rad52, mre11, xrs2, mutants lacking IDPs 
(plc1, arg82, kcs1 and ipk1/kcs1) showed no increased sensitivity to γ-irradiation. 
This is the first observation, to our knowledge, in which mutants sensitive to bleomycin are 
resistant to IR. Bleomycin is described as a γ-ray mimetic, yet frequent reports show that 
ligation of DNA following bleomycin-induced damage proceeds more slowly that 
following γ-irradiation (Moore, 1990). The possible explanation for this would be that the 
adducts formed in vivo are different between these two agents. Also, higher survival of 
irradiated cells than bleomycin-treated cells could be implicated to fewer DSDBs 
generated by γ-irradiation compared to bleomycin (Moore et al., 2000).  
Of all the mutants tested in this study, hypersensitivity of kcs1 was intriguing (Fig. 3.2.1). 
Kcs1, a key enzyme involved in the synthesis of all IDPs (InsP7, PP-InsP4 and [PP]2-InsP3) 
excluding InsP8, is a slow growing and temperature sensitive (best grown at 30 ºC) mutant 
which failed to survive after bleomycin and 5FU treatment. A similar outcome of 
decreased viability and reduced recovery has been observed in a recent study with kcs1, 
in response to radiomimetic antibiotics and hydroxyurea (Jadav et al., 2013). The study 
concluded that such sensitivity was due to failure of efficient DNA repair. This finding is 
in support of our hypothesis that IDPs are vital for DNA damage repair. Conversely, there 
are reports suggesting that human homologue of kcs1, IP6K2, and the associated IDPs are 
necessary to activate apoptosis during stress conditions (Morrison et al., 2001; Morrison et 
al., 2009; Nagata et al., 2005). Experiments relating to this showed inability of IDP-
deficient cells to induce apoptosis and instead induced untimely activation of various cell 
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cycle arrest genes during stress (Koldobskiy et al., 2010). Although a possible role for kcs1 
in tumour suppression has been indicated in these studies, there is no strong direct 
evidence so far to prove this.  
It was speculated earlier that bleomycin and 5FU converge through the APN family of 
repair proteins.  To understand the role of Apn1 and its preceding protein Ung1 in the 
repair pathway of bleomycin- and 5FU-induced DNA damage, series of experiments were 
performed. The first approach was to come up with ways to nick the mismatched ds-DNA 
at AP-site which is the target for Apn1. Denaturing urea-PAGE technique was employed to 
determine whether the DNA was cleaved. Urea-free PAGE gels failed to show clear 
separation of ss- from ds-DNA and also resulted in poor resolution of gels (Fig. 3.6.1). A 
number of variations were introduced to the prevailing urea-PAGE technique (Owen et al., 
2007) to develop a system that suits our experimental needs. It was found that running the 
fluorescein-tagged mismatched DNA (both ss- and ds-DNA) in a higher concentration urea 
(7 M) gel with an added stacking gel, vastly helped in the resolution of the gel and also in 
clear differentiation between the strands [Fig. 3.3.1(f)]. Although this setting failed to 
dissociate the ds-DNA, a partial degradation was evident in the absence of a stacking gel 
[Fig. 3.6.2(a)].  
Use of denaturants such as glycerol, DMSO and even formamide proved ineffective in 
separation of ds-DNA at room temperature [Fig. 3.4.1(a), (c) and (e)]. Formamide’s ability 
to lower melting temperature and destabilize the helical state of DNA has been reported to 
be dependent on the G+C composition, helix conformation and state of hydration (Blake 
and Delcourt, 1996). Since the G+C composition is slightly high in the oligonucleotide 
substrate used in this experiment, it is possible that they serve as energetic barriers to 
further melting of the DNA. Use of formaldehyde as denaturant in this experiment 
appeared to damage the fluorescein molecule and thereby result in loss of fluorescence 
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signal. Such effect was obvious when formaldehyde was heated with the substrate 
containing fluorescein molecule (Fig. 3.5.1).  
It was found that irrespective of the presence or absence of denaturants, running the gel at 
60 ºC in a 7 M urea gel greatly aids in dissociating the ds-DNA [Fig. 3.4.1(b), (d) and (f)]. 
These results are in agreement with a recently published report where the combination of 
urea and temperature of 45-55 ºC during the gel run was shown to dissociate unstructured 
DNA or RNA molecules (Summer et al., 2009). However, unlike their technique, our 
method does not involve ‘pre-running of the gel’ step, yet it did not appear to affect our 
results.   
Various DNA-N-glycosylases in BER have been shown to act on damaged bases of ss-
DNA (Boorstein et al., 2001; Dou et al., 2003). However, APE1 is long thought to act on 
AP-sites of only ds-DNA, with a view to allow insertion of correct nucleotide during 
repair. Experiments in this study have shown that both APE1 [Fig. 3.7.1(a)] and UDG 
[(Fig. 3.7.2(a)] can act on AP-sites of ss-DNA. However, AP-site of ds-DNA was 
observed to be 10-times more sensitive to the enzymes than that of ss-DNA. A study by 
Marenstein et al. (2004) found the catalytic efficiency of AP-site in ss-DNA to be 
approximately 20-fold less than that of ds-DNA. Their study also found that unlike the 
activity of AP-sites in ds-DNA, APE1 demonstrates no product inhibition when acting on 
an AP-site in ss-DNA. Due to such lack of product inhibition, APE1 is let free to dissociate 
from the ss-break instead of participating in the coordinated transfer of ss-break to 
downstream repair enzymes, polβ. Further processing of this toxic intermediate is 
mandatory and repair proteins such as XRCC are thought to repair ss-DNA breaks in 
mammalian cells (Marenstein et al., 2004). 
Subsequently, extracts from wild-type and kcs1 yeast were checked for the activity of 
Ung1 and Apn1 enzymes. The ability of the yeast extracts to recognise and create AP-site 
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by removal of the mismatched ‘uracil’ from the oligonucleotide substrate was checked 
using the Glycosylase/UDG activity assays. Results of this experiment showed varied 
results depending on (a) presence or absence of Tween-20 and, (b) concentration of EDTA 
in the sonication/lysis buffer. Wild-type yeast, regardless of EDTA concentration and 
inclusion or exclusion of Tween-20, showed UDG-like activity (Fig. 3.8.1). In contrary, 
kcs1 extract lacked UDG-like activity in the absence of Tween-20 and presence of lower 
concentration of EDTA. This would mean that kcs1 which lacked IDPs did not participate 
in DNA repair. However, a higher concentration of EDTA (100 mM) in the lysis buffer, 
irrespective of inclusion or exclusion of the detergent, was found to greatly increase UDG-
like activity (Fig. 3.8.1). From these experiments, it is clear that presence of either Tween-
20 or a high concentration of EDTA is necessary to release the repair enzymes from the 
yeast strains.  
A possible role of the detergent or EDTA in inhibiting or enhancing the activity of the 
repair enzymes cannot be completely disregarded. Increase in the activity of enzymes 
when prepared in the presence of a detergent has been previously shown in different 
experimental setups (Arthur et al., 1984; Martin et al., 2003). A recent study has found 
Tween-20, at a concentration of 0.2 %, to induce genotoxic effects and exhibit DNA 
cleavage properties in cancer and endothelial cell lines (Eskandani et al., 2013). However, 
there appears to be no similar report published with yeast cells. Moreover, provided that 
the yeast cell wall is very tough to disrupt, lowering concentrations of detergent/Tween-20 
and/or EDTA may not be sufficient to lyse cells and successfully release the proteins.  
Furthermore, combination of (10 mM each) of EDTA and Mg
2+
 together has been 
implicated in loss of activity of enzymes such as nictotinamide adenine dinucleotide 
(NADH) dehydrogenase (Madden et al., 2004). The endonuclease activity of APE1 on 
both ss- and ds-DNA is Mg
2+
-dependent (Marenstein et al., 2004). EDTA, being a 
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powerful chelator of divalent cations, could potentially seize the Mg
2+
 ions and stop the 
APE1 from functioning (stops the APE1 reaction on 3′-PG moieties). However, results 
from this study show UDG-like activity with extracts prepared only in the presence of 
higher concentration of EDTA. This result could mean that incorporation of EDTA into the 
extraction procedure may either help in release of the sought activity or activate the 
enzymes once extracted. Experiments to distinguish between these two outcomes resulted 
in the finding that EDTA at a higher concentration (100 mM) completely inhibits UDG-
like activity (Fig. 3.10.1). This result confirms that (a) EDTA in the lysis buffer helps in 
the release of enzyme activity and, (b) EDTA, added to yeast extract, is involved in 
inhibiting the enzyme activity and not activating it.  
Heat-treatment of abasic DNA is reported to cause double-strand cleavage (Sugiyama et 
al., 1994). In this study, the presence or absence of APE1-like activity in the yeast extracts 
appeared indecisive as the experimental protocol involved exposure of samples to high 
temperatures. Thus, NaBH4 was used to reduce the heat-labile unstable abasic DNA to 
generate a heat-protected stable complex (Hill et al., 2001; Petronzelli et al., 2000). 
Outcome of this experiment confirmed the presence of APE1-like activity in both the wild-
type and kcs1 extracts (Fig. 3.9.1). However, the APE1-like activity found in the extracts 
was inefficient in removing 3′-PG group of 16-PGmer. This may have resulted in poor 
repair of the strands or linking of HP to 16-mer by T4 ligase and thus resulted in a faint 
high molecular weight product (Fig. 3.11.1). Appearance of such band could also merely 
be due to the presence of some unphosphoglycolated starting material. Using human whole 
cell extracts, Parsons et al. (2004) demonstrated that repair of an oligonucleotide 
containing 3′-PG is much slower compared to repair of same length oligonucleotide 
without 3′-PG. However, with the yeast extracts in this study, there was no sign of efficient 
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repair of 3′-PG even after an hour of recovery time. It is possible that the yeast biology is 
different to human in this aspect.  
Human APE1 and APE2 proteins, which shares extensive homology with yeast Apn2, 
accounts for only <10% of AP endonuclease activity in yeast. The majority of AP 
endonuclease activity in yeast is carried out by Apn1, which shares high homology with E. 
coli endonuclease IV (Guzder et al., 2004). Thus, some of the repair process seen in yeast 
cannot be translated to humans (Guzder et al., 2004). Kcs1 in yeast is a much larger 
protein (120 kDa) than its mammalian counterpart IP6K (50-60 kDa). Considering the 
large protein size, it is likely that Kcs1 is multifunctional and therefore its knockdown in 
yeast may affect other activities not yet ascribed to this protein (Dubois et al., 2002). 
However, as this protein is present in plc1 and arg82this explanation is not convincing. 
In this study, confirmation of the presence of both UDG- and APE1-like activity in yeast 
lacking IDPs fails to support our initial hypothesis. However, the activity of these repair 
proteins was observed in kcs1 only when the extracts where prepared with either Tween-
20 or high concentration of EDTA, suggesting that UDG- and APE-1 like proteins may be 
mislocalised and unavailable to access the damage site and repair DNA following 
bleomycin- or 5FU-insult. Hence, the fluorescent-tagging of proteins that often offers a 
rapid and effective route to their localisation and isolation was employed. GFP-tagging in 
the wild-type yeast yielded better success rate compared to kcs1. In addition to exhibiting 
growth impaired phenotype (evident with temperature above 30 ºC), kcs1 were also 
observed to contain swollen [Fig. 3.12.1(a) and (d)] and leaky vacuoles with related 
compromise on stress responses and defects in cell wall integrity (Dubois et al., 2002). 
Provided with such a fragile and morphologically abnormal yeast mutant, it was 
challenging to get a higher rate of successful transformants. Anecdotal evidence observed 
during this and previous studies in the lab showed that transfection and DNA manipulation 
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is particularly difficult in kcs1 with less than 1% the efficiency of wild-type yeast. 
However, we were able to obtain cells expressing GFP-tagged DNA repair enzymes being 
expressed under their native promoters.  
Confocal microscopy studies of the successful clones, due to poor GFP signal/expression 
of tagged proteins, failed to show the clear localisation and movement of the tagged 
proteins before or after bleomycin insult. However, Rad51 in the wild-type background 
showed a clear and bright fluorescent GFP signal [Fig. 3.12.1(c)]. Monitoring of the 
protein following bleomycin treatment showed no clear foci formation required for DNA 
repair. Failure to transmit good signals by the fluorescent molecules could be because of 
the following reasons: (a) the GFP may have misfolded thereby losing on the native 
expression signals and resulting in a poor signal  (b) protein tagging at the C-terminal may 
have made the GFP fusion protein unstable and/or non-functional (Honda and Selker, 
2009) (c) the native expression of these proteins is inherently low. Problems encountered 
in (b) and (c) could have been resolved by N-terminal tagging of the proteins or using an 
overexpression vector with a strong promoter. An alternative approach would be to use 
antibodies against each protein. This was not attempted as the use of fluorescent tags was 
thought more cost-effective. However, it is clear that these studies may now need to be 
performed.  
InsP7 has been shown to participate in non-enzymatic pyrophosphorylation of both 
mammalian and yeast proteins (Saiardi et al., 2004). Such pyrophosphorylation events 
suggest a role for InsP7 in post-translational modification of proteins (Bhandari et al., 
2007; Onnebo and Saiardi, 2009). The differential sensitivity observed in wild-type and 
kcs1 yeast may be due to altered InsP7-mediated phosphorylation and 
pyrophosphorylation of proteins/repair enzymes. Exogenous pyrophosphorylation of β 
subunit of adaptor protein–3 (a serine-rich acidic region) was found to be significantly 
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higher in kcs1 compare to wild-type (Azevedo et al., 2009). Such pyrophosphorylation 
events have also been proposed to mediate and inhibit protein-protein interactions. 
3.14 Conclusion 
In this study a panel of genetically modified yeast with modulated levels of IPs were used 
to examine the role of IDPs in the DNA repair process. Two well-known anticancer drugs, 
bleomycin and 5FU, which causes DSDBs were used to induce DNA damage in yeast 
cells. Experiments revealed that mutants kcs1 and arg82 yeast, which lacks all the IDPs, 
were hypersensitive to both bleomycin and 5FU. However, vip1, which lacks InsP8 failed 
to show sensitivity. Although the two anticancer treatments act through different pathways, 
they appeared to converge through APN family of repair proteins. The effects seen with 
the mutants were suspected to be mediated by the inability of yeast to regulate the repair 
proteins in the absence of co-factors such as IDPs. Hence, the kcs1 were checked for the 
presence of functional repair proteins Ung1 and Apn1. Glycosylase and sodium 
borohydride assays confirmed the presence of both UDG-like and APE1-like repair 
proteins in the kcs1 yeast extract. However, the proteins appeared to be mislocalized in 
the cell, unable to reach the damage site to initiate repair process. Thus, the repair proteins 
were GFP-tagged to detect their subcellular localisation in the cell. However, confocal 
microscopy studies failed to show clear localisation or movement of these proteins 
following bleomycin insult. This raises the question of whether tagging of GFP to the 
protein rendered it non-functional.  
  
143 
 
 
 
 
 
 
 
 
 RESULTS - KINETIC CHARACTERISATION 4.
OF THE DIPPs 
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4.1 Introduction 
While little is known about the role(s) IDPs play in cell biology, the enzymes involved in 
their formation and breakdown have now been identified. IP6Ks are involved primarily in 
the formation of InsP7 with PPIP5Ks being able to phosphorylate InsP6 as well as InsP7. 
The breakdown of all IDPs is governed by the DIPP family of proteins. However, little is 
known regarding the Michaelis-Menten kinetics parameters for Ddp1p/DIPPs. Although 
there are some kinetic data reported for 5-InsP7, there is no information available for 1-
InsP7 isomer and InsP8. Moreover, with the recent improvements in the enzymatic (Loss et 
al., 2011) and chemical methods (Capolicchio et al., 2013; Wu et al., 2013) for generating 
IDPs, the quality of some of the previously published data on 5-InsP7 is being questioned 
for its reliability. For instance, Michaelis constant (Km) values for 5-InsP7 vary from 4 nM 
for DIPP-1 (Safrany et al., 1998) to 4 µM for DIPP-3β (Leslie et al., 2002). Provided that 
the DIPP catalytic domain shares high similarity between these two isoforms, the variation 
in the substrate concentration seems unreliable.  
In this study, using improved methods for the enzymatic synthesis and electrophoretic 
purification of 1-InsP7, 5-InsP7 and InsP8 (Loss et al., 2011), DIPP family has been 
kinetically characterised. 
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4.2 Ddp1 kinetics 
The main aim of this study has been to perform the first side-by-side kinetic 
characterization of human and yeast DIPP forms for each of their substrates: 5-InsP7, 1-
InsP7 and InsP8. The recombinant Ddp1 from S. cerevisiae was assayed first (Fig. 4.2.1). 
HPLC was used to analyse Ddp1-mediated dephosphorylation of 1-InsP7 and 5-InsP7 and it 
was found that they both were metabolised to single product, InsP6 [Fig. 4.2.1(a) and (b)]. 
InsP8 was also dephosphorylated to InsP6, but with relatively little accumulation of InsP7 
[Fig 4.2.1(c)]. Substrate saturation plots (Fig. 4.2.1) showed that the Km values for each 
substrate tested were very similar (93 nM, 105 nM, 148 nM in Table 4.3.1). Similar was 
the trend with the rates of hydrolysis of 5-InsP7 and InsP8, but 1-InsP7 was hydrolysed 5 to 
6-fold faster (Table 4.3.1).     
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Figure 4.2.1 Analysis of the catalytic activities of Ddp1. Shown are substrate saturation 
curve for Ddp1. HPLC was used to obtain substrate saturation plots for Ddp1 against either 
(a) 1-InsP7, (0-1024 nM incubated with 2 ng Ddp1 for 0-25 min); (b) 5-InsP7, (0-512 nM 
incubated with 8 ng Ddp1 for 0-25 min); (c) InsP8, (0-512 nM incubated with 8 ng Ddp1 
for 0-25 min). Insets provide illustrative HPLC analysis using Protocol 1 (Section 2.2.23): 
(a) 10 nM 1-InsP7, 20 ng Ddp1, 10 min (not used in the substrate saturation plot). (b) 10 
nM 5-InsP7, 10 ng Ddp1, 6 min (not used in the substrate saturation plot). (c) 16 nM InsP8, 
8 ng Ddp1, 4 min. In the insets, black open circles represent controls with no enzyme and 
coloured filled circles represent enzyme treated substrates. 
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4.3 Human DIPP kinetics  
Next, substrate saturation plots (not shown) for all the five human DIPP-types-1, 2α, 2β, 3α 
and 3β were obtained, from which Km and kcat values for each were determined (Table 
4.3.1). The kcat data indicated DIPP-1 to be the most active enzyme of this group of 
phosphatases, irrespective of the substrate.  
Similar to the reaction rates seen with Ddp1, the Kcat values for 1-InsP7 was noted to be 5-
20 fold  higher than those for 5-InsP7 and InsP8 (Table 4.3.1). However, the Km data only 
differ over a 4-fold range (35 to 148 nM), across every enzyme and every substrate. The 
results demonstrate that rates of InsP7 dephosphorylation in general equal or exceed those 
of InsP8 metabolism (Table 4.3.1). 
 
 
Substrates      
/ 
enzyme 
1-InsP7 5-InsP7 InsP8 
Km (nM) 10
2
 x
 
kcat (s
-1)
 Km(nM) 10
2
 x
 
kcat (s
-1)
 Km (nM) 10
2
 x
 
kcat (s
-1)
 
Ddp1 
 
105 2.4 ± 0.05 93 0.4 ± 0.1 148 0.5 ± 0.1 
DIPP-1 
 
42 110 ± 30 52 13 ± 3 85 10 ± 2 
DIPP-2α 
 
60 5 ± 2 35 0.7 ± 0.2 55 0.24 ± 0.08 
DIPP-2β 
 
70 1.7 ± 0.5 40 0.3 ± 0.09 42 0.16 ± 0.02 
DIPP-3α 
 
104 23 ± 2 146 4 ± 2 126 2.2 ± 0.4 
DIPP-3β 
 
73 8 ± 2 63 0.88 ± 0.07 78 0.37 ± 0.06 
Table 4.3.1 Ddp1/DIPP kinetic data. Kinetic data were obtained as described in Section 
2.2.23 and 2.2.30. Average (N = 3-5) substrate affinities were first compiled as –logKm 
(SEMs were < 3% of the mean) and then transformed to Km for the Table.  kcat are presented 
as mean ± SEM (N=3-5). 
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4.4  Understanding positional specificity of DIPPs towards InsP8 
A full understanding of physiological fluxes through the different pathways of IDPs 
turnover would be advanced if we knew the positional specificity of DIPPs towards the 1- 
and/or 5-diphosphate groups of InsP8 (Fig. 1.2.1 in chapter 1). This question has not been 
addressed in previous experiments with recombinant DIPPs, mostly due to insufficient 
accumulation of InsP7 during dephosphorylation of InsP8 (e.g. Fig. 4.4.1). Moreover, it is 
difficult to separate 1-InsP7 from 5-InsP7 by strong anion-exchange HPLC. In the current 
study, a consistent 1 min peak-to-peak separation of 1-InsP7 from 5-InsP7 was recorded 
[Fig. 4.4.2(a)]. The columns used in these experiments yielded a partial separation, 
particularly when smaller fractions were collected from a shallower gradient [Fig. 
4.4.2(a)].         
During the dephosphorylation of InsP8 by Ddp1, DIPP-1, DIPP-2α and DIPP-3α, the 
accumulation of new InsP7 product was 45-70% above the level of the (predominantly) 1-
InsP7 that was present in the zero time assays (Fig. 4.4.2). During this metabolism, the 
increase in InsP7 peak height and the larger peak spreading indicates some accumulation of 
both 1- InsP7 and 5-InsP7. However, the kcat data (Table 4.3.1) obtained from these 
experiments conveys that, 1-InsP7 formed as a result of dephosphorylation of InsP8 is 10-
fold faster to degrade than the 5-InsP7 that is produced. In other words, the rate of 5-
phosphate removal from InsP8 (producing 1-InsP7) is underestimated relative to the rate of 
1-phosphate removal from InsP8 (generating 5-InsP7). Further, to confirm this result, equal 
quantities of 1-InsP7 and 5-InsP7 were incubated with DIPP-1 in the presence of either [
3
H] 
1-InsP7 or [
3
H] 5-InsP7 to monitor rates of breakdown of each under these conditions. Yet 
again, 1-InsP7 was found to undergo dephosphorylation at a faster rate than 5-InsP7 (Fig. 
4.4.3).   
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Figure 4.4.1 HPLC analysis of hydrolysis of InsP8 by DIPP-2β and DIPP-3β. HPLC 
analysis (Protocol 1; Section 2.2.23) of the metabolism (red filled circles) of 16 nM InsP8 
at 37 ºC in the presence of (a) 10 ng DIPP-2β for 6 min, or (b) 22.5 ng DIPP-3β for 2 min. 
Blue filled circles represent zero-time controls.  
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Figure 4.4.2 Analysis of InsP8 dephosphorylation by Ddp1, DIPP-1, DIPP-2α and DIPP-3α. 
Representative HPLC runs (Protocol 2; Section 2.2.23) are shown for reactions containing either no 
enzyme [(a); “zero”], or (b) 16 ng Ddp1, (c) 2 ng DIPP-1, (d) 20 ng DIPP-2α and (e) 10 ng DIPP 3α, 
all incubated for 8 min with 16 nM InsP8. The right hand panels in each pair amplify the InsP7 region 
of the chromatography (all symbols excluding star; InsP7 is quantified as percentage of total); star 
symbols show elution of 1-InsP7 and 5-InsP7 standards (determined individually).  
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Figure 4.4.3 Dephosphorylation of InsP7 isomers by DIPP-1. Metabolism of a 1:1 
mixture of 1-InsP7 and 5-InsP7 by DIPP-1. Both the InsP7 isomers, 10 nM each, were 
together incubated for 10 min with 0.3 ng DIPP-1 along with about 1000 D.P.M of either 
1-[
3
H]InsP7 [left-hand bar; 27 ± 6 % metabolism, n = 3 (mean ± SEM)] or 5-[
3
H]InsP7 
[right-hand bar; 5.7 ± 0.9 % metabolism, n = 3 (mean ± SEM)]. HPLC analysis was 
employed to determine the metabolism of each InsP7. *p = 0.02 (t-test; N=3).  
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4.5 Discussion  
In this study, the dephosphorylation of [
3
H]-radiolabeled substrates [
3
H] 1-InsP7, [
3
H] 5-
InsP7 or [
3
H]-InsP8 have been kinetically characterised. HPLC analysis indicated the purity 
of IDPs prepared to be less than 100% (Section 2.2.22) and a slight decomposition was 
apparent. Such decomposition of pyrophosphate groups appears inevitable during 
preparation and storage of high energy molecules such as IDPs, however, this does not 
significantly affect the DIPP activity in the assays performed (Wu et al., 2013).    
The first assay was designed to check the activity of Ddp1 on the IDP substrates. In 
agreement with the previous report (Safrany, Ingram, et al., 1999), Ddp1 was found to 
hydrolyse 5-InsP7 to a single product, InsP6 [Fig. 4.2.1(b)]. Furthermore, Ddp1 was also 
shown to dephosphorylate 1-InsP7 [Fig. 4.2.1(a)] and InsP8 [Fig. 4.2.1(c)] to InsP6. There 
was relatively little build-up of InsP7 in the case of InsP8 breakdown [Fig. 4.2.1(c)]. No 
previous studies have described Michaelis-Menten kinetic parameters for Ddp1 activity 
towards either 1-InsP7 or InsP8. There is one earlier study that incubated Ddp1 with 250 
µM of either 1-InsP7 or 5-InsP7; in an electrophoresis analysis, and found only 1-InsP7 to 
be dephosphorylated to yield a product (Lonetti et al., 2011). The inability to detect 5-
InsP7 metabolism in their study may reflect lack of assay sensitivity when the 
concentration of substrate exceeds the Km value by 3 orders of magnitude (Table 4.3.1). 
Also, SDS-PAGE mass analysis is less sensitive than is HPLC analysis of [
3
H]-labelled 
substrates. So although it is known that Ddp1 favours 1-InsP7 over 5-InsP7 (Lonetti et al., 
2011), the new kinetic data from the current study indicate that the relative rates of Ddp1-
mediated dephosphorylation of the two InsP7 isoforms (Table 4.3.1) are much closer than 
previously thought. 
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The next aim was to obtain substrate saturation plot for all the five human DIPPs. In 
accordance with previously concluded results (Leslie et al., 2002; Safrany et al., 1998), the 
kcat data indicated DIPP-1 to be the most active enzyme amongst the five DIPPs, 
irrespective of the substrate (Table 4.3.1). Thus, for example, the relative levels of cellular 
expression of DIPP-1, versus the 20- to 60-fold less active DIPP-2 isoforms, could dictate 
the rapidity of IDP turnover on a cell-to-cell basis. This is similar to how differential 
expression of cyclic adenosine monophosphate-phosphodiesterases isoforms regulate cell-
to-cell differences in the sensitivity of agonist-mediated cyclic adenosine monophosphate 
signalling (Houslay, 1998).  
The kinetic data from this study demonstrates the rates of InsP7 dephosphorylation in 
general to be equal or exceed those of InsP8 metabolism (Table 4.3.1). In other words, the 
InsP7 was found to rapidly convert to InsP6. This explains why so little InsP7 accumulates 
when InsP8 was incubated with DIPPs (Fig. 4.4.1). Further, the kinetic data from this study 
leads to some significant physiological conclusions. First, since cellular concentrations of 
5-InsP7 are about 1-2 µM (Ingram et al., 2003; Leslie et al., 2002), these can now be 
considered sufficient (refer Table 4.3.1) to be at a saturating concentration for all DIPPs. 
Second, kcat values for 5-InsP7 dephosphorylation are 5 to 9-fold lower than that of 1-InsP7 
(Table 4.3.1). However, the affinity of the two isoforms of InsP7 to DIPPs are similar, so it 
appears likely that the steady-state rates of dephosphorylation of 1-InsP7 and 5-InsP7 will 
be quite similar in vivo, so they will compete for the DIPP active sites in direct proportions 
to their cellular concentration ratios. Third, the steady-state levels of 1-InsP7 in mammalian 
cells are 10 to 15-fold lower than that of 5-InsP7 and therefore, it is unlikely that the 
steady-state rates of hydrolysis of the previous will be significantly greater than that for 5-
InsP7 in vivo. 
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Furthermore, the positional specificity analysis (Fig. 4.4.2) and metabolism results for 1-
InsP7 and 5-InsP7 (1:1 mixture; with DIPP-1; Fig. 4.4.3) obtained from this study suggests 
that, 1-InsP7 formed from InsP8 is 10-fold faster to degrade than the 5-InsP7 that is 
produced. Thus, it can be concluded that Ddp1 (Table 4.3.1), and at least some of the 
DIPPs (Fig. 4.4.2), preferentially, although not exclusively, hydrolyses the 5-phosphate 
from InsP8. Positional specificity in case of DIPP-2β/3β was less clear. However, based on 
the similarity observed in terms of both sequence conservation and enzyme kinetics, it 
appears likely that even they will show positional specificity for the 5-phosphate of InsP8.  
Thus, the pathway that InsP8 chose to degrade (via 1-InsP7) is metabolically distinct from 
the main pathway for InsP8 synthesis (via 5-InsP7).  
4.6 Conclusion 
This study, by presenting the first kinetic characterization of Ddp1/DIPP-mediated 
hydrolysis of 1-InsP7, 5-InsP7 and InsP8 has increased the insight into the turnover of IDPs. 
Each DIPP was found to display similar Km values for every substrate tested (range: 35-
148 nM). The rank order of Kcat values (1-InsP7 > 5-InsP7 = InsP8) was identical for each 
enzyme, although DIPP-1 activity was observed to be 10- to 60-fold more than DIPP-2α/β 
and DIPP-3α/β. Through this study it is also clear that InsP8 prefers to dephosphorylate 
through 1-InsP7. In contrary, metabolically and functionally significant steady-state route 
of InsP8 synthesis was observed to be via 5-InsP7.              
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 RESULTS - EFFECTS OF ASPIRIN 5.
ANALOGUES ON OESOPHAGEAL CANCER 
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5.1 Introduction to aspirin analogues 
There is abundant evidence indicating that NSAIDs, including aspirin are anticarcinogenic 
and can prevent CRC in humans (See chapter 1). Recent studies have also shown aspirin’s 
utility in treating oesophageal cancer (Ahmadi et al., 2010; Corley et al., 2003). However, 
universal use of aspirin as an anticancer drug is restrained because of its potential side 
effects (Laine, 2002). Thus there is an overwhelming rationale to identify aspirin-related 
compounds that retain the specific toxicity to cancer but are safer and more effective than 
aspirin itself.  
In this regard several derivatives of salicylate/aspirin molecule have been tested for their 
anticancer property. For example, mesalazine (5-aminosalicylic acid), NCX-4040 (an NO 
releasing aspirin, 2-(acetyloxy)benzoic acid 4-[(nitrooxy)methyl] phenyl ester), NCX-4016 
(an NO derivative of aspirin, 2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl] phenyl ester), 
MDC-43 (a para-positional isomer of phosphoaspirin, 4-[(diethoxyphosphoryloxy)methyl] 
phenyl 2-acetoxybenzoate) were all found to inhibit cell growth in several cancer types 
(Claudius et al., 2014). 
A panel of variants of salicylate were developed recently at the University of 
Wolverhampton [Dr Iain Nicholl and Dr Chris Perry] with an intention to identify 
molecules that show the anticancer effects of aspirin against CRC, but with increased anti-
proliferative activity. The aspirin analogues developed include diaspirins, 
benzoylsalicylates and carbonates. Structures and purity of the compounds were verified 
using standard procedures such as nuclear magnetic resonance, IR, UV spectra and thin-
layer chromatography analysis.  
Previous investigations on these novel analogues revealed that diaspirins, in particular 
PN517 (fumaryldiaspirin, F-DiA, Fig. 5.1.1), to be the most potent agent exerting anti-
159 
 
proliferative effect against SW480 colon cancer cells (Claudius et al., 2014; Deb et al., 
2011). The study also revealed that analogues exerted their anticancer effects by causing 
repression of NFκB-driven transcription. Promising results, both in vitro and in in vivo 
mouse model with CRC, suggests potential role of F-DiA as an efficient chemotherapeutic 
agent (Claudius et al., 2014). 
Having witnessed the efficiency of aspirin analogues on CRC, we wanted to investigate if 
these analogues have any effect on oesophageal cancer cell lines. In this regard, the 
anticancer effects of a number of in-house synthesized novel aspirin analogues on three 
established oesophageal cancer cell lines was examined: Flo-1 (oesophageal 
adenocarcinoma), oe33 (oesophageal adenocarcinoma) and oe21 (squamous cell 
carcinoma). Representative morphology of the three oesophageal cancer cell lines under 
phase contrast microscope is shown in the Fig. 2.2.5. Aspirin analogues used in this study 
include: diaspirins (PN508, PN510, PN511, PN512 and PN517), benzoylsalicylates 
(PN514, PN524, PN525, PN528 and PN529) and carbonates (PN526 and PN527). 
Structure and molecular weight of the aspirin analogues used in this study are shown in the 
Fig. 5.1.1.  
To start with, the panel of aspirin analogues mentioned above were all screened on the 
three oesophageal cancer cell lines, looking for the most potent agents. Cell viability assay 
(MTT) was employed for this purpose. COX inhibitor screening assay was performed 
simultaneously to determine whether the analogues inhibited any of the COX enzymes.  
Based on the cell killing ability data from initial screening, potent aspirin analogues were 
chosen for further pharmacodynamic analysis. More MTT assays were performed to 
construct dose-response curves and calculate IC50s for aspirin and its analogues on the 
three oesophageal cancer cell lines. In order to validate that the killing by these novel 
analogues is through programmed cell death and not necrosis, both qualitative 
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(fluorescence imaging of apoptosis cells) and quantitative (flow-cytometric analysis of 
apoptosis) assays were performed. Further, ability of the drug-treated-cell-population to 
recover, following withdrawal of the drug was also checked to find out whether the 
analogues are cytotoxic or cytostatic in nature.   
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Figure 5.1.1 Structure and molecular weight of aspirin and aspirin analogues. 
Adapted from (Claudius et al., 2014). 
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5.2 Screening aspirin analogues for their potency on oesophageal cancer 
cell lines 
Effect of aspirin compounds on the three oesophageal cancer cell lines were examined 
using cytotoxicity (MTT) assay. Oesophageal cancer cell lines: oe21, oe33 and flo-1 were 
exposed to aspirin, salicylic acid (SA) and aspirin analogues at a concentration of 1 mM 
for 72 h. The screened aspirin analogues include diaspirins: PN508, PN510, PN511, 
PN512 and PN517; benzoylsalicylates: PN514, PN524, PN525, PN528 and PN529; 
carbonates: PN526 and PN527. Aspirin and SA were included in the experiment as 
controls given that they are reported to be protective against cancer (Pathi et al., 2012). 
Percentages of cells that are viable after drug treatment were determined. Screening results 
showed that several aspirin analogues had better killing ability than aspirin in all the three 
cell lines tested. In case of both oe21 and oe33 cell lines, benzoylsalicylates and in 
particular PN524, PN528 and PN529 compounds were significantly more potent than 
aspirin [Fig. 5.2.1(a) and (b)]. Although not as effective as benzoylsalicylates, the 
diaspirins- PN508 and especially PN517 showed robust killing ability. Other compounds 
such as PN512 and PN514 showed moderate effect on both oe21 and oe33 cell lines. 
Conversely, flo-1 cell line was resistant to almost all the compounds tested other than 
PN528 and PN529 [Fig. 5.2.1(c)]. SA showed similar toxicity to aspirin in the cancer cell 
lines tested. Compounds including PN510, PN511, PN525, PN526 and PN527 failed to 
show robust cancer killing ability in the all the three cell lines and thus were not used for 
further experiments. 
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Figure 5.2.1 Screening and assessment of the potency of aspirin analogues on 
oesophageal cancer cell lines in vitro.  (a) oe21, (b) oe33 and (c) flo-1 cells were plated 
at a density of 10
4
 cells/ml in 96-well microtitre plates (200 µl/well) in their respective 
basal medium. Twenty-four hours after seeding, the cells were treated with compound-
containing culture medium for a further 72 h. The anti-proliferative effects were measured 
in an MTT assay (Section 2.2.26). All compounds were prepared as stock solutions in 
DMSO (0.5 M stocks) and further diluted to 1 mM final concentration in culture medium 
(Section 2.2.25). The MTT results were plotted as percentage of cell viability against drug 
concentration using GraphPad Prism 6. Data plotted as mean ± SEM (N=3). The effect of 
aspirin and SA is included for comparison. 
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5.3 IC50 analysis of the potent aspirin analogues 
Aspirin analogues that were found potent against oesophageal cancer cells compared to 
aspirin in the initial screening experiment were chosen for the IC50 analysis. Appropriate 
drug stock solutions were prepared fresh using DMSO for each experiment (DMSO 
content in the working solution was kept well within the tolerated dose by the cells i.e., 
~10%). All the three cell lines were incubated for 72 h with the compounds (30 µM – 3 
mM) individually and assayed using MTT.  A dose response curve was plotted using the 
data obtained from MTT analysis and IC50 for each of the compound was calculated 
(Section 2.2.30). IC50 values for compounds tested on oe21, oe33 and flo-1 cell lines are 
listed in the Table 5.3.1 and represented in Fig. 5.3.1.  
Aspirin analogues were found to supress the proliferation of oesophageal cancer cell lines 
in a dose-dependent manner. From the results, it was clear that PN529 was the most 
cytotoxic compound with IC50 values as low as 100 µM and high as 400 µM in oe21 and 
oe33 cell lines respectively (Table 5.3.1). This was followed by PN528 with IC50 values 
ranging between 0.2 – 1.6 mM. Statistical analysis of the MTT data highlighted PN517 to 
be an interesting and important analogue with a distinct Hill slope profile in all the three 
cell lines (Table 5.3.1; Fig. 5.3.1). IC50 values for PN517 ranged between 0.4 – 1.1 mM. 
The other analogue with significant killing curve was PN524 with IC50 values: 0.24, 0.7 
and 0.9 mM in oe21, oe33 and flo-1 cells respectively (Table 5.3.1). PN512 and PN514 
showed only moderate killing ability in these cell lines. In general, the low IC50 trend for 
compounds exposed to oe21 cells suggest that it is the most sensitive cell line out of the 
three tested.  Although flo-1 cells were sensitive to some of the benzoylsalicylate 
compounds, resistance to most of the analogues was apparent with high IC50 values (Table 
5.3.1). 
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Figure 5.3.1 Dose response curves for oe21 cell line 
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Figure 5.3.1 Dose response curves for oe33 cell line 
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Figure 5.3.1 Dose response curves for flo-1 cell line 
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Figure 5.3.1 Dose response curves for cell lines oe21, oe33 and flo-1 treated with 
aspirin and aspirin analogues. Aspirin analogues used herein include PN508, PN512, 
PN517, PN514, PN524, PN528 and PN529. Oe21 cells at a density of 2.5×10
3 
cells/ml and 
oe33, and flo-1 cells at a density of 10
4
 cells/ml was plated in 96-well plates in their 
respective basal medium. Twenty-four hours after seeding, the cells were treated with 
compound-containing culture medium for a further 72 h. The anti-proliferative effects were 
measured in an MTT assay (Section 2.2.26). All compounds were prepared as stock 
solutions in DMSO and further diluted to a final concentration of 30 µM, 100 µM, 300 
µM, 1 mM and 3 mM in culture medium (Section 2.2.25). Data plotted as mean ± SEM 
(N=3) (Section 2.2.30). The effect of aspirin and DMSO (vehicle control) is included for 
comparison. 
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 aspirin 
analogues 
aspirin PN508 PN512 PN517 PN514 PN524 PN528 PN529 
oe21 pIC50 
±SEM 
2.90± 
0.04 
3.07± 
0.01 
3.07± 
0.04 
3.34± 
0.04 
3.189± 
0.007 
3.62± 
0.10 
3.64± 
0.05 
3.99± 
0.04 
IC50 (in 
mM)  
1.3 0.86 0.85 0.45 0.65 0.24 0.23 0.1 
Hill slope 
±SEM 
2.0 
±0.3 
1.9 
±0.1 
1.8 
±0.1 
5.6 
±0.7 
1.9 
±0.1 
1.5 
±0.3 
1.7 
±0.1 
1.7 
±0.6 
oe33 pIC50 
±SEM 
2.57 
±0.07 
3.02 
±0.06 
3.03 
±0.09 
3.3 
±0.1 
2.83 
±0.02 
3.17 
±0.06 
2.80 
±0.07 
3.4 
±0.1 
IC50 (in 
mM) 
2.7 0.95 0.9 0.5 1.5 0.67 1.6 0.4 
Hill slope 
±SEM 
1.0 
±0.3 
0.97 
±0.04 
1.5 
±0.6 
1.3 
±0.3 
0.7 
±0.2 
1.8 
±0.4 
0.79 
±0.05 
1.0 
±0.2 
flo-1 pIC50 
±SEM 
2.16 
±0.02 
2.80 
±0.03 
2.65 
±0.09 
2.95 
±0.05 
2.4 
±0.1 
3.05 
±0.07 
3.15 
±0.05 
3.62 
±0.03 
IC50 (in 
mM) 
6.9 1.6 2.2 1.1 4.2 0.9 0.71 0.24 
Hill slope 
±SEM 
1.0 
±0.1 
1.1 
±0.4 
0.9 
±0.3 
2.0 
±0.5 
0.56 
±0.06 
1.26 
±0.05 
0.87 
±0.05 
0.80 
±0.04 
 
Table 5.3.1 IC50 values for aspirin and aspirin analogues on the three oesophageal 
cancer cell lines. IC50 values were obtained by non-linear regression (GraphPad Prism 6) 
with 4 variables. pIC50 and Hill slope are shown and are expressed as the mean ± SEM of 
the data from three independent experiments (Section 2.2.30). 
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5.4 Do aspirin analogues mediate cell death through apoptosis? 
Differential cell killing ability of aspirin analogues was evident from the MTT data. The 
next step was to examine whether treatment with aspirin analogues resulted in cell death 
through apoptosis or necrosis. For this purpose, two assays: fluorescence activated cell 
sorting (FACS) or flow cytometric analysis of apoptosis (quantitative assay) and 
fluorescence imaging of apoptotic cells (qualitative assay) were performed.  
Irinotecan hydrochloride (irinotecan or IRI or CPT-11), a potent anticancer drug, has been 
reported to exhibit its cytotoxicity in colon cancer cells in vitro by inducing apoptosis (Deb 
et al., 2011; Rudolf et al., 2012). On the other hand, hydrogen peroxide (H2O2) at a higher 
concentration has been reported to induce necrosis in human breast cancer cell lines 
(McKeague et al., 2003). Hence, irinotecan and H2O2 were used as positive controls for 
apoptosis and necrosis respectively in the following experiments. 
5.4.1 Flow cytometric analysis of apoptosis 
For FACS analysis, Annexin-V-Fluos apoptosis staining kit which responds to 
phospholipid scrambling, a unique feature of the apoptotic pathway (Vermes et al., 1995), 
was used. Use of a counter-stain such as propidium iodide (PI) along with the principal 
stain in apoptosis experiments enabled easy discrimination of viable cells from non-viable 
and apoptotic cells from necrotic cells (Vermes et al., 1995). Viable cells do not take up 
either stain whereas non-viable cells take up only PI stain. Apoptotic cells take up the 
principle Annexin-V stain but not PI whereas necrotic/late apoptotic cells take up both 
Annexin-V and PI stain (Fig. 2.2.7). Oesophageal cancer cell lines at 50% confluency (in 
culture flasks) were treated with aspirin and aspirin analogues at a final concentration of 1 
mM for 24 h, 48 h and 72 h (Section 2.2.27a). Irinotecan (25 µM), H2O2 (2 mM) and a 
vehicle control for DMSO was included in the experiments for comparison. Representative 
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flow cytometry plots showing the oe21 cells undergoing apoptosis, late apoptosis and/or 
necrosis following treatment with irinotecan, H2O2 and aspirin analogue PN524 are 
illustrated in Fig. 5.4.1a.   
 
Figure 5.4.1a Flow cytometric analysis of apoptosis and necrosis. Induction of 
apoptosis/necrosis in oe21 cells following treatment with irinotecan, H2O2 and aspirin 
analogue PN524 for 24, 48 and 72 h were checked by labelling the cells with Annexin-V 
and PI stains. The above figure represents Annexin-V versus PI contour plots with 
quadrant gates showing four populations. Oe21 cells that were viable and non-apoptotic 
showed negative staining for both Annexin-V and PI and were observed to fall in quadrant 
PN524irinotecan H2O2
24 h
72 h
48 h
Annexin-V
P
ro
p
id
iu
m
 I
o
d
id
e
1 2
34
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1 (see top left figure). Early apoptotic cells which showed positive staining for only 
Annexin-V were observed in quadrant 2. Late apoptotic cells which showed positive 
staining for both Annexin-V and PI were observed in quadrant 3. Cells or sometimes 
debris that shows positive staining for PI only were observed to move towards quadrant 4 
(Refer Fig. 2.2.7 in Section 2.2.27a). Treatment with irinotecan or PN524 for 48 h showed 
a small proportion of oe21 cells undergoing apoptosis (positively stained Annexin-V cells 
in quadrant 2). With the increase in the treatment time (at 72 h), the cells appeared to be in 
their late apoptotic stage (positively stained cells for both Annexin-V and PI in quadrant 
3). Treatment with H2O2 caused abrupt cell death apparent between 24 and 48 h. The 
profile of PN524 was similar to irinotecan, causing death by apoptosis. 
 
All the compounds tested were able to drive apoptosis, which was observable by 24 h. 
Increased time of treatment increased the number of cells undergoing apoptosis (Fig. 
5.4.1b). This was the case with all three cell types, but more evident in oe21 cells [Fig. 
5.4.1b(i)]. Oe33 cells appeared to induce more apoptosis than oe21 [Fig. 5.4.1b(ii)], 
however, most of this population was suspected to be auto-fluorescent debris from the cells 
and not apoptotic cells. Flo-1 cells were resistant to most of the compounds and thus, in 
general, showed low percentage of apoptotic cells [Fig. 5.4.1b(iii)]. As expected, 
irinotecan treatment greatly induced apoptosis in all three cell types (Fig. 5.4.1a and Fig. 
5.4.1b). H2O2 treatment also presented some apoptosis at 24 h, however, this population 
decreased with increase in treatment time (Fig. 5.4.1a). In oe21 cells, PN524 treatment 
exhibited highest percentage of apoptotic cells (Fig. 5.4.1a), followed by PN517 treated 
cells. In oe33 cells, PN517 treatment induced highest percentage of apoptotic cells, 
followed by PN524 and PN528. In flo-1 cells, PN529 followed by PN528 showed 
increased apoptosis compared to other compounds. 
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Figure 5.4.1b   Flow cytometric analysis of aspirin analogues-induced-apoptosis in oe21 
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Figure 5.4.1b   Flow cytometric analysis of aspirin analogues-induced-apoptosis in oe33 
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Figure 5.4.1b   Flow cytometric analysis of aspirin analogues-induced-apoptosis in flo-1 
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Figure 5.4.1b Flow cytometric analysis of aspirin analogues-induced-apoptosis in (i) 
oe21, (ii) oe33 and (iii) flo-1 cell lines. Oesophageal cancer cells were cultured to 50% 
confluency and treated with compound-containing culture medium for a further 24 h, 48 h 
and 72 h. After treatment, cells were stained with Annexin-V-Fluos and counter-stained 
with PI (Section 2.2.27a). The population of cells undergoing apoptosis or necrosis were 
measured by FACS analysis using flow cytometer. All compounds were prepared as stock 
solutions in DMSO and further diluted to a final concentration of 1mM in culture medium 
(Section 2.2.25). Data plotted as mean ± SEM (N=3). Irinotecan (represented as IRI in the 
Fig.) and H2O2 were used as positive controls for apoptosis and necrosis, respectively. The 
effect of aspirin and DMSO (vehicle control) is included for comparison. * p ≤ 0.05 and ** 
p ≤ 0.01 (Section 2.2.30). 
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5.4.2 Flow cytometric analysis of necrosis 
Although most of the aspirin analogues largely exerted cell killing via apoptosis, some of 
them appeared to induce more necrosis than apoptosis and some showed mixture of both 
populations. However, the percentage of apoptosis or necrosis population varied between 
the three cell lines. Drug-induced necrosis at 24 h in the three cell lines are shown in the 
Fig. 5.4.2a as an example. Necrosis after this time period was not taken into account, as it 
was difficult to differentiate actual necrosis from secondary necrosis (late apoptosis). As 
predicted, H2O2 efficiently induced necrosis within 24 h in all three cell types and in 
contrast, irinotecan initiated very little necrosis (Fig. 5.4.2a). All the compounds, except 
for PN529, appeared to be poor inducers of necrosis in oe21 and flo-1 cell types (Fig. 
5.4.2a). Oe33 cells showed increased necrosis with almost all the compounds. This result 
is again suspected to be due to the noise created by the debris (auto-fluorescent) from the 
cells (Fig. 5.4.2a).  
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Figure 5.4.2a Flow cytometric analysis of aspirin analogues-induced necrosis in 
oesophageal cancer cell lines at 24 h. Experimental procedure (treatment and staining), 
flow cytometric and statistical analysis are the same as with apoptosis analysis (Fig. 
5.4.1b). * p ≤ 0.05 and ** p ≤ 0.01 (Section 2.2.30). 
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5.4.3 Fluorescence imaging of apoptotic cells 
An Apo-TRACE cell staining kit that again responds to phospholipid scrambling was used 
for fluorescence imaging of apoptotic cells. The Apo-TRACE compound stains the 
cytoplasm of the apoptotic cells (Damianovich et al., 2006). PI counter-stain, in contrary, 
stains only non-viable cells. Late stage of apoptosis and death are characterised by cells 
taking up both Apo-TRACE stain and PI counter-stain.  In this experiment, oesophageal 
cancer cells grown to 50% confluency on glass-coverslips were treated with aspirin and 
aspirin analogues at a concentration of 1 mM for 24 h (data shown only for oe21 cell line) 
and 48 h (Section 2.2.27b). Irinotecan (25 µM), H2O2  (2 mM) and vehicle control were 
included in the experiment for comparison.  
In all the cell lines, irinotecan treatment induced largely apoptosis (blue stained cytoplasm 
only) and H2O2 treatment induced largely necrosis (blue stained cytoplasm with red stained 
nuclei) (Fig. 5.4.3a). Images of oe21 cells, at both 24 h and 48 h, suggest that most of the 
analogues exert their toxicity through induction of apoptosis. However, necrosis was 
observed with PN528 and significantly more with PN529 treatment [Fig. 5.4.3a(i) and Fig. 
5.4.3a(ii)]. Oe33 and flo-1 cells treated with the compounds for 24 h showed mostly 
healthy cells with very few apoptotic cells (visual observation). However, large numbers of 
non-viable dead cells were seen floating within 24 h of treatment with PN529 suggesting it 
causes, at least in part, necrosis (visual observation). Images of oe33 [Fig. 5.4.3a(iii)] and 
flo-1 [Fig. 5.4.3a(iv)] cells at 48 h suggest that most of the analogues largely exert their 
toxicity via induction of apoptosis, although necrosis was quite evident with PN529 
treatment. PN528 appeared to induce apoptosis in both oe33 and flo-1 cells [Fig. 5.4.3a(iii) 
and Fig. 5.4.3a(iv)].  
In general, PN517 treated cells were found to contain a mixture of apoptotic and necrotic 
cells (more apoptotic than necrotic) at 48 h [Fig. 5.4.3a(ii), (iii) and (iv)]. Apo-TRACE 
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was observed to accumulate more (both in terms of concentration/stain intensity inside 
cells and number of cells) in cells treated with PN524 and PN528 indicating that these 
analogues are more apoptotic (Fig. 5.4.3a). Compared to oe21 and flo-1 cell lines, the 
number of cells undergoing apoptosis/necrosis (stained cells) was found to be very few in 
oe33 cell line. Also, Apo-TRACE was observed to irregularly accumulate/stain cytoplasm 
of irinotecan-treated oe33 cells [Fig. 5.4.3a(iii)]. Both, PN512 and PN514 induced 
apoptosis in all the three cell lines. However, number of cells undergoing apoptosis was 
more with oe21 cells [Fig. 5.4.3a(ii)] compared to the oe33 and flo-1 cells. 
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Figure 5.4.3a(i) Fluorescence imaging of oe21 cells (24 h) 
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Figure 5.4.3a(ii) Fluorescence imaging of oe21 cells (48 h) 
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Figure 5.4.3a(iii) Fluorescence imaging of oe33 cells (48 h) 
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Fig.5.4.3a(iv) Fluorescence imaging of flo-1 cells (48 h) 
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Figure 5.4.3a Fluorescence imaging of cells treated with aspirin compounds and 
stained with the Apo-TRACE cell staining kit. Oe21 cells exposed to compounds for (i) 
24 h and (ii) 48 h. Oe33 cells exposed to compounds for (iii) 48 h. Flo-1 cells exposed to 
compounds for (iv) 48 h. Oesophageal cancer cell lines at 50% confluency were treated 
with compound-containing culture medium for a further 24 h and 48 h. After treatment, 
cells were stained using Apo-TRACE cell staining kit (Section 2.2.27b) and observed by 
fluorescence microscopy. All compounds were prepared as stock solutions in DMSO and 
further diluted to a final concentration of 1mM in culture medium. Cells stained blue-only 
are apoptotic and cells stained both blue and red are late apoptotic/necrotic. Irinotecan and 
H2O2 were used as positive control for apoptosis and necrosis, respectively. Aspirin and 
vehicle control were included in the experiment for comparison. Images herein are 
representation of two individual experiments. The images were taken at 100x 
magnification (Olympus Bx60). 
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5.5 Do aspirin analogues act as cytostatic drugs? 
During the exposure of some aspirin analogues to oesophageal cancer cells, a delay or 
inhibition in the cell growth was observed. To examine whether treatment with analogues 
induced the cells to undergo cytostasis, recovery experiments were performed (Section 
2.2.28). Oesophageal cancer cells were treated with aspirin and aspirin compounds at a 
concentration of 1 mM for 72 h. The cells were removed from the medium containing drug 
and were further allowed to recover for 72 h to see if the cells continued to proliferate. 
Number of cells at the end of the experiment was counted and compared with the initial 
seeding number to decide if the drug was cytotoxic or cytostatic. Aspirin, irinotecan and 
H2O2 were included in this experiment for comparison  
Oesophageal cancer cells treated with PN508 and especially aspirin, showed cell recovery 
equal to or more than that of untreated control cells, following withdrawal of the drug.  In 
general, treatment with irinotecan and H2O2 affected the cancer cells irreversibly and thus 
cells struggled to grow during recovery period. Oe21 cells following treatment with the 
analogues PN517, PN524, PN528 and PN529 failed to recover as well as untreated control 
cells, suggesting that these analogues are more cytotoxic with oe21 cell line (Fig. 5.5.1). 
Recovering ability of oe33 cells following treatment with these analogues was found to be 
affected, although not as severe as with oe21 cells (Fig. 5.5.1). Conversely, recovery of 
flo-1 cells after treatment with PN517 and PN524 analogues showed signs of regained 
proliferation ability. However, flo-1 cells treated with PN528 and PN529 showed poor cell 
recovery, following withdrawal of the drug (Fig. 5.5.1). Thus, in general, compounds 
PN528 and more significantly PN529 were cytotoxic to all three cancer cell lines tested. 
PN517 and PN524 appeared to be more cytotoxic to oe21cells but were more cytostatic to 
flo-1 cells.         
189 
 
 
 
 
 
c
o
n
tr
o
l
v
e
h
ic
le
a
s
p
ir
in
5
0
8
5
1
7
5
2
4
5
2
8
5
2
9
IR
I
H
2
O
2
0
2 0
4 0
6 0
8 0
1 0 0
R e c o v e r y  o f  o e 3 3  c e lls
1 m M
N
u
m
b
e
r
 o
f 
c
e
ll
s
/1
,0
0
0
**
c
o
n
tr
o
l
v
e
h
ic
le
a
s
p
ir
in
5
0
8
5
1
7
5
2
4
5
2
8
5
2
9
IR
I
H
2
O
2
0
1 0
2 0
3 0
4 0
5 0
R e c o v e r y  o f  o e 2 1  c e lls
1 m M
N
u
m
b
e
r
 o
f 
c
e
ll
s
/1
,0
0
0
**
**
**
** ** **
190 
 
 
 
 
Figure 5.5.1 Recovery of oesophageal cancer cells following withdrawal of aspirin and 
aspirin compounds. Oe21, oe33 and flo-1 cells were seeded at a density of 5×10
3
,
 
2×10
4
 
and, 2×10
4
 cells/ml, respectively, in 6-well plates in their respective basal medium. 24 h 
after seeding, the cells were treated with drug-containing culture medium (1mM final 
concentration) for a further 72 h. After treatment time, viable/adherent cells were 
harvested, counted and re-seeded (same as initial density) in fresh 6-well plates with drug-
free-medium (Section 2.2.28). After 72 h of recovery, cell counts were determined. Data 
plotted as mean ± SEM (N=3, performed in duplicates). The effect of aspirin, DMSO 
(vehicle control), irinotecan (IRI) and H2O2 is included for comparison. * p ≤ 0.05 and ** p 
≤ 0.01 (Section 2.2.30). 
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5.6 COX inhibitor screening 
Inhibitory activity of aspirin analogues against COX-1 and COX-2 enzymes was 
investigated with a COX inhibitor screening assay kit (Section 2.2.29). Values for IC50 
were obtained by non-linear regression analysis (Section 2.2.30). The results showed 
aspirin to be the only potent inhibitor of COX-1 activity, with IC50 value of 0.6 mM. Other 
than PN526 and PN527 none of the aspirin analogues inhibited COX-1 (Fig. 5.6.1). In all 
the experiments performed, aspirin failed to inhibit COX-2 enzyme even at a high 
concentration of 10 mM. Similarly, most of the analogues appeared to not inhibit COX-2 
enzyme (Fig. 5.6.1). The high absorbance recorded in case of PN528 and PN529 appeared 
to be due to the drug coming out of the solution. These results therefore need to be treated 
with caution. 
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Figure 5.6.1 The inhibitory effect of aspirin analogues on COX-1 and COX-2. Aspirin 
compounds were prepared as stock solutions in DMSO. All the drug samples were added 
at a final concentration of 10 mM as DMSO solutions (10 µl final volume) to the assay 
mixture. The COX inhibition assay was performed at 37 ºC as described in the Section 
2.2.29 and the absorbance of the samples were measure at 590 nm using a plate reader. 
Data plotted as mean ± SEM (N=3). Aspirin and SA was included in the experiment for 
comparison.     
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5.7 Discussion 
Oesophageal cancer is a major cause of cancer-related mortality worldwide [CRUK(b)]. 
Present treatments are associated with significant morbidity and generally provide 
marginal benefit. Aspirin, though reported to provide only marginal anticancer benefit 
against several cancers, is one of the very few drugs that offer protection against GI 
cancers (NCI). Unlike most of the cancer drugs which have a single target, aspirin affects 
multiple pathways and influence physiological process including apoptosis and 
angiogenesis that are crucial for cancer progression (Langley et al., 2011). Despite the 
benefits, use of aspirin for chemopreventative purposes universally is restricted because of 
(a) the potential gastropathy involved with long-term use (Laine, 2002) and (b) the 
unconfirmed dose regimen for safe and efficient use (NCI). Even the use of proton-pump 
inhibitors (long-term) to overcome aspirin-induced side effects are reported to involve side 
effects of its own (Sheen and Triadafilopoulos, 2011). Hence, there is an overwhelming 
rationale for novel developments that would lead to a reduction and/or in cancer-related 
morbidity and fatality. 
Herein, the aspirin analogues with greater anti-proliferative effect against oesophageal 
cancer cells in vitro than aspirin and SA have been demonstrated. Diaspirin and 
benzoylsalicylate group of compounds were found to be highly potent against all three 
oesophageal cancer cell lines (i.e., flo-1, oe33 and oe21) compared to carbonates, aspirin 
and SA (Fig. 5.2.1). Based on the IC50 data, the potency of the compounds were found to 
be in the order as follows: in case of flo-1 cell line- 
PN529>PN528>PN524>PN517>PN508>PN512>PN514>aspirin; in case of oe21 cells- 
PN529>PN528>PN524>PN517>PN514>PN512>PN508>aspirin; in case of oe33 cells- 
PN529>PN517>PN524>PN512>PN508>PN514>PN528>aspirin (Fig. 5.3.1; Table 5.3.1).  
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PN529 was the most potent drug (IC50<0.5mM) amongst all the analogues tested and 
across all the cell lines used. However, it appeared to lack specificity as it killed all the 
three cell lines efficiently at a lower concentration and at a short treatment time (Fig. 5.3.1; 
Table 5.3.1). In support of this finding, lack of specificity of PN529 was also observed in 
colorectal (SW480, HCT116, LoVo) and non-colorectal (A549, MCF7, EA.hy926) cancer 
cell lines (Claudius et al., 2014). PN528 was the second most potent drug in case of flo-1 
and oe21 cell lines but showed less killing ability towards oe33 cell line. Poor potency of 
PN528 to oe33 cells could be due to resistance of the cell line or poor drug-uptake by cells 
due to precipitation of the drug. PN528, a methyl ester of benzoyl-salicylic acid (also 
known as, benzosalin), is a highly hydrophobic drug which although prepared as stock 
solution in a strong solvent such as DMSO, precipitated easily when introduced into 
growth medium (RPMI and DMEM). Precipitation and crystal-like formation was quite 
evident when observed under the microscope. Use of diluted stock solution of PN528 in 
DMSO (0.250 M) for experiments was of only little use. A similar precipitation concern 
was also observed with PN529 analogue. Whether such precipitation of compounds has an 
effect on pharmacodynamics of the drug on the cells is unclear. However, a historic study 
found benzosalin to be a useful drug for rheumatism and neuralgia (Bodenstein, 1907). The 
study also found benzosalin to have no unpleasant gastric-related side effects in patients as 
it dissociates to its constituents only in the intestine. 
The most interesting and promising drugs in this study include PN517 and PN524. IC50 
data from cytotoxicity assays demonstrated PN524 to be a more potent drug than PN517 in 
oesophageal cancer cell lines, except for oe33 cell line (PN517 was slightly more potent 
than PN524) (Fig. 5.3.1; Table 5.3.1). However, PN517 and PN508 were shown to have 
profound antitumour effect than PN524 in SW480 CRC cells (Claudius et al., 2014). 
Further investigation of cytotoxic effects of these aspirin analogues on other oesophageal 
cancer cell lines and more importantly non-cancerous/normal human oesophageal 
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epithelial cells would prove to be of great use in confirming the specificity of these 
compounds to oesophageal cancer cells. 
Based on the cytotoxicity profile of PN517 from this study and study by Claudius et al. 
(2014) it is evident that PN517 exhibits modicum of specificity for not only CRC cell lines 
but also to oesophageal cancer cell lines in vitro. Furthermore, the study also demonstrated 
that PN517 and PN508 had potent antitumour action in vivo, in an implantable mouse 
model of CRC and also confirmed no drug-related side effects when introduced to mice 
intravenously over a 10-day period.  
In this study, oe21 SCC cells were found to be the most sensitive to aspirin analogues 
compared to oe33 and flo-1 ADC cells. A difference in response to anticancer treatment 
has been previously observed between SCC and ADC. SCC cells are reported to be more 
sensitive to anticancer agents than ADC according to a study (Darnton et al., 1995). 
Considerable resistance of flo-1 cells to compounds was evident with the increased cell-
viability and higher IC50 values for the compounds (Fig. 5.3.1; Table 5.3.1). Flo-1 
(compared to oe33) cells have been reported to exhibit resistance to chemotherapy due to 
increased expression of insulin-like growth factor binding protein-2 both at mRNA and 
protein level (Silvers et al., 2012). In this study, the observed variations in drug-sensitivity 
(IC50s) across the different oesophageal cancer cell lines could be associated with 
proliferative rate of the cells. Cytotoxic cancer drugs are known to work by interrupting 
DNA synthesis or function and are believed to selectively affect the rapidly proliferating 
cells (Mitchison, 2012). This could be a possible explanation as to why the fast-growing 
oe21 cells are more sensitive to aspirin compounds, whereas slow-growing flo-1 cells are 
more resistant.  
It has been stated in Claudius et al. (2014) study that cells cultured in DMEM show 
reduced sensitivity to aspirin compounds. Since flo-1 cells cultured in DMEM medium 
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were used for the experiments in this study, it is possible that the observed resistance to 
compounds was partly due to growth medium. Studies have reported that components of 
applied media (DMEM, MEM and RPMI) can influence cell proliferation and viability of 
cells (Lopez-Cazaux et al., 2006; Wu et al., 2009). DMEM is a nutrient-rich medium 
consisting of higher concentration of calcium (1.8 mM) and glucose (4.5 g/L) and lower 
concentration of phosphate (1 mM). In contrast RPMI, amino-acids-rich medium, contains 
higher levels of phosphate (5 mM), but carries low concentrations of calcium (0.8 mM) 
and glucose (2 g/L). Studies have shown that calcium rich medium can induce cell 
proliferation (Lopez-Cazaux et al., 2006; Maeno et al., 2005). Several studies have also 
shown reduced glucose level to enhance proliferation and higher glucose level to induce 
senescence in cells (Kim et al., 2006; Stolzing et al., 2006). Perhaps growing all the 
oesophageal cancer cell lines in either DMEM or RPMI basal medium for experiments 
could avoid such variability due to culture conditions. However, introducing the cell lines 
to a non-native culture medium for experimental purpose might affect the normal growth 
and vitality of the cells.  
In this study, aspirin and most of the aspirin analogues tested other than PN529 (Fig. 
5.4.2a) (induced necrosis in the tested cell lines within 24 h) largely exerted their toxicity 
via inducing apoptosis (Fig. 5.4.1b and Fig. 5.4.3a). PN529 has been previously shown to 
induce necrosis in CRC cell lines (Deb et al., 2011). Both qualitative and quantitative 
apoptosis assays confirmed PN517, PN524, PN528 and PN529 to be the most potent 
analogues to oesophageal cancer cell lines. PN524 was the only compound which 
consistently showed more apoptosis in all the three tested cell lines (Fig. 5.4.1b and Fig. 
5.4.3a). In contrast, compounds PN517 and PN528 appeared to induce both apoptosis and 
necrosis in the cell lines (Fig. 5.4.3a). Since such mixture of cells were observed mostly 
after 48 h of drug treatment, it is possible that the cells were in late-apoptosis/secondary 
necrosis stage and thus have taken up both PI and Apo-TRACE staining. Studies have 
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stated that features of both apoptosis and necrosis can coexist in the same cell as a response 
to certain dose of death-inducing drugs (Zong and Thompson, 2006). In addition, process 
known as secondary necrosis, where the dead cells in their late apoptotic stage (not 
engulfed by means of phagocytosis), may present necrotic features due to loss of cellular 
energy and plasma membrane integrity has also been reported (Majno and Joris, 1995). 
NSAIDs such as indomethacin have been reported to induce both necrosis and apoptosis in 
gastric mucosal cells of guinea pig (Tomisato et al., 2001). Although PN517 was initially 
shown to exert their toxicity in SW480 colon cancer cells via the necrotic pathway (Deb et 
al., 2011), later it was reported to largely induce apoptosis (Claudius et al., 2014).  
In apoptosis experiments, use of H2O2 at a necrosis-inducing-dose proved beneficial to 
compare and judge whether the aspirin compounds induced necrosis or not. Use of 
irinotecan as positive control for apoptosis was beneficial; however, it induced low levels 
of apoptosis at the chosen concentration (25 µM) (Fig. 5.4.3a). Also, fluorescent imaging 
of drug-treated oe33 cells showed poor uptake of apoptosis-cell stain and in particular cells 
treated with irinotecan showed an aberrant uneven uptake of Apo-TRACE stain [Fig. 
5.4.3a(iii)]. However, flow cytometric analysis (used Annexin-V-fluos staining) of drug-
treated oe33 cells showed increased number of necrotic cells/noisy debris [Fig. 5.4.1b(ii) 
and Fig. 5.4.2a]. One explanation for this could be that the cell debris generated by oe33 
cells is rather auto-fluorescent. Although there is no experimental evidence from this study, 
one possibility is that the so called ‘noisy debris/auto-fluorescent population’ may as well 
be a side population (SP) containing stem-like cells (Donnenberg and Donnenberg, 2007). 
Dye-effluxing SP cells that are resistant to chemotherapy and resemble cancer stem cells 
were found in oesophageal cancer cell lines (Zhao et al., 2014). In their study, oe33 cells 
(8.8% ± 2.7) were shown to have more SP cells than oe21 cells (0.6% ± 0.3).  
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From the apoptosis data, oe21 can again be concluded as the most sensitive cell line with 
PN524 being the most potent apoptosis-inducing agent [Fig. 5.4.1b(i) and Fig. 5.4.3a(ii)]. 
PN517 was the most potent in the case of oe33 [Fig. 5.4.1b(ii)]. Flow cytometric analysis 
confirmed flo-1 cells to be the most resistant with the least number of apoptotic cells at 72 
h for most of the compounds [Fig. 5.4.1b(iii)]. 
Although, the MTT assay showed decreased viability of cells in response to treatment with 
certain aspirin compounds, the number of cells that actually underwent apoptosis appeared 
to be relatively low in the apoptosis experiments. Also, a delay or inhibition in the cell 
growth was observed with exposure of oesophageal cancer cells to some of the most potent 
compounds. Recovery experiment conducted in this study revealed that the cytostatic 
and/or cytotoxic status of PN517 and PN524 compounds are hugely dependent on the cell 
line under investigation (Fig. 5.5.1). However, PN528 and PN529 compounds were found 
to be more cytotoxic in all the three cell lines. Failure to recover after PN517 and PN524 
treatment confirmed oe21 to be the most sensitive cell line whereas quick recovery of cells 
after drug removal proved flo-1 to be a more resistant cell line (Fig. 5.5.1). Earlier studies 
have shown oe21 and oe33 cell lines to be sensitive and lack ability to recover following 
5FU or cisplatin insult (O'Donovan et al., 2011). Their report is in support with the 
observation from this study that oe21 cells and oe33 cells (not as sensitive as oe21) are 
sensitive to cytotoxic drugs. Such loss of cell viability during recovery from cytotoxic drug 
could be attributed to a defect in DNA repair. 
In comparison to aspirin analogues, aspirin treated cells were found to recover as well as or 
even better than the untreated cells (Fig. 5.5.1). Provided that aspirin has a short half-life in 
human circulation (Dovizio et al., 2012), administering it in low doses for a longer time 
(~5 years) (Rothwell, Price, et al., 2012) becomes necessary to reap the preventative 
anticancer benefits. A study observed aspirin to be ineffective in reducing the risk of CRC, 
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if its use was discontinued within 4 years (Chan et al., 2008). Furthermore, discontinuation 
of aspirin therapy within 2 years prior to the study was attributed to threefold increase in 
risk for pancreatic cancer (Streicher et al., 2014). It is possible that a similar repetitive 
dosing regimen is required to witness aspirin’s therapeutic effects. However, this was not 
employed in this study and hence the observed ineffectiveness.  A recent study also found 
aspirin to be weak in inhibiting intestinal adenomatous polyposis compared to a promising 
anticancer agent acetyl-11-keto-β-boswellic acid (Wang et al., 2014). Moreover, the study 
proposed that unlike the latter, aspirin does not exhibit anticancer effect by modulating the 
Wnt/β-catenin pathway. 
Finding the COX-inhibition status of aspirin analogues was important to have an insight 
into the potential mechanism behind analogues-mediated-anticancer effect and also to 
predict the possible COX-related side effects. For this purpose, Cayman Chemical’s COX 
inhibitor screening assay kit (ovine) was employed. From the analysis, aspirin was found 
to inhibit COX-1with an IC50 of 600 µM (Fig. 5.6.1) which is much higher than the stated 
range (< 4 µM) in the literature. Such variations in the inhibitory concentration might be 
due to the difference in assays and in COX proteins (i.e., ovine, bovine, recombinant 
human).   However, almost all the aspirin analogues tested in this study (other than 
carbonates) failed to inhibit COX-1 enzyme even at a very high concentration (10 mM). In 
case of COX-2, no inhibition was observed with aspirin or any other aspirin analogues at 
10 mM concentration (Fig. 5.6.1). A higher concentration of the compounds could not be 
used for these experiments due to the limitation in solubility. However, it is clear that the 
aspirin analogues tested are genuinely poor inhibitors of COX enzymes and their 
cytotoxicity effects are not mediated by COX inhibition. Since the aspirin analogues lack 
an acetyl group that could readily acetylate serine molecule of COX enzymes, it is possible 
that these compounds inhibit the COX isoforms at a very minimal level or do not inhibit at 
all. In the tested assay system, salicylic acid failed to inhibit the COX isoforms. Several 
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studies have shown salicylic acid to be a poor inhibitor of COX in vitro (Mitchell et al., 
1993) but an active inhibitor of COX at the site of inflammation in vivo (Mitchell et al., 
1997).    
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5.8 Conclusion 
To sum up, novel aspirin compounds synthesised in-house were identified to be more 
potent against oesophageal cancer cell lines than aspirin itself. The aspirin compounds that 
showed strong killing ability include fumaryldiaspirin (PN517) and benzoylsalicylates 
(PN524, PN528 and PN529). Both, quantitative and qualitative apoptosis experiments 
conducted revealed that these compounds largely induce apoptosis, although some necrosis 
was noted with PN528 and PN529. Failure to recover following the treatment with these 
analogues emphasized that these drugs are largely cytotoxic in nature. Low IC50 values for 
the compounds, increased induction of cell death and poor recovery following treatment 
indicated oe21 (SSC) to be the most sensitive cell line, whereas flo-1 (ADC) cells were 
found to be more resistant. The anticancer properties of these novel aspirin compounds 
appear to not involve the COX-enzymes at the tested concentrations. These initial findings 
support further studies into the potential of these aspirin analogues as chemotherapeutic 
agents against oesophageal cancer. Future studies on the mechanisms of action that 
contributes to the anti-proliferative effect of these agents would prove valuable. Further, 
testing these agents in genetically defined mouse models of oesophageal cancer would help 
in understanding the toxicity profile, if any, of these compounds in vivo.   
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Concluding Remarks 
The following conclusions can be made from this thesis: 
1. IDPs are crucial for DNA repair following bleomycin or 5FU insult. 
2. Yeast mutants- arg82 and kcs1, both lacking IDPs are hypersensitive to bleomycin 
and 5FU. 
3. Mutant ipk1 and vip1 show sensitivity similar to that of wild-type yeast, suggesting 
that neither InsP6 nor InsP8 play a crucial role in DNA repair. 
4. The kcs1 yeast contains both UDG-like and APE1-like protein that is required to 
perform BER repair of damaged DNA. However, extreme extraction methods are required 
to access these proteins. APE1-like protein extracted from yeast was not efficient in 
removing the PG group. 
5. Ung1, Apn1, Rad52 in both wild-type and kcs1 yeast and Rad51 in wild-type were 
successfully GFP-tagged for localisation studies. Due to poor GFP signal, confocal 
microscopy study was unable to reveal the exact localisation or movement of these GFP 
tagged proteins post bleomycin insult.  
6. Ddp1, the yeast DIPP, was capable of hydrolysing not only 5-InsP7 but also 1-InsP7 and 
InsP8 to a single product, InsP6.  
7. InsP7 accumulation was observed to be relatively little during InsP8 breakdown by 
DIPPs. Such low build-up was found to be due to rapid conversion of InsP7 to InsP6. 
8. DIPP-1 is the most active enzyme amongst the five human DIPPs, irrespective of the 
substrate. 
203 
 
9. InsP8 prefers to dephosphorylate through 1-InsP7. In contrary, metabolically and 
functionally significant steady-state route of InsP8 synthesis was observed to be via 5-
InsP7.        
10. The pathway that InsP8 chose to degrade (via 1-InsP7) is metabolically distinct from the 
main pathway for InsP8 synthesis (via 5-InsP7).  
11. Novel aspirin analogues synthesised in-house were identified to be more potent against 
oesophageal cancer cell lines than aspirin itself. Particularly, PN517, PN524, PN528 and 
PN529 analogues showed high killing ability. 
12. Both quantitative and qualitative apoptosis experiments conducted revealed that these 
compounds largely induced apoptosis. 
13. Inability of the cancer cells to recover following treatment with these analogues 
suggests that these drugs are cytotoxic and not cytostatic in nature. 
14. Oe21 was found to be the most sensitive cell line, whereas flo-1 cells were found to be 
more resistant. 
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Future Studies 
1. Tagging GFP at N-terminus of DNA-repair proteins to better the chances of visualising 
the signal much more efficiently 
2. Use relevant antibodies to confirm the presence of Kcs1 and DNA repair proteins, check 
their functionality, and phosphorylation status.  
3. Pursue Rad52, to determine whether Kcs1 is part of the epistasis group.   
4. Determine whether IDPs act as cofactors acutely or are required for activation of 
enzymes prior to extraction. 
5. Confirm that aspirin analogues induce apoptosis by checking the apoptotic protein levels 
(caspase activation, Bcl-2, Bax).  
5. Determine levels of inositol lipids (particularly PIP3) in order to determine whether the 
PI3K pathway is involved in aspirin analogues mediated killing of oesophageal cancer 
cells. Subsequent analysis of downstream proteins (e.g. PDK1, Akt). 
6. Test the key aspirin analogues in an implantable mouse model of oesophageal cancer to 
confirm that there are no drug-related side effects when introduced. 
 
       
 
 
 
  
205 
 
Scientific Poster Presentations at Conferences 
Signalling 2013 - Effect of aspirin analogues on oesophageal cancer. 
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